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A B S T R A C T  
 
The LIM-only (LMO) family of proteins are transcriptional regulators that are critical for 
the regulation of many developmental processes. In early red blood cell development one 
family member, LMO2, regulates blood cell development (erythropoiesis) through 
involvement in a transcriptional complex that also contains Tal1, E2a proteins, Gata1 and 
LDB1. Two components of this complex, Tal1 and LMO2, along with their homologues 
Lyl1, LMO1 and LMO3, are oncogenes in T-cell acute lymphoblastic leukaemia 
(T-ALL). Complexes similar to the erythropoietic LMO2 transcriptional complex are 
thought to drive the onset of T-ALL. This thesis investigates the protein-protein 
interactions of potential constituents of both normal and oncogenic complexes, focussing 
on in vitro experiments that use recombinant interaction domains from the relevant 
proteins expressed in E. coli. 
A full set of tethered LMO1–4-LDB1 sub-complexes was designed to accommodate 
better defined ends of domains and include the previously uncharacterised LMO1 and 
LMO3. These constructs were generated, purified and characterised using size-exclusion 
chromatography and multi-angle laser-light scattering (SEC/MALLS), far-UV circular 
dichroism (CD) spectropolarimetry and 1D 
1
H-NMR. The proteins were folded, 
predominantly monomeric and may be more stable than previously generated versions. 
Attempts to crystallise the previously uncharacterised LMO1-LDB1 and LMO3-LDB1 
constructs are described. 
Lyl1-E2a heterodimers appear to be unstable compared with Tal1-E2a heterodimers. 
Attempts to generate Lyl1 by extending the termini of the construct and by making a 
series of Lyl1 to Tal1 point mutants, suggest that this protein is intrinsically less stable, 
ii 
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and less capable of forming either homo or heterdimers than its close homologue, Tal1. 
However, sufficient Lyl1-E2a complexes could be generated for further study. 
GST-pulldown experiments were used to show that LMO1–3-LDB1 but not 
LMO4-LDB1 can bind to Tal1-E2a and Lyl1-E2a heterodimers in the absence of DNA. 
Mutational analysis of LMO2 was not able to determine the basis for this difference. 
Electrophoretic mobility shift assays (EMSAs) were used to characterise 
heterodimer-DNA binding and higher order complex formation. These data indicate that 
the bHLH proteins likely undergo dimer exchange, such that in the presence of DNA, 
Tal1-E2a proteins form substantial amounts of homodimers as well as heterodimers, but 
heterodimer formation is favoured by interaction with LMO-LDB1 proteins, and/or 
reducing the concentration of DNA. No evidence of Lyl1-E2a heterodimer formation on 
DNA was observed by EMSA, but this heterodimer was stabilised through higher order 
complex formation with LMO2-LDB1. 
Microscale thermophoresis (MST) and isothermal titration calorimetry (ITC) were used 
in attempts to quantify the binding of LMO1–4-LDB1 with Tal1-E2a heterodimers. 
Binding affinities determined by MST appear to be underestimated, possibly due to 
protein labelling artefacts, but demonstrate no binding by LMO4 and similar levels of 
binding for LMO1–3-LDB1. Estimates of binding by ITC were higher, but both 
experiments may be difficult to measure accurately because of complex equilibria 
between various sub-complexes. A protein engineering approach was thus used to 
generate extended Tal1-E2a constructs that were designed to promote heterodimer 
formation through addition of designed heterodimeric coiled-coil sequences. These 
engineered complexes appear to be more stable than the parent complex and do have an 
increased tendency to form heterodimers, as judged by SEC/MALLS and thermofluor 
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assays. These complexes should be useful for further characterising higher order complex 
formation in the future. 
Finally, MST and ITC experiments were used to assess interactions of Gata1–3 with 
LMO2-LDB11, and DNA. It was shown that Gata2 and Gata3 bind with similar, but 
slightly lower affinity, and that only the C-terminal finger of Gata1 shows appreciable 
independent binding to DNA containing GATC/G motifs. 
The implications of this data for the mechanisms of transcriptional complex formation, 
and how variant complexes can up- and down-regulate different sets of genes throughout 
normal development and T-cell leukaemia are discussed. 
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6-FAM 6-carboxyfluorescein 
A260nm absorbance at a wavelength of 260 nm 
AcBSA acetylated BSA 
ALL acute lymphoblastic leukaemia  
AMKL acute megakaryoblastic leukaemia  
AML acute myeloid leukaemia  
AMP ampicillin 
ATP adenosine triphosphate 
bHLH basic helix-loop-helix 
Bis-Tris 2-[Bisamino]-2--1,3-propanediol 
BSA bovine serum albumin 
CAM chloramphenicol 
CASTing cyclic amplification and selection of targets 
CAT chloramphenicol acetyltransferase 
CD circular dichroism spectropolimetry 
cDNA complementary deoxyribonucleic acid 
CF/C-finger carboxy-terminal zinc finger 
CFP Cyan fluorescent protein 
ChIP-seq chromatin immunoprecipitation and next generation sequencing 
CNS central nervous system 
CSA camphor sulfonic acid 
D2O deuterium oxide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
dsDNA double stranded deoxyribonucleic acid 
DSS 2,2-dimethyl-2-silapentane-5-sulfonate 
DTT dithiothreitol 
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E-box enhancer box 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EMSA electrophoretic mobility shift assay 
FOG1 friend of Gata1 
GSH glutathione 
GST glutathione s-transferase 
HIS 6  histidine tag 
HPLC high-pressure liquid chromatography 
HRP horseradish peroxidase 
HRV human rhinovirus  
HSC haematopoietic stem cells 
IPTG isopropyl β-d-thiogalactopyranoside 
ITC isothermal titration calorimetry 
KA association constant 
KD dissociation constant 
LB Luria-Bertani broth 
LCR locus control regions 
LDB1 LIM domain binding protein 1 
LDS lithium dodecyl sulfate 
LED light-emitting diode 
LID LIM interacting domain 
LIM Domain first discovered in Lin-11, Isl-1, Mec-3 
LMO LIM-only protein 
Lyl1 lymphoblastic leukaemia protein 1 
MALDI matrix-assisted laser desorption/ionization 
MALLS multi-angle laser-light scattering 
MCS multiple cloning site 
MEL Mouse erythro-leukaemia 
MES 2-(N-morpholino)ethanesulfonic acid 
MQW milli-Q water 
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T-ALL T-cell acute lymphoblastic leukaemia 
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X-SCIDs X-linked severe combined immunodeficiency  
 
Nomenclature of proteins used in this thesis is uppercase for non-DNA-binders and lowercase for 
DNA-binders. This is the approach used historically in the laboratory to distinguish proteins from 
DNA motifs (such as GATA). 
C H A P T E R  O N E  
I N T R O D U C T I O N  
1.1 HAEMATOPOIESIS 
Haematopoiesis is the process by which the cellular components of blood develop from 
haematopoietic stem cells (HSCs). The first phase of this process in mammals is referred 
to as primitive haematopoiesis, which occurs in the yolk sac during embryogenesis. 
Primitive haematopoiesis is characterised by the production of erythroblasts. These are 
primitive nucleated erythrocytes that express embryonic globin genes and are important 
for embryonic survival.
1,2
 During the second phase, definitive haematopoiesis, 
haematopoietic cells colonise the foetal liver.
3
 Definitive haematopoiesis is characterised 
by a mature red blood cell population that expresses adult haemoglobins and populations 
of mixed haematopoietic progenitor cells that give rise to all blood cell lines. Following 
birth the primary site of haematopoiesis occurs in the bone marrow.  Here residing HSCs 
are multipotent and self renewing (Figure 1.1).  
 
Figure 1.1 Haematopoiesis. Haematopoietic stem cells (HSC), formed in embryogenesis, are self 
renewing and capable of differentiating into various blood cell lineage pathways. As differentiation 
progresses the cells become more specialised and decrease in multipotency. 
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1.1.1 Regulation of haematopoiesis  
The process of haematopoiesis, from HSC maintenance to lineage commitment, 
proliferation and terminal differentiation, is controlled largely at the level of transcription. 
The specific up- or down-regulation of target genes is mediated by transcription factors, 
proteins that bind regulatory elements (such as promoters and enhancers) of target genes. 
Both ubiquitously expressed and lineage-specific transcription factors can be involved, 
with the latter being tightly controlled throughout differentiation.
4
 
Many transcription factors that have been identified as important regulators of 
haematopoiesis have lineage-specific functions. These transcription factors modulate the 
expression of multiple developmental red blood cell (immature erythrocyte) specific 
genes. A prime example is Gata1, a DNA-binding zinc-finger protein that is essential for 
erythrocyte development. Gata1 modulates the expression of a vast number of erythroid 
genes and is therefore known as a ‘master regulator’ of red blood cell development 
(erythropoiesis). 
Although each haematopoietic transcription factor can regulate multiple erythroid genes, 
many factors are thought to form complexes via specific protein-protein interactions. For 
example, Gata1 has been found to bind multiple transcriptional regulators, including 
LMO2,
5
 FOG1,
6
 PU.1
7
 and Krüppel-like factors (EKLF and RUNX1).
8,9
 Recent 
chromatin immunoprecipitation experiments coupled to next generation sequencing 
methods (ChIP-seq) have shown that sets of transcriptional factors can bind in different 
combinations to many different sites in the genome.
10,11
 These data suggest that erythroid 
transcription factors participate in different complexes with different DNA binding 
specificities. 
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The deregulation of many transcription factors has been associated with genetic 
abnormalities and leukaemias (Table 1.1). These diseases are often due to chromosomal 
translocation, where there is rearrangement of parts between non-homologous 
chromosomes. Chromosomal translocations can result in either the fusion of two proteins 
or genes being placed under the control of the wrong promoter or enhancer, leading to 
irregular expression of the target gene. If that target gene is a transcription factor, it can 
disrupt the control of many subsequent downstream gene products. Some chromosomal 
translocations which lead to the onset of leukaemia include genes such as TAL1, LMO1, 
LMO2, and LYL1, which are discussed in more detail in Section 1.3. 
Table 1.1 Leukaemic association of a selection of haematopoietic transcription factors 
Transcriptional 
regulator 
Haematopoietic lineage Leukaemia association  
Gata1  erythroid/megakaryocytes/eosinophils AMKL12 
Gata2 erythroid/myeloid/HSC AML13 
Gata3 lymphoid - 
E2a lymphoid ALL14 
Pu.1 lymphoid/myeloid AML15 
FOG1 erythroid/megakaryocytes - 
Tal1 HSC/erythroid/megakaryocytes T-ALL16 
Lyl1 HSC/ B-cell lymphoid T-ALL17 
LMO2 HSC/erythroid T-ALL18 
Runx1 HSC AML19 
 
1.2 The pentameric LMO2 transcriptional complex 
One transcriptional complex that is involved in the regulation of haematopoiesis is the 
so-called pentameric LMO2 transcriptional complex (Figure 1.2).
5,20-23
 This multiprotein 
complex, which has roles in erythropoiesis, also contains LIM (domain found in Lin-11, 
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Isl-1, Mec-3) domain-binding protein 1 (LDB1), Tal1, E2a proteins (E12 or E47), and 
Gata1. The presence of this transcriptional complex was postulated when all constituents 
were found to form a novel DNA-binding complex in MEL (Mouse erythro-leukaemia) 
cells that was capable of transcriptional transactivation activity in luciferase activity 
assays.
20
 The same study showed, using a site selection approach known as CASTing 
(cyclic amplification and selection of targets, where a consensus site is determined by the 
enrichment of random polynucleotides that bind to the target protein or complex),
24
 that 
the complex binds a bipartite DNA motif comprising E-box (CANNTG) and GATA sites. 
 
1.2.1 LMO proteins 
LMO2 is a member of the LMO (LIM-only) family of proteins, which are small (~160 
residue) transcriptional regulators. In mammals there are four family members, LMO1–
4.
25
 As their name suggests the proteins contain little more than a pair of tandemly 
Figure 1.2 The pentameric LMO2 erythropoietic transcriptional complex. The complex binds 
the promoter of target genes via a bipartite motif including an E-box sequence (CANNTG) ~10bp 
upstream of a GATA site. The complex facilitates transcriptional transactivation of the target gene. 
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arrayed LIM domains (Figure 1.3A).
26
 The LIM domain is a cysteine/histidine rich motif, 
which coordinates two zinc ions (Figure 1.3C) to form two zinc-binding modules. 
Structures of all LIM domains solved to date resemble two closely packed GATA-type 
zinc fingers.
27,28
 However, unlike typical GATA-type zinc fingers, which are known to 
bind both protein and DNA, LIM domains are not known to bind DNA. Rather, their 
major function is to mediate protein-protein interactions. LIM domain-containing 
proteins are common to Eukaryotes, where these proteins are known to play a diverse set 
of roles, including functions within cytoskeletal organisation
29
 and transcriptional 
regulation.
30
 They are found more rarely in prokaryotes.
31
 
The LMO family have high sequence similarity within their LIM domains. LMO1 and 
LMO3 are the most closely related (89% identical) in their LIM domains and LMO4 is 
the most divergent (Figure 1.3B).  
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Figure 1.3 LMO proteins. A) Schematic of a typical LMO protein and the corresponding 
sequences of the LIM domains of mouse LMO family members, where LMO2–4 are aligned with 
LMO1. Sequences identical to LMO1 are indicated (-) and only fully conserved residues are shown 
in consensus sequence (Cons.). Zinc-ligating residues are coloured and correspond to those in C). 
Sequences are of Mus musculus origin and their GenBank accession numbers are: LMO1 
(AAH53074); LMO2 (AAH57880); LMO3 (AAH57086); and, LMO4 (AAH03488). B) Pairwise 
sequence identity between LMO proteins as determined using CLUSTAL W2. C) LIM domain 
topology where coloured residues are zinc ligating residues from LMO proteins (colouring 
corresponds to A). X denotes any amino acid.  
A 
B 
C 
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1.2.2 The LMO family are nuclear adaptor proteins 
LMO proteins were originally thought to lack activation domains,
25
 but the potential to 
activate genes has since been identified. For example the amino-termini of LMO1 and 2 
were found to activate transcription in chloramphenicol acetyltansferase (CAT)-reporter 
assays.
32
 A second, more crucial, activation region at the carboxy-terminus of LMO2 was 
identified in similar CAT-reporter assays.
33
  
LMO proteins are generally thought to act as bridging molecules, such that their 
LIM-domains can simultaneously interact with several binding partners to form 
multiprotein transcriptional complexes. As LMO proteins do not themselves have 
DNA-binding domains, they interact with DNA-binding proteins to associate with their 
target genes. For example, LMO2 has been reported to interact using its LIM domains 
with proteins such as Gata1 or Tal1.
21
 
1.2.3 Normal roles of LMO proteins 
Whereas LMO1 and LMO3 appear to be expressed in a tissue-specific manner, LMO2 
and LMO4 tend to be more broadly expressed. LMO1 and LMO3 have overlapping 
expression patterns; they are both expressed at moderate levels in the embryonic brain 
and adult central nervous system (CNS).
34-36
 Null Lmo1/Lmo3 mutations are lethal in 
mice, but single mutants survive with no discernible phenotype,
37
 suggesting that these 
two closely related proteins have redundant functions.
38
 
LMO2 is widely expressed in most human tissues
25,26,34
 with the notable exception of the 
thymus.
25,39
 The highest levels of Lmo2 mRNA are found in the spleen, foetal brain
34
 and 
foetal liver,
26
 where the protein is an essential regulator of haematopoiesis. LMO2 is 
found in the nucleus of erythroid precursors and megakaryocytes.
40
 Mice with 
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homozygous Lmo2 knockout mutations die during primitive haematopoiesis due to 
failure of yolk sac-derived blood cell development.
20,40,41
 LMO2 also appears to be 
important for haematopoiesis in later stages of development and adulthood, as null Lmo2 
chimeras had interrupted definitive haematopoesis but the reintroduction of LMO2 
rescued development of all blood cell lineages.
42
 Lmo2-null chimeras have been reported 
to show inhibited angiogenesis (remodelling of primary capillaries into mature 
vasculature).
43
 Thus, LMO2 may have roles outside blood cell development. 
LMO4 is widely expressed throughout development and adulthood with highest levels of 
detection in the pancreas, small intestine, lymph nodes, colon, lung, liver, spleen, thymus 
and brain.
44,45
 LMO4 functions in neuronal development, neuronal activity and brain 
formation, and contributes to the balance of neuron types in the ventricle spinal cord.
46
 
Null Lmo4 mutant mice exhibit axial skeleton and cranial nerve defects, as well as 
exencephaly or anencephaly—conditions where the brain forms outside of the skull or 
fails to form completely, respectively.
47,48
 
LMO4 is also involved in breast tissue growth and milk production. During pregnancy, 
LMO4 expression in increased in the mammary glands.
49,50
  Lmo4 knockout mice were 
found to have a reduced ability to produce the milk proteins alpha and beta casein and 
whey acidic protein,
50
 and impeded mammary gland development.
51
 
1.2.4 The other members of the pentameric LMO2 complex  
LDB1 
LDB1 was originally identified by screening a mouse cDNA expression library for 
encoded LIM-binding factors.
52
 The protein has also been referred to as NLI (nuclear 
LIM interactor),
53
 Clim2,
54
 and CHIP in Drosophila melanogaster.
55
 LDB1 has a self-
association domain at its amino-terminus and a LIM interaction domain (LID) at its 
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carboxy-terminus (Figure 1.4A).
56
 The self-association domain, which is essential for the 
biological activity of most of the LIM protein partners, appears to form trimers in vitro,
57
 
and is likely to be the main mediator of long range chromatin interactions associated with 
this complex.
58,59
 The LID enables LDB1 to bind the LIM domains of LMO proteins and 
related LIM-homeodomain proteins.
52
 
Structures of LDB1LID bound to various LMO and LIM-homeodomain proteins have been 
determined. LDB1LID binds LIM domains in an extended, head-to-tail fashion, forming 
multiple β-strands that augment existing β-hairpins in the LIM domains (Figure 1.4B).60-
63
 The interactions are stabilized by hydrogen bonds, extensive hydrophobic interactions, 
and a limited number of electrostatic interactions. 
LDB1 is widely expressed in many tissue types and plays multiple important roles in 
development. Ldb1 null mice die at ~E10, where they display defective yolk sac 
formation, a lack of haematopoiesis, truncation of the head, and irregular heart and 
foregut formation.
64
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bHLH heterodimer 
Tal1 and E2a proteins (E12 and E47), are all bHLH (basic helix-loop-helix) transcription 
factors. bHLH proteins are important in many developmental processes such as in the 
nervous system and haematopoiesis.
65,66
 The helix-loop-helix motif of these proteins was 
first suggested from secondary structure predictions,
67
 and later confirmed to be a 
parallel, four-helix bundle with conserved hydrophobic residues.
68
 These proteins 
dimerise via their bHLH domains
69
 to facilitate recognition of DNA at E-box sites by 
their basic regions (Figure 1.5).
67
   
 
Figure 1.4 LDB1. A) Schematic of LDB1 indicating the amino-terminal self-association domain and 
a carboxy-terminal LID (LIM interaction domain). B) Ribbon diagram of LIM1 of LMO2 (cyan and 
magenta) and the equivalent binding region of LDB1LID (yellow) Zinc atoms are represented as grey 
spheres. Image taken from Deane et. al. (2003).  
A 
B 
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E12 and E47 are splice variants of the E2A gene,
67
 and are class I bHLH proteins. These 
E2a proteins are widely expressed and can either homodimerise, or heterodimerise with 
class II bHLH proteins such as Tal1. Class II bHLH proteins, such as Tal1, are tissue 
specific proteins that must dimerise with class I proteins to bind DNA,
70
 although the 
protein domains themselves may form homodimers.
71
 
In haematopoietic cell lines Tal1 expression is restricted to erythroid, mast and early 
myeloid cell lines, whereas E2a expression was observed throughout the haematopoietic 
lineages.
72
 Tal1 appears to have a role in primitive haematopoiesis as disruption to the 
Tal1 gene leads to defects in embryonic blood formation similar to those found in Gata1 
and Lmo2 knockout mice.
73
 In contrast E2a proteins act in the developmental progression 
of all early haematopoietic progenitors.
74
 
 
Figure 1.5 The structure of Tal1-E47 bound to 
DNA. The bHLH domain of Tal1 (red) and E47 
(yellow) bound to DNA. The basic domain of each 
protein is coloured green. PDB:2YPB 
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Gata1 
Gata1 belongs to the Gata family of zinc finger transcription factors, which is divided up 
into two subfamilies based on their expression profiles; the haematopoietic subfamily 
consists of Gata1–3,75 and the non-haematopoietic subfamily consists of Gata4–6.76 Gata 
proteins have an amino-terminal activation domain, an amino-terminal zinc finger 
(N-finger) and a carboxy-terminal zinc finger (C-finger).  
The C-finger of Gata1 binds DNA at GATA consensus sites with high affinity and 
specificity.
77
 The predominant function of the N-finger of Gata1 appears to be as a 
protein interaction domain; it is known to bind FOG1
78-80
 and LMO2.
81
 However, the 
N-finger has also been reported to bind DNA. It was shown to bind GAT(C/G) sequences 
independently when carrying an amino-terminal GST-tag
82
 or to double-GATA-sites in 
context of the full length protein or in constructs that contain both the N- and 
C-fingers.
83,84
 For example, the C-finger binds the GATA site on the leading strand and 
the N-finger binds the GATG site on the opposite strand of oligonucleotides containing 
the pseudo-palindromic mPal sequence (CATCTGATA) (Figure 1.6). This target 
sequence has been found on the cis-regulatory elements of all globin genes and many 
other erythroid specific genes.
85,86
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Like most of the other constituent components of the complex, Gata1 is essential for red 
blood cell development. Mice with Gata1 null mutations are unable to produce mature 
red blood cells or platelets but other haematopoietic lineages are largely unaffected.
87-89
  
1.3 LMO PROTEINS AND BINDING PARTNERS IN T-ALL 
All LMO proteins play important roles in a variety of cancers. LMO4 is implicated in 
several cancers, including pancreatic,
90
 neuroblastomic,
91
 prostate,
92
 lung
93
 and breast 
cancer.
49,94,95
 LMO2 has been implicated in B-cell malignancies, prostate cancer and 
pancreatic cancer. LMO1 and LMO3 are both involved in neuroblastomas.
34,96
 Finally, 
Figure 1.6 Gata1 zinc fingers bound to a double-GATA-site. A) Structure 
(PDB:3VEK) and B) schematic of the N-finger (red) and the C-finger (blue) 
bound to GATG (orange) and GATA (cyan) sites, respectively.  
A 
B 
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but most relevant for the work presented here, LMO1 and LMO2 are associated with 
T-cell acute lymphoblastic leukaemia (T-ALL). Known binding partners of LMO2 have 
also been implicated in T-ALL with strong evidence supporting the involvement of a 
complex similar to the pentameric LMO2 transcriptional complex described above 
(Figure 1.4).  
1.3.1 LMO transcriptional complexes and T-ALL 
Both LMO2 and Tal1 were originally discovered as genes interrupted by chromosomal 
translocations in T-ALL cell lines. These translocation occurred between the T-cell 
receptor alpha (TCRα) breakpoint and either the Tal1 gene, t(1;14)(p32;q11),16 or the 
LMO2 gene t(11;14)(p13;q11).
18
 Additional translocations were found between LMO2 
and TCRδ t(7;11)(q35;p13).97 The translocations mean that LMO2 or Tal1 genes, which 
are not normally expressed in T-cells, are up-regulated in maturing T-cells by 
mechanisms that drive the expression of TCRs as part of normal T-cell development.
98
 
The irregular expression of these proteins is predicted to be responsible for the onset of 
T-ALL.
99
 
Another genetic rearrangement has been implicated in LMO2-activated T-ALL. It was 
found that T-ALL patients with the chromosomal deletion del(11)(p12p13), which is 
thought to remove an LMO2 negative regulatory region, show inappropriate expression 
of the LMO2 gene in leukaemic cells.
100
 It has been estimated that 9% of T-ALL cases 
exhibit overexpression of LMO2 due to chromosomal abnormalities,
100
 but the aberrant 
expression of both LMO2 and Tal1 is observed in the majority of T-ALL cases (30–
60 %), even in the absence of identified chromosomal abnormalities.
41,101
 
More evidence of the link between LMO2 and T-ALL came following gene therapy trials 
for the treatment of X-SCIDs, an immunodeficiency disorder where patients have very 
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few T-cells or natural killer cells as a result of mutations in the interleukin 2 receptor 
gamma gene. Five out of twenty patients from two trials developed T-ALL after gene 
therapy treatment.
102-104
 It was found that in four of these five patients the gene therapy 
retrovirus vector had integrated proximal to the LMO2 gene promoter leading to the 
uncontrolled expression of LMO2 and the resultant rapid proliferation of immature 
T-cells.
102,105
 
Finally, transgenic mice overexpressing either LMO2 or Tal1 have been found to develop 
T-cell malignancies in several independent studies. In these cases, the long-latency of 
disease onset indicates that secondary genetic alteration may be required for the 
disease.
106,107
 However, mice carrying transgenes for both proteins formed tumours with 
reduced latency (3 months faster on average) compared to single transgenes, suggesting 
that LMO2 and Tal1 act synergistically to trigger the onset of disease.
108
  
The pentameric LMO2 complex also appears to be directly related to T-ALL. Complexes 
containing LMO2, Tal1, E2a proteins and LDB1 were identified in the T-cells of LMO2 
transgenic mice, where E2a and LDB1 are endogenously (natively) expressed but LMO2 
and Tal1 are ectopically (non-natively) expressed.
22
 Gata1 is unlikely to play a direct role 
in these complexes because it is not expressed in T-cells, nor is it known as a T-ALL 
oncogene (i.e., it is not generally up-regulated as part of the onset of T-ALL). However, 
the close homologue Gata3 is endogenously expressed in T-cells and is a likely candidate 
to substitute for Gata1 in a pentameric complex. In support of this theory, Gata3 not only 
increases transcriptional activity of Tal1/LMO2 in reporter gene assays,
109
 but has been 
found to synergistically act with Tal1 and LMO2 in T-ALL.
110-112
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1.3.2 Other LMO and bHLH proteins associated with T-ALL 
LMO2 is not the only LMO protein related to T-ALL. Although more research has 
focussed on LMO2, the role of LMO1 in T-ALL is well established. The LMO1 gene, the 
founding member of the LMO family, was originally identified at a breakpoint of a 
malignant T-cell line translocation [t(11;14)(p15;q11)], leading to its pathogenic 
activation.
113,114
 LMO1 protein was found to be expressed in a T-ALL cell line at a much 
greater level than its native expression in the brain.
36
  
Although LMO1 is not normally expressed in any blood cells, in T-ALL cells LMO1 has 
been found associated with LMO2 binding partners, Tal1 and LDB1. Independent studies 
have shown that Tal1 synergises with each of LMO1 and LMO2 to accelerate disease 
onset and severity.
115,116
 LMO1 is also often associated with LDB1 in 
LMO1-translocation positive T-ALL cells.
117
 Finally, Gata3 was found to direct LMO1 
and Tal1 to target genes in T-ALL cell lines.
110
 
Tal1 has a close homologue that has been implicated in the onset of T-ALL. Lyl1 is a 
class II bHLH protein with functions in haematopoietic cell development, and the bHLH 
regions of Lyl1 and Tal1 have high levels of sequence identity (85%). Lyl1 was 
discovered at the breakpoint of a T-ALL translocation with TCRδ [t(7;19)(p35;q13)].118 
In addition to Lyl1 translocation positive T-ALL, ectopic expression of the protein has 
been observed in numerous T-ALL patients.
101
 Lyl1 is also associated with LMO proteins 
in T-ALL. For example, LMO2 is expressed at significant levels in Lyl1 translocation-
activated T-ALL samples.
101
  
Recently, T-ALLs have been categorised into five molecular pathways that lead to the 
onset of the disease [1) Hox11, 2) Hox11L2, 3) Tal1 plus Lmo1/2, 4) Lyl1 plus Lmo2, and 
5) Mll-Enl].
119
 Of these pathways, the two categories involving the combinatorial 
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activation of Tal1/Lyl1 and LMO1/LMO2 oncogenes have very similar outcomes such as 
poor prognosis, suggesting similar molecular pathways.  
Interactions, as indicated by mammalian two-hybrid and co-immunoprecipitation 
experiments, were observed between each of the LMO proteins (LMO1 and LMO2), with 
each of the bHLH proteins (Tal1 and Lyl1),
41
 suggesting that the overlapping oncogenic 
roles of the protein combinations stems from their ability to form transcriptional 
complexes in T-cells that change transcriptional programs. It is generally thought that 
LMO1 and Lyl1 function in T-ALL by taking the place of their homologues in 
pentameric complexes (Figure 1.7).  
 
1.3.3 Mechanisms of oncogenesis 
Block in T-cell differentiation  
One of the first mechanisms proposed for Tal1 and LMO2 oncogenesis in T-ALL is 
inhibition of E2a-mediated gene expression. E2a proteins are essential for normal T-cell 
Figure 1.7 T-ALL constituents may form similar complexes to the pentameric LMO2 
transcriptional complex from red blood cells. The erythroid pentameric complex consists of 
LDB1, LMO2, Tal1, E2a and Gata1. It is thought that T-ALL oncogenes LMO1 and Lyl1 and T-cell 
protein Gata3 can replace their homologous counterparts to participate in a similar oncogenic 
complex.  
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differentiation, and loss of the E2a gene is associated with T-cell malignancies. These 
malignancies are very similar to those observed in LMO2- and Tal1-induced leukaemia 
in mice models of disease.
120
 The role for an inhibitory mechanism was supported by 
observations that genes thought to be activated by E2a were down-regulated in the 
Lmo2/Tal1 transgenic mice. Amongst these E2a regulated genes are those which lead to 
the progression of T-cell differentiation from DN T-cells to double positive (DP) stages 
(such as pTα).98,121  
HSC self-renewal 
The forced expression of Lmo2 in T-cells induces self-renewal of DN3 stage T-cell 
precursors, named precancerous stem-cells (pre-CSC) as they go on to cause overt 
disease.
122
 The ability of these cells to self-renew is thought to be brought about by the 
up-regulation of stem cell transcriptional programs. For example, HSC genes (such as 
Hhex) are up-regulated in LMO2-induced T-ALL.
123
 Other proteins overexpressed in 
LMO2-induced pre-CSC include the Kit-receptor, Stat3 and Stat5.
123
 These proteins are 
associated with a stem cell factor (SCF) signalling pathway that is critical for DN3 cell 
survival. Thus in addition to down-regulation of E2A genes, the pentameric complex is 
thought to up-regulate different sets of genes. 
LMO2 and Tal1 therefore likely function in the development of T-ALL by forming a 
complex that acts in multiple transcriptional reprogramming events. These include 
sequestering E2a proteins to inhibit normal progress through T-cell differentiation, 
activating HSC genes that promote DN3-stage self-renewal and other factors involved in 
self-renewal of DN3 T-cells (Figure 1.8).  
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1.4 BIOPHYSICAL CHARACTERISATION OF THE 
PENTAMERIC COMPLEX 
Biophysical methods have been employed to characterise the different protein-protein 
interactions involved in the pentameric complex (containing LMO2, LDB1, Tal1, an E2a 
protein and Gata1) and the overall assembly of the complex.  
1.4.1 The interaction between LMO2 and Tal1 
Fluorescence anisotropy combined with mathematical modelling was used to show that 
Tal1 forms a 1:1 heterodimer (KA = 3.5 × 10
7
 M
-1
) with E12.
71
 LMO2 can directly 
Figure 1.8 LMO2 and Tal1 complex to reprogram multiple transcriptional 
events. A) In T-cells E2a homodimerises to initiate transcription of target genes 
critical to T-cell differentiation, however, when LMO2 and Tal1 are 
overexpressed E2a is sequestered away from its normal function. B) As well as 
inhibition of E2a-regulated genes, LMO2 and Tal1 induce expression of genes 
involved in HSC self-renewal. 
A 
B 
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interact with Tal1 in vivo based on co-immunoprecipitation and mammalian two-hybrid 
techniques,
5
 and isothermal titration calorimetry (ITC) was used to show that  
LMO2-LDB1 binds the Tal1-E12 heterodimer with an association constant (KA = 1.8 × 
10
8
 M
-1
) ~300-fold greater than to Tal1 alone (KA = 6.3 × 10
5
 M
-1
).
71
 Multi-angle 
laser-light scattering, in combination with size-exclusion chromatography (MALLS/SEC) 
confirmed that the LMO2-LDB1-Tal1-E12 complex forms on DNA with a 1:1:1:1:1 
stoichiometry. In contrast, ITC and electrophoretic mobility shift assay (EMSA) data 
demonstrated that the LMO2-LDB1 complex could not bind E12 in the absence or 
presence of DNA.
71
 
In 2013 the structure of LMO2-LDB1 bound to Tal1-E47 on DNA was published (Figure 
1.9) providing new insights into the structural basis of binding within the pentameric 
complex.
124
 It was revealed that the interaction is heavily influenced by LMO2LIM1, with 
only two residues from LMO2LIM2 participating in the interaction. This LIM1 domain 
binds mainly to the second helix and loop of Tal1 with a smaller number of contacts 
being made by E47. The interaction is stabilised by surface-exposed hydrophobic 
residues from Tal1 and LMO2 as well as a salt-bridge and two hydrogen bonds. By 
comparison with the structure of Tal1-E47 bound to DNA, published in the same paper, it 
appears that LMO2 binding induces the formation of new contacts at the Tal1-E47 
interface.  
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The two LIM domains of LMO and related LIM-homeodomain proteins are thought to 
have some flexibility between the LIM domains where one or two residues act as a 
hinge.
125
 X-ray crystal structures of LMO2 and LMO4 in complex with LDB1 have 
shown that despite close structural similarity of individual LIM domains, the relative 
orientation of LIM1 and LIM2 can vary (e.g., Figure 1.10).
126,127
 Prediction algorithms 
assessing flexibility of structures identified residues F82 in LMO2 and E349 in LDB1 at 
the hinge region.126 Mutations of F82 that were designed to disrupt flexibility at the hinge 
region resulted in reduced LMO2/Tal1 activity in luciferase reporter assays.
126
 This 
suggests that LIM interdomain flexibility of LMO2 may be important in the LMO2/Tal1 
interaction. However, it is also possible that mutation of F82 disrupts formation of a 
small hydrophobic core in LMO2LIM1, which could affect the interaction.
128
 
Figure 1.9 The structure of Tal1-E47 bound to LMO2-LDB1 and DNA. The bHLH domain 
of Tal1 (red) and E47 (yellow) bound to DNA and LMO2-LDB1 (blue and cyan, respectively). 
PDB:2YPA 
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1.4.2 The interaction between LMO2 and Gata1 
A combination of GST-pulldown experiments and NMR chemical shift perturbation 
experiments were used to show that the minimal domain of the N-terminal and C-
terminal zinc fingers of Gata1 is sufficient to interact with LMO2-LDB1, but the main 
proponents of binding were the Gata1 N-finger and the LIM2 domain of LMO2, which 
bind weakly in vitro (KA = 5 × 10
4
 M
-1
).
81
 As noted above, CASTing experiments and 
EMSAs have previously identified a consensus recognition site for the pentameric LMO2 
transcriptional complex as a bipartite E-box-GATA motif where the two motifs are 
separated by 8–9 bases.22 EMSAs using this sequence were used to show that Gata1 and 
Tal1-E12 can simultaneously bind an LMO2-LDB1 construct, supporting a model in 
which Tal1-E12 and Gata1 bind the same LMO2 molecule (Figure 1.4), but that the 
related LMO4-LDB1 does not bind Tal1-E12 or Gata1 on DNA.
81
 
Figure 1.10 LIM domains can move relative to each other. Two independently determined 
structures of LMO2-LDB1 showing LDB1 in magenta and LMO2 from the C2 crystal form or P21 
crystal form in green and blue, respectively. The hinge revolves around residue F82 of LMO2. 
Image adapted from El Omari et al., 2011. 
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1.5 OUTLINE OF THIS THESIS 
LMO1, LMO2, Tal1 and Lyl1 play roles in T-ALL. It is likely that in leukaemic T-cells 
these oncogenes, in combination with LDB1, E2a proteins and Gata3, form a complex 
similar to the erythroid pentameric LMO2 transcriptional complex. It has been proposed 
that this complex functions to sequester endogenous E2a proteins from their normal roles 
to alter gene expression patterns in cells by down-regulating transcriptional programs that 
bring about T-cell differentiation, and up-regulating transcriptional programs that 
promote stem cell-like behaviour. However, most of the interactions associated with these 
alternate complexes have not been thoroughly investigated. In this thesis I investigate the 
various protein-protein interactions involved in these alternate pentameric complexes and 
assess the ability of LMO and Tal1/Lyl1 proteins to sequester E2a proteins. The methods 
used in these investigations are outlined in Chapter 2. Chapter 3 and 4 describe the 
engineering and production of LMO-LDB1 and Lyl1 recombinant constructs for in vitro 
studies. These constructs were used in Chapter 5 and 6 in in vitro binding experiments to 
assess the population distributions associated with Tal1/Lyl1, E2a and LMO. Chapter 7 
presents interaction studies between Gata1–3 and LMO2. Chapters 5 and 7 evaluate the 
DNA binding abilities of the bHLH heterodimers and Gata proteins. Finally, in 
Chapter 8, the mechanistic implications of the LMO-containing complexes from these 
studies are discussed. 
 
C H A P T E R  T W O  
M A T E R I A L S  A N D  M E T H O D S  
2.1 CHEMICALS AND REAGENTS 
All solutions and media were made using Milli-Q® water (MQW) and all chemicals and 
solvents were of analytical reagent grade and supplied Boehringer Mannheim (Castle 
Hill, NSW, AUS), Sigma (Castle Hill, NSW, AUS) or Univar (Auburn, NSW, AUS), 
unless otherwise specified. Table 2.1 outlines other chemicals and reagents and Table 2.2 
enzymes. 
Table 2.1 Reagents and consumables 
Reagent Supplier 
2-log DNA ladder New England Biolabs (Beverly, MA,USA) 
2,2-dimethyl-2-silapentane-5-sulfonate (DSS) Sigma  
α-HIS antibody GE Healthcare (Piscataway, NJ, USA) 
α-mouse-HRP conjugate antibody Abcam® plc (Cambridge, UK) 
Acetonitrile (HPLC grade) Allied Signal Inc. (Mskegon, MI, USA) 
Amylose resin New England Biolabs 
Agarose VWR International (Murarrie, QLD, AUS) 
Ampicillin (AMP), sodium salt Sigma  
β-Mercaptoethanol Sigma  
Bacteriological agar Amyl Media (Kings Langley, NSW, AUS)  
BioTrace™ NT Nitocellulose transfer PALL Gelman (Ann Arbor, MI, USA) 
Casein peptone Amyl Media  
CelluSep®H1 dialysis membrane (1kDa) Fisher Biotec (Wembley, WA, AUS) 
Chloramphenicol (CAM) sodium salt Sigma  
Deuterium oxide (D2O) Sigma  
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Dimethyl sulfoxide (DMSO) Sigma  
Dithiothreitol (DTT) Sigma  
DNase I Roche (Castle Hill, NSW, AUS) 
Ethidium bromide Bio-Rad (Regents Park, NSW, AUS) 
Ficoll-400 Sigma  
Glucose  Univar  
Glutathione Amerco (Solon, OH, USA) 
Glutathione Sepharose® 4B beads GE Healthcare  
Glycerol Univar  
IGEPAL® CA-630 Sigma  
Imidazole Sigma 
Isopropyl β-ᴅ-thiogalactopyranoside (IPTG) VWR International 
Kodak diagnostic X-omat™ LS film Sigma  
Mark12™ protein standards Invitrogen (Mt. Waverly, VIC, AUS) 
MES buffer Invitrogen  
Ni-NTA agarose Qiagen (Doncaster, VIC, AUS) 
Novex® Sharp Pre-stained protein standard Invitrogen  
NuPAGE® Novex 4–12% Bis-Tris precast gels Invitrogen  
Phenymethylsulfonyl fluoride (PMSF) Sigma  
QIAprep® spin miniprep kit Qiagen  
QIAquick® gel extraction kit Qiagen  
SnakeSkin™ 3.5 & 10 kDa MWCO dialysis tubing Pierce (Rockford IL, USA) 
Tris(hydroymethyl)methylamine (base) Ajax Finechem (Taren Point, NSW, AUS) 
Tryptone Oxoid (Basingstroe, HA, UK) 
Tween®-20 Astral Scientific (Gymea, NSW, AUS) 
Viaspin sample concentrators  GE Healthcare  
Western Lighting™ chemiluminescence reagent 
plus kit 
PerkinElmer™ Life Sciences (Boston, 
MA, USA) 
Yeast extract Amyl Media  
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Table 2.2 Enzymes 
Reagent Supplier 
Bam HI (EC 3.1.21.4) New England Biolabs 
Bgl II (EC 3.1.21.4) New England Biolabs  
Eco RI (EC 3.1.21.4) New England Biolabs 
Lysozyme (from chicken egg white) (EC 3.2.1.17) Sigma  
Pfu DNA polymerase (EC 2.7.7.7) In-house 
Quick-Stick ligase (EC 6.5.1.1) Bioline (Alexandria, NSW, AUS) 
T4 DNA ligase (EC 6.5.1.1) New England Biolabs 
Thermo-sensitive alkaline phosphatase (TSAP) Promega  
Thrombin (from bovine plasma) (EC 3.4.1.5) Sigma  
Xho I (EC 3.1.21.4) New England Biolabs  
 
2.2 PRODUCTION OF TARGET CONSTRUCTS 
Most constructs were generated from template plasmids available in the laboratory using 
polymerase chain reaction (PCR) methods. The LMO1–4-LDB1 sequences were 
purchased as synthetic genes (GENEWIZ Inc., South Plainfield, NJ, USA) and 
IAAL-E3/K3 coiled-coils for fusion constructs were generated using synthetic 
oligonucleotides and multiple rounds of extension PCR (Section 2.2.5). The fragments 
were engineered with flanking restriction endonuclease recognition sequences for 
insertion into plasmids (Section 2.2.3). Colonies containing plasmids were screened using 
standard PCR (Section 2.2.5) and sequenced for confirmation (AGRF; Westmead, NSW, 
AUS). 
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2.2.1 Oligonucleotides  
Single-stranded DNA (ssDNA) oligonucleotides were used for PCR synthesis of target 
inserts and DNA sequencing reactions. These were supplied by Sigma or Integrated DNA 
technologies (Coralville, IA, USA).  
2.2.2 Bacterial strains and culture media  
Plasmid DNA was produced using Escherichia coli DH5α strain (supE44, ΔlacU169, 
[ⱷ80lac ZΔM15], hsdR17, recA1, endA1, gyrA96, thi-1, relA1), Bethesda Research 
Laboratories (Gaithersburd, MD, USA). Protein overexpression was performed using 
either the E. coli strain BL21 (F
 -
, opmT, [Ion], hsdS
B
(rB
-
mB
-
)) carrying the DE3 λ 
prophage, which contains the T7 RNA polymerase gene under the control of the lac 
promoter (Integrated Sciences; Willoughby, NSW) or the E. coli strain Rosetta II (F
-
, 
opmT, hsdS
B
(rB
-
mB
-
), gal, dcm (DE3), pLysSRARE2 (Cam
R
)) (Novagen®, Merk 
Millipore; Bayswater, VIC, AUS).  Bacteria were grown in sterile (autoclaved) 
Luria-Bertani (LB) broth [1% (w/v) tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) Yeast 
extract] or LB-agar plates [LB broth containing 1.5% (w/v) bacteriologic agar). 
Antibiotics, ampicillin (50/100 µg mL
-1
) and/or chloramphenicol (34 µg mL
-1
), were 
added to LB after autoclaving and cooling to ~55 ˚C. 
2.2.3 Plasmids   
The pGEX-2TKE (D. Ryan, University of Sydney; for LMO-LDB1 and Gata1–3NF) and 
pGEX-6PE (E. Cram, University of Sydney; for Lyl1(1)–(4)) plasmids were used to 
express proteins with an amino-terminal glutathione S-transferase (GST) tag. In both 
cases this was the ~26 kDa Schistosoma japonicum GST. pGET-2TKE is derived from 
pGEX-2T (Amersham Biosciences; Uppsala, Sweden). It contains a lysine to glutamic 
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acid mutation at 194 of GST (K194E), that removes a pseudo-thrombin cleavage site and 
introduces a Xho I cleavage site. Following treatment with thrombin, proteins expressed 
from pGEX-2TKE are left with a 2-residue N-terminal GS tag. pGEX-6PE is also a 
modified version of pGEX-2T and contains a HRV-3C protease site rather than a 
thrombin cleavage site. It resembles the commercially available pGEX-6P site with a 
simplified multiple cloning site (MCS), which contains Bam HI and Eco RI restriction 
sites only.  
A modified form of pRSET-A (pRSET-AΔ; M. Proctor, University of Cambridge, UK) 
was used to produce Lyl1(1)–(4) with N-terminal 6  histidine tags (HIS). In this 
modified version of pRSET a single thrombin-recognition sequence has replaced the 
region upstream of the MCS; including the T7 gene 10 leader sequence, enterokinase 
cleavage recognition sequence and Xpress epitope sequence. Proteins expressed in this 
vector are left with a 17-residue N-terminal tag (amino acid sequence; 
MRGSHHHHHHGLVPRGS).  
Co-expression of bHLH proteins was carried out using the bicistronic pETDUET vector 
(Novagen®, Merk Millipore), where Tal1 or Lyl1 (in MCSI) were expressed with 
N-terminal 6  histidine (HIS) tags and left with a 14-residue N-terminal tag (amino acid 
sequence; MGSSHHHHHHSQDP) and E2a proteins (in MCSII) were expressed in an 
untagged format and left with a 4-residue N-terminal tag (amino acid sequence; MADL). 
Gata1CF was expressed in an untagged form from pET11A. 
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2.2.4 Agarose gel analysis and purification of double-stranded 
DNA 
DNA preparations were mixed at a ratio of 4:1 with 40% (w/v) sucrose and loaded onto a 
1–2% (w/v) agarose gel [1  TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) 
with ethidium bromide (~0.5 µg mL
-1
)] and subjected to electrophoresis at ~100 V for 
~45 min. DNA was visualised by UV-light transillumination and bands isolated for DNA 
to be excised from agarose using QIAquick® gel-extraction kit (Qiagen). 
2.2.5 Polymerase chain reaction (PCR) 
PCR was performed in a T3000 Thermocycler (Biometra GmbH; Goettingen, Germany). 
The final 50 µL reaction contained ~50–500 ng of template DNA, two primers (40 pmol), 
20 nmol dNTPs (5 nmol of each dATP, dCTP, dGTP, dTTP), 1  Pfu buffer (20 mM Tris 
(pH 8.0), 2 mM MgSO4, 10 mM KCl, 10 mM (NH4)2SO4, 1% (v/v) Triton-X®100, 
0.1 mg mL
-1
 BSA) and 1 U Pfu DNA polymerase.  
Reactions were subjected to 12 cycles of the following temperature sequence: 94 ˚C 
(1 min), ~55 ˚C* (1 min), 72 ˚C (10 min) (*generally set to 5 degrees below Tm of primer 
annealing regions). For constructs that required extensions at the 5’ and/or 3’ end of the 
insert primers were designed to include non-annealing extension regions (Figure 2.1A). 
The resulting dsDNA fragments of the target were subsequently cloned into desired 
vectors using endonuclease digestion of the insert and vector, and ligation as described in 
the following sections.  
In optimised overlap extension PCR
129
, used to introduce a point mutation into a DNA 
sequence, a pair of primers were designed (Figure 2.1B) with an overlapping region at the 
mutation flanked by ~9 bp of wild type sequence on either side (common to both primers; 
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with an identical melting temperature; Tm(pp)) and a non-overlapping sequence of ~ 18 bp 
of wild type sequence extending at the 3’ ends of each primer (unique to the primers; 
with similar melting temperature; Tm(no)). In this optimised overlap extension PCR the 
initial 12-cycle PCR was followed by the temperature sequence: 41 ˚C** (1 min), 72 ˚C 
(30 min) (in these cases * was set to 5 degrees below Tm(no) and ** was set to 5 degrees 
below Tm(pp)). This last step amplifies the whole template plasmid containing the 
mutation and is followed by treatment with DpnI to digest non-mutant template DNA. 
These plasmids are transformed directly into bacteria; single-strand breaks are repaired 
by bacterial DNA repair processes.  
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Figure 2.1 PCR methods. A) Standard PCR used for 3’ and 5’ extensions. Primers have three 
regions; one that anneals to the template DNA (black), the extension sequence (red) and restriction 
endonuclease sites for insertion into vectors (blue). B) Optimised overlap extension PCR. Primers 
have two regions; an overlapping region common to both primers (black) which surrounds the 
mutant codon (red cross) and the non-ovelapping sequence unique to each primer (blue). In this 
case the product is a vector. 
 
A 
B 
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2.2.6 Restriction endonuclease digestion of DNA 
All restriction endonuclease digestion reactions were performed in a final reaction 
volume of 30 µL containing 20 U of each restriction endonuclease and 3 µL of the 
supplied 10  reaction buffer. In addition, 3 µL of BSA (10 mg mL-1) was included if 
specified in the manufacturer’s advice. Double-digest reactions (using two different 
enzymes simultaneously) were carried out in buffers that yielded optimal activity for both 
enzymes, as recommended by the manufacturer. Reactions were performed at 37 ˚C for 
1–2 h. In the case of plasmid DNA, dephosphorylation was performed to prevent 
self-ligation; 1 U alkaline phosphatase was added to the reaction with incubation at 37 ˚C 
for a further 30 min. Digested DNA was purified on 1–2% (w/v) agarose gels. 
2.2.7 Ligation 
T4 DNA ligations were performed in a total volume of 10 µL containing digested DNA, 
1 µL of commercially supplied 10  T4 DNA ligase buffer (400 mM Tris, 100 mM 
MgCl2, 100 mM DTT, 5 mM ATP) and 1 Weiss unit of T4 DNA ligase (1 µL). Reactions 
were incubated shaking at 16 ˚C for ~ 15 h.  
Quick-Stick ligations were performed in a total volume of 20 µL containing digested 
DNA (total ~100 ng), 5 µL of commercially supplied 4  Quick-Stick ligase buffer and 
Quick-Stick ligase (1 µL). Reactions were incubated shaking at ~25 ˚C for ~ 10 min. 
In each method of ligation, DNA was combined in three ratios (k = 1, 3 or 6) of digested 
plasmid to insert DNA (Section 2.2.6) to give a total of ~ 100 ng of total DNA. Ratios 
were designed to consider the size of the plasmid and inserts (Equation 2.1).  
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2.2.8 Transformation of E. coli 
KCM competent-cell preparation Untransformed E. coli cells were streaked out onto 
LB-agar plates (with 34 µg mL
-1
 chloramphenicol for Rosetta II or without antibiotic for 
other strains) and incubated overnight at 37 ˚C. A single colony was used to inoculate 
10 mL of LB broth and grown shaking overnight (~ 15 h) at 37 ˚C. SOC media [2% (w/v) 
tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 1% (w/v) glucose] was inoculated (1:1000) with the overnight culture and grown 
shaking at 37 ˚C until OD600nm ~0.4 was reached. Cells were pelleted by centrifugation 
(5000  g, 4 ˚C) and resuspended on ice with 20 mL chilled resuspension buffer (LB 
broth containing 10% (w/v) PEG-3350, 5% (v/v) DMSO, 10 mM MgCl2, 10 mM MgSO4, 
10% (v/v) glycerol, pH 6.1). Cells were aliquoted, snap-frozen in liquid nitrogen and 
stored at -80 ˚C. 
Transformation Plasmid DNA (~0.2–1 µg of prepared plasmid DNA or ligation 
mixture) was added to 10 µL KCM competent-cell preparation and 50 µL KCM 
(100 mM KCl, 30 mM CaCl2, 50 mM MgCl2). Cells were incubated on ice for 10 min, 
heat-shocked at 42 ˚C for 90 s followed by an incubation on ice for 60 s. Cells were 
allowed to propagate for ~45 min (or ~3 h for ligation mixtures) at 37 ˚C with 200 µL of 
sterile LB broth. Cells were then spread onto LB agar plates containing antibiotics as 
           
        
       
          (Equation 2.1) 
Where m  is mass (ng), l  is length of the dsDNA (bp) and k  is the ratio of plasmid to 
insert (k = 1, 3 or 6). 
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required: ampicillin (100 µg mL
-1
) to maintain plasmids in all cell types with additional 
use of chloramphenicol (34 µg mL
-1
) in Rosetta II strain to maintain the pRARE plasmid. 
2.2.9 Plasmid preparations 
A single colony of DH5α E. coli cells transformed with plasmid DNA (Section 2.2.8) was 
used to inoculate 10 mL of LB broth containing 100 µg mL
-1
 ampicillin and incubated 
shaking overnight at 37 ˚C. Cells were pelleted by centrifugation (5000  g, 4 ˚C, 10 min) 
and plasmid DNA extracted using QIAprep® spin miniprep kits (Qiagen) by following 
the manufacturer’s instructions. Final solutions of plasmid DNA were stored at -20 ˚C. 
2.3 LARGE SCALE OVEREXPRESSION AND AFFINITY 
PURIFICATION 
2.3.1 Protein overexpression 
Protein overexpression was carried out in the E. coli BL21 strain (F
 -
, opmT, [Ion], 
hsdS
B
(rB
-
mB
-
)) carrying the DE3 λ prophage, which contains the T7 RNA polymerase 
gene under the control of the lac promoter (Integrated Sciences; Willoughby, NSW, 
AUS) or in the case of all versions of bHLH protein expression in pETDUET vectors the 
E. coli strain Rosetta II (F
-
, opmT, hsdS
B
(rB
-
mB
-
), gal, dcm (DE3), pLysSRARE2 (Cam
R
); 
Novagen®, Merk Millipore) was used. Growth media was the same as described in 
Section 2.2.2, and cells were transformed according to Section 2.2.8.  
Starter cultures were made by inoculating 50 mL LB broth containing the appropriate 
antibiotics (100 µg mL
-1
 ampicillin in both strains, plus chloramphenicol 34 µg mL
-1
 in 
Rosetta II cells) with a single transformed BL21(DE3) or Rosetta II colony and incubated 
shaking at 37 ˚C overnight. The starter culture was subsequently used to inoculate 50 mL 
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to 1 L of LB broth containing antibiotics to OD600nm ~0.05. For all versions of bHLH 
protein expression in pETDUET vectors the LB broth was supplemented with 2% 
glucose that had been sterilised by filtration. Cultures were left to incubate with shaking 
at 37 ˚C until OD600nm ~0.6 was reached, when the culture was cooled to 20–25 ˚C and 
induced with 0.4 mM IPTG and incubated with shaking at 20–25˚ C for ~ 15 h. The cells 
were pelleted by centrifugation (5000  g, 4˚ C, 20 min) and stored at -20 ˚C until 
processed. Samples were taken immediately prior to induction and at harvest for 
SDS-PAGE analysis (Section 2.5). 
2.3.2 Cell lysis 
Cell pellets were resuspended in 20 mL (per 1 L culture or 12 mL per 200 mL for 
small-scale cultures) of the appropriate lysis buffer (Table 2.3) with lysozyme 
(0.2 mg mL
-1
), DNase (10 µg mL
-1
) and phenymethylsulfonyl fluoride (PMSF; 2 mM) 
and incubated rotating at 4 ˚C for 1 h. Cells were sonicated on ice for 1–3 min 30 s bursts 
and soluble fractions separated by centrifugation (4000  g, 4 ˚C, 20 min). Soluble 
fractions were subjected to affinity purification (Section 2.3.3). It should be noted that 
buffers for lysis, purification and analysis were selected to lie away from the proteins pI. 
Table 2.3 Lysis buffers 
Protein Vector Lysis Buffer Composition  
LMO-LDB1  pGEXT-2TEK 
50 mM Tris (pH 8.0), 50 mM NaCl, 5% (v/v) Triton X-100, 
1 mM DTT 
bHLH proteins pETDUET 20 mM Tris (pH 9.0), 150 mM NaCl, 1 mM DTT 
Coiled-coil bHLH 
tethered proteins 
pETDUET 20 mM Tris (pH 8.0), 150 mM NaCl, 1 mM DTT 
Lyl1(1)–(4) pGEX-6P 
PBS buffer (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM 
NaCl, 2.7 mM KCl) (pH 7.4) 
Gata1–3NF pGEX-2TKE 20 mM Tris (pH 7.5), 100 mM NaCl, 1 mM DTT 
Gata1CF pET11A 50 mM Tris (pH 9.0), 50 mM NaCl, 1 mM DTT 
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2.3.3 Application to and elution off affinity or ion-exchange beads 
GSH or SP-Sepharose resin (~ 5 mL per litre of culture) was washed in MQW and 
equilibrated in five column volumes of lysis buffer. The soluble fractions from 
Section 2.3.2 were applied to the equilibrated resin and allowed to bind for 1 h with 
rocking at 4 ˚C. The beads were washed in five column volumes of wash buffer (lysis 
buffer with 10% glycerol).  
LMO-LDB1 on GSH-resin  
Glutathione (GSH)-resin was equilibrated in thrombin buffer (Table 2.4). 
GST-LMO-LDB1 proteins were released from the tag by proteolytic cleavage with 
bovine thrombin protease (100 U) in 10 mL of thrombin buffer with rocking at 4 ˚C for 
~15 h. Cleaved protein was then eluted from the column in 6  5mL fractions of thrombin 
buffer. The eluate was subjected to size-exclusion chromatography (Section 2.4). 
Gata1–3NF on GSH-resin  
GSH-resin was equilibrated in thrombin buffer and eluted from the column in 4  5 mL 
alternate fractions of thrombin buffer and thrombin buffer with reduced GSH (30 mM). 
Eluates were treated with bovine thrombin protease (50 U/5 mL) with rocking at 4 ˚C for 
~ 15 h to release proteins from the tag. Samples were then subjected to cation-exchange 
chromatography (Section 2.4). 
bHLH proteins on SP-sepharose and Ni-NTA resin  
bHLH proteins were eluted in 8  2-mL fractions of lysis buffer with increasing 
concentrations of NaCl (1  150, 260, 375, 500 mM and 4  600 mM NaCl). Eluates 
containing the proteins were subsequently applied to Ni-NTA affinity agarose (5 mL) 
which had been washed with MQW and equilibrated with five column volumes of 
Ni-NTA buffer (Table 2.4). Protein was eluted in 8  2-mL fractions of Ni-NTA buffer 
CHAPTER TWO: MATERIALS AND METHODS 37 
 
with increasing concentrations of imidazole (1  0, 60, 125, 200 mM and 4  250 mM). 
Imidazole was removed from eluates using PD10 columns (Invitrogen) using the 
manufacturer’s instructions by elution into Ni-NTA buffer. Protein was stored at 4 ˚C. 
Gata1CF on SP-sepharose resin  
Gata1CF was eluted in 6  10-mL fractions of lysis buffer with increasing concentrations 
of NaCl (0.2, 0.4, 0.6, 0.7, 0.8 and 1 M NaCl). The NaCl was reduced by dilution with 
lysis buffer (1:1) and eluates subjected to cation-exchange chromatography.  
Table 2.4 Affinity purification buffers 
Buffer Composition  
Thrombin 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM CaCl2, 1 mM DTT 
Ni-NTA 20 mM Tris (pH 9.0), 500 mM NaCl, 1 mM DTT 
 
2.4 LIQUID CHROMATOGRAPHY  
Liquid chromatography was performed on BioLogic DuoFlow (Bio-Rad) 
chromatography system. All solvents and samples were passed through 0.45 µm filters 
prior to use. All columns were purchased from Amersham Biosciences (GE Healthcare; 
UP, Sweden) or Bio-Rad (Regents Park, NSW, AUS). The elution of proteins was 
monitored by absorbance at 280 nm and fractions containing the target protein were 
collected. Purified proteins were stored at 4 ˚C or snap-frozen in liquid nitrogen and 
stored at -20 ˚C.  
Size-exclusion chromatography 
Combined elution fractions from the GST-affinity purification of LMO-LDB1 
(Section 2.3.3) were concentrated using Vivaspin centrifugal filters (GE Healthcare; 
Piscataway, NJ, USA). Filters were chosen with a molecular weight cut off at least 
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3  smaller than the protein size. Protein samples were applied to a HiLoad Superdex 75 
16/60 size-exclusion column running in 20 mM Tris (pH 8), 150 mM NaCl, 1 mM DTT 
at a rate of 1.0 mL min
-1
.  
Cation-exchange chromatography 
Combined elution fractions of Gata1–3NF or Gata1CF (Section 2.3.3) were applied to a 
UnoS cation-exchange column. The column was run in 50 mM Tris, 1 mM DTT (pH 7.5 
for Gata1–3NF and 9 .0 for Gata1CF) at a flow rate of 1.5 mL min
-1
. Protein was eluted 
using a NaCl gradient of 50 mM–1 M (run over ~ 20 mL). 
2.5 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS 
(SDS-PAGE) 
Precast NuPAGE Bis-Tris 4–12% gels (Invitrogen) run in X-cell Surelock cells were 
used for SDS-PAGE. All samples were combined with loading buffer (Invitrogen; Mt. 
Waverly, VIC, AUS) and fresh reducing agent, then heated at ~85 ˚C for 5 min prior to 
loading (with the exception of samples containing high levels of imidazole). Mark12 (GE 
Healthcare; UP, Sweden) protein molecular weight standards (~12 µL) were run on all 
gels except those for western blotting analysis.  
Gels were submerged in NuPAGE MES running buffer (Invitrogen) and subjected to 
electrophoresis at 175 V until the dye-front had migrated nearing the bottom of the gel 
(~40 min). Gels were fixed in fixing solution (3% (v/v) methanol, 10% (v/v) acetic acid) 
for 10 min, stained (0.125% (w/v) Coomassie BB-R, 40% (v/v) methanol, 7% (v/v) acetic 
acid) for ~1 h and destained in fixing solution.  
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2.6 SPECTROPHOTOMETRIC DETERMINATION OF SAMPLE  
CONCENTRATION 
Protein and DNA sample concentrations were determined via UV-spectrophotometry 
conducted on a Nanodrop ND-1000 spectrophometer (Thermo Scientific; Wilmington, 
DE, USA). Concentrations of plasmid DNA were determined by absorbance readings at 
260 nm (A260nm) and the assumption that a concentration of 50 µg mL
-1
 gave an 
A260nm = 1.0.  Concentrations of proteins were determined using the Beer-Lambert 
equation (Equation 2.2) and the extinction coefficients at 280 nm (Table 2.5). 
 
In the case of E12 and E47, where proteins do not have significant absorbance at 280 nm, 
samples of protein in complex with HIS-Tal1 or HIS-Lyl1 were measured with the 
assumption of a 1:1 stoichiometry based on the absorbance of the partner protein. 
  
  
              (Equation 2.2) 
Where Aλ  is the sample asorbance at wavelength λ, ελ is the molar extinction 
coefficient (M-1 cm-1), c  is the concentration of the sample (M) and l  is the path 
length (m) Absorbance’s of protein samples were measured at 280 nm.  See Table 
2.5 for specific extinction coefficients. 
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Table 2.5 Extinction coefficients. Estimated using ProtParam
130
 or in 
the case of Tal1, determined experimentally
71,131
. 
Protein construct Tag ε280 (M
-1 cm-1) 
  Pre-cleavage Final product 
LMO1-LDB1  GST 37360 14440 
LMO2-LDB1 GST 47330 24410 
LMO3-LDB1 GST 37360 14440 
LMO4-LDB1 GST 42860 19940 
Tal1 HIS - 17600 
E12/E47 - - 0 
Lyl1 HIS 6990  
Lyl1(1)-(4) GST 49850 6990 
Tal1-K3 HIS - 17600 
E47-E3 - - 0 
Gata1–3NF GST 51340 8480 
Gata1CF - - 6990 
    
2.7 GST-PULLDOWN ASSAYS 
2.7.1 Production of bait proteins 
GST-fusion bait proteins were produced from small scale (200 mL) cultures of 
BL21(DE3) cells, grown as described in Section 2.3.1. Lysis and application to affinity 
resin was performed as described in Section 2.3 with the exception of buffer composition 
(Table 2.6), and GST-only bait protein used for negative controls was incubated with 
resin for a shorter time (~5 min). Estimates of the relative amounts of GST-fusion bait 
proteins were obtained from running bead samples on SDS-PAGE.  
2.7.2 Production of prey proteins and the GST-pulldown assay 
Cultures containing HIS-fusion prey protein complexes were expressed from small scale 
(200 mL) cultures and lysed as described in Section 2.3 with the exception of buffer 
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composition (Tabl1 2.6) and without the incubation step. Immobilised GST-fusion 
(~10 µg) was added to 100 µL of pulldown buffer (Table 2.6) and 1 mL of HIS-fusion 
soluble lysate. The samples were incubated with rotation at 4 ˚C for ~2 h. The beads were 
allowed to settle by gravity and the supernatant removed. The beads were washed with 
5  1-mL of pulldown wash buffer (Table 2.6), resuspended in 0.5 mL pulldown wash 
buffer and transferred to MicroSpin™ columns (Amersham), where buffer was removed 
by centrifugation (6000  g, 1 min). Beads in columns were incubated with 30 µL 
1  SDS-PAGE loading buffer at 80 ˚C for 5 min. Samples were eluted with 
centrifugation (6000  g, 1 min) into fresh microfuge tubes and an additional 15 µL of 
4  SDS-PAGE loading buffer was added. Samples were loaded onto two SDS-PAGE 
gels with 5% input samples (HIS-fusion prey protein soluble lysate) for Coomassie 
staining (10 µL of sample with 12 µL Mark12 molecular weight standards) or western 
blotting (20 µL of sample with 10 µL of each Novex® Sharp Pre-stained protein standard 
(Invitrogen) and MagicMark™ XP western protein standard (Life Technologies; 
Carlsbad, CA, USA). 
Table 2.6 Pulldown Buffers 
Buffer Composition  
Bait lysis Buffer  
20 mM Tris (pH 8.0), 150 mM NaCl, 0.5 mM β-mercaptoethanol, 
2 mM PMSF 
Bait wash buffer 
50 mM Tris (pH 8.0), 50 mM NaCl, 0.5% (v/v) IGEPAL, 0.5 mM 
β-mercaptoethanol 
Prey lysis buffer 
20 mM Tris (pH 8.0), 150 mM NaCl, 0.5 mM β-mercaptoethanol, 
2 mM PMSF 
Pulldown buffer 
20 mM Tris (pH 8.0), 250 mM NaCl, 0.5% (v/v) IGEPAL, 10% (v/v) 
glycerol, 0.5 mM β-mercaptoethanol 
Pulldown wash buffer 
50 mM Tris (pH 7.5), 50 mM NaCl, 0.5% (v/v) IGEPAL, 0.5 mM 
β-mercaptoethanol 
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2.7.3 Western-blot analysis 
Proteins that had been separated during electrophoresis in tris/glycine gels (15%) were 
transferred to BioTrace™ NT nitrocellulose transfer membrane (0.45 µm) (PALL 
Gelman) using Hoefer TE 22 Mighty Small Transphor system (Amersham Biosciences) 
at 30 V in transfer buffer (Table 2.7) for 1 h at ~25 ˚C.  
All following steps were conducted at room temperature and all solutions were made up 
in PBS-T buffer (Table 2.7). Extensive washing (3  5 min in 10 mL) with PBS-T was 
carried out between each step. After transfer, the membrane was blocked in 10% (v/v) 
skim milk powder for 1 h. After wash steps the membrane was exposed to mouse-derived 
monoclonal α-HIS antibody (GE Healthcare) (1:3000) for 1 h followed by α-Mouse-HRP 
antibody conjugate (1:1000) for 0.5 h. 
Images were developed using Renaissance® Western Blot Chemiluminescence Reagent 
Plus kit on Kodak diagnostic X-omat™ film or on a C-Digit Chemiluminescent Western 
Blot Scanner (LI-COR Biosciences; Lincoln NE, USA). 
Table 2.7 Western-blot Buffers 
Buffer Composition  
Transfer buffer  1  MES running buffer (Invitrogen), 20% (v/v) methanol 
PBS-T 
85 mM NaCl, 2.5 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.1% (v/v) 
Tween, pH 7.4 
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2.8 BASIC PROTEIN CHARACTERISATION 
2.8.1 Size-exclusion chromatography and multi-angle laser-light 
scattering (SEC/MALLS) 
Experiments were performed on an ÄKTA Basic chromatography system (Amersham 
Biosciences; Uppsala, Sweden). All buffers and samples were filtered using 0.45 µm 
filter. Chromatography was conducted on a Superose™ 12 10/30 column (Amersham 
Biosciences) at a flow rate of 0.6 mL min
-1
 in 20 mM Tris (pH 8.0), 150 mM NaCl, and 
1 mM DTT. Eluting species were monitored at 280 nm and 215 nm. 
Light-scattering data were collected on an inline miniDawn Tristar laser-light scattering 
detector with a 690 nm laser-light source and detector angles of 41.5˚, 90.0˚ and 138.5˚ 
(Wyatt Technology Corp; Santa Barbara, CA, USA). Monomeric BSA (~1 mg) was used 
to normalise detector signals with respect to the signal received at 90˚. The 
concentrations of eluting species were determined using an inline Optilab DSP 
interferometric refractometer with a 690 nm light source. A refractive index increment 
(dn/dc) estimate of 0.190 mL g
-1
 was used for protein concentration determination
132
 and 
data analysed using Astra software (Wyatt Technology).  
2.8.2 Far-UV circular dichroism (CD) spectropolarimetry 
All protein samples were dialysed into circular dichroism (CD) buffer (20 mM Tris, 
150 mM NaF, 1 mM TCEP [tris(2-carboxyethyl)phosphine], pH 8) at 4 ˚C (~15 h) using 
SnakeSkin™ 3.5 kDa molecular weight cut-off dialysis tubing (Thermo Scientific). CD 
buffer was used to establish baselines. CD spectra were collected using protein 
concentrations of ~5 µM and were recorded in 1-mm path-length cells at 25 ˚C in a Jasco 
J-815 spectropolarimeter equipped with a peltier controlled sample holder that had been 
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calibrated with a CSA (camphor sulfonic acid) standard (0.6 g mL
-1
). CD spectra were 
collected over 180–260 nm, at a speed of 20nm min-1, with a step resolution of 0.5 nm, a 
bandwidth of 1 nm and a response time of 1 s. Final spectra were the average of three 
scans, and were baseline corrected and smoothed using nine-point adjacent averaging in 
Origin Version 6.0 (MicroCal; Northampton, MA, USA). Raw data were converted to 
mean residue ellipticity ([θ] deg cm2 dmol-1) using Equation 2.3. 
 
Estimates of secondary structure were made using the CDPro suite of programs
133
 using 
reference set 7 or a concentration independent method.134 
2.8.3 Nuclear magnetic resonance (NMR) spectroscopy 
Purified protein samples were dialysed into nuclear magnetic resonance (NMR) buffer 
(20 mM NaH2PO4/Na2HPO4 (pH 7.0), 50 mM NaCl and 1 mM DTT) with 5% (v/v) D2O 
and 2 µM DSS. One dimensional 
1
H NMR spectra were recorded at 25 ˚C on a 600 MHz 
Bruker DRX-600 spectrometer (Bruker BioSpin; Alexandria, NSW, AUS) equipped with 
a 5-mm triple resonance inverse probehead. Water suspension was achieved by 
pulsed-field gradients. Spectra were processed using XWINNMR (Bruker BioSpin) and 
referenced to 2,2-dimethylsilapentane-5-sulfonic acid (DSS). 
2.8.4 Thermofluor thermal denaturation assays 
A 7500 Fast Real-Time PCR System (Applied Biosystems; Mulgrave, VIC, AUS) was 
used for Thermofuor scans.
135
 Purified protein samples (~25 µL, ~0.6 mg mL
-1
) were 
         
    
    
 (Equation 2.3) 
Where M0  is the mean residue weight, θλ is the observed ellipticity (deg) at the 
wavelength λ, d  is the path length (cm), and c  is the concentration (g mL-1). 
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dialysed into 20 mM NaH2PO4 (pH 7.4), 150 mM NaCl and 1 mM DTT and combined 
with 15  SYPRO® Orange (Invitrogen). Samples were added to each well of a 
MicroAmp® Fast Optical 96-well reaction plate (Applied Biosystems) and thermal scans 
were performed at ~25 ˚C and at a rate of 2 ˚C min-1 from 20–95 ˚C with data points 
collected every 0.2 ˚C and SYPRO® Orange fluorescence monitored (λex = 465 nm, λem = 
610 nm).  Data were scaled to reflect the fraction of unfolded protein and Tm values 
determined at a 0.5 fraction of unfolded.  
2.9 CRYSTALLOGRAPHY 
Crystallisation trials for LMO1-LDB1 and LMO3-LDB1 constructs were carried out 
using commercially available sparse matrix screens. Initial screening was carried out with 
protein samples at starting concentrations of 10 mg mL
-1
 and 20 mg mL
-1
 in 96-well 
plates (Greiner Bio-One GmbH; Frickenhausen, Germany). NeXtal deep-well block 
(Qiagen; 75 µL of well solution) PACT and JCSG+ suites were used in sitting drop 
format, whereas AmSO4 MPD, Cations, PEGs and Classic suites were used in hanging 
drop format. A Mosquito
® 
liquid-handling robot (TTP Labtech Ltd.; Cambridge, UK) 
was used to set up drops comprising 200 nL of well solution mixed with 200 nL of 
protein sample. 
Manual screens were also set up in 24-well plate format (1.7  1.6 cm) (Linbro®, MP 
Biomedicals Inc.; Solon, OH, USA) using 500 µL of well solution. Samples were mixed 
1:1 with well solution (4 µL in total) and dropped onto siliconised glass covered slides 
(22 mm) (Hampton Research Corp.; Aliso Viejo, CA, USA) and sealed with Dow 
Corning vacuum grease (Dow Corning Corp.; Midland, MI, USA).  
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All crystal screens were incubated at ~18 ˚C and inspected for crystal formation weekly 
initially and less frequently (every couple of months) after ~3 months. Crystals were 
mounted on a MerResearch desktop beamline (MarResearch GmbH; Norderstedt, 
Germany), and checked for diffraction in-house using a Rigaku RU200H generator 
(Rigaku; The Woodlands, TX, USA) with a copper rotating anode target.  
2.10 MASS SPECTROMETRY  
2.10.1 Sample preparation  
In-gel tryptic digestion Bands were excised from SDS-PAGE gels run in fresh running 
buffer and stained with Coomassie blue stain. Bands were diced into small pieces and 
destained ( 3) by soaking in 25 mM ammonium bicarbonate in 50% acetonitrile 
(~100 µL) for 15 min at ~25 ˚C, followed by decanting of the buffer. Gel pieces were 
rinsed in 100% acetonitrile (~100 µL) and dried before incubation with trypsin 
(12 ng µL
-1
) for ~1 h at 4 ˚C to allow for re-hydration. Excess trypsin solution was 
removed and ammonium bicarbonate (25 mM) added for incubation at 37 ˚C ~15 h.  
Treatment of purified protein Protein (0.5 mg) was acidified by addition of formic acid 
(final concentration 2%) and loaded into SepPak tC18 columns (Waters; Rydalmere, 
NSW, AUS) activated in 90% acetonitrile, 0.1% formic acid and equilibrated in 0.1% 
formic acid. Eluted sample was lyophilised and dissolved in 100 µL of 2% formic acid 
and 50% acetonitrile. 
2.10.2 Spotting and mass spectrometry 
Samples (1 µL) were spotted on a MALDI (matrix assisted laser desorption ionisation) 
target plate with an equal volume of matrix solution (0.1% (v/v) trifluoroacetic acid, 
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70% (v/v) acetonitrile, saturated α-cyano-4-hydroxycinnamic acid) and fully dried before 
analysis by N. Shepherd (University of Sydney) in a Voyager DE STR MALDI-TOF 
(time-of-flight) Mass Spectrometer (Applied Biosystems).  
2.11 PREPARATION OF DOUBLE-STRANDED 
OLIGONUCLEOTIDES 
Single-stranded oligonucleotides (Appendix B) were purchased in an unlabelled form or 
with a 5’ 6-FAM (6-fluorescein amidite) modification (Integrated DNA Technologies). 
DNA was resuspended to a concentration of 100 µM in 20 mM Tris (pH 8.0), 150 mM 
NaCl, 1 mM DTT. Equimolar amounts of oligonucleotides were mixed and denatured by 
incubation at 92 ˚C for 15 min then allowed to anneal by cooling slowly (over ~15 h) to 
~25 ˚C. Double stranded DNA (dsDNA) oligonucleotides were purified using 
sixe-exclusion chromatography (Section 2.4) with elution of DNA monitored at 250 nm 
and 280 nm. Samples were stored at 4 ˚C 
2.12 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)  
2.12.1 Radiolabelled oligonucleotide probe preparation 
Unmodified dsDNA oligonucleotide (Section 2.11) (~100 ng) were 5’-end labelled with 
10 pmol [γ-32P] ATP (~3 µCi pmol-1) at 37 ˚C for 1 h with 10 U of T4 polynucleotide 
kinase in PNK buffer (70 mM Tris (pH 7.6), 10 mM MgCl2 and 5 mM DTT). Reactions 
were heated to 65 ˚C for 20 min and applied to MicroSpin™ columns (Amersham 
Biosciences) to remove unincorporated ATP, where flow through was removed and DNA 
eluted in elution buffer by centrifugation (6000  g, 1 min). Radiolabelled 
oligonucleotides were stored at -20 ˚C for no longer than 3 weeks.  
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2.12.2 Sample preparation and native-PAGE analysis 
Protein (0.02–20 µM) was mixed with 1  MSB (Table 2.8) containing 1 mM DTT and 
~33 µg mL
-1
 AcBSA. Radiolabelled (7 nM) or 6-FAM (6–100 nM) (Section 2.11) 
dsDNA oligonucleotide was added to each reaction mixture and 5 µL of anti-HIS 
monoclonal antibody was added where required. Samples were allowed to incubate on ice 
for ~30 min prior to being combined with EMSA loading dye (Table 2.8) and loaded onto 
180  160  1.5 mm 10% (w/v) non-denaturing polyacrylamide gels (19:1 
acrylamide:bis-acrylamide) made up in 1  TBE (Table 2.8). Gels were subjected to 
electrophoresis in 0.5  TBE at 16 mA for 2–3 h at ~25 ˚C. 
Table 2.8 EMSA buffers 
Buffer Composition  
MSB 10 mM HEPES (pH 7.9), 30 mM NaCl, 1 mM MgCl2, 1 mM EDTA 
TBE 50 mM Tris (pH 8.3), 90 mM boric acid, 2.5 mM EDTA 
 
2.12.3 Image analysis 
Phosphor image analysis Gels containing radiolabelled oligonucleotides were 
transferred to Whatman 3MM nitrocellulose membrane (GE Healthcare) and exposed to 
phosphorimage screens for ~15 h. Screens were scanned on a Typhoon FLA 7000 
Phosphorimager™ (GE Healthcare) and data analysed using ImageQuant™ 4.2 software 
(Molecular Dynamics).  
Fluorescence image analysis Gels containing 6-FAM labelled oligonucleotides were 
scanned immediately on a Typhoon FLA 7000 Phosphorimager™ (GE Healthcare) and 
data analysed using ImageQuant™ 4.2 software (Molecular Dynamics). 
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2.13 MICROSCALE THERMOPHORESIS (MST) 
Protein was generated by expression with a carboxy-terminal cyan fluorescence protein 
(CFP) tag or by labelling using a Monolith™ Protein Labelling Kit RED-NHS 
(NanoTemper Technologies GmbH; Munich, Germany) according to the manufacturer’s 
instructions. Oligonucleotides were prepared as in Section 2.11 with a 5’ 6-FAM 
modification on the leading strand. Serial dilutions of unlabelled protein were made 
(10 nM–1.5 mM) to give 12 samples. Dilutions were combined with labelled protein or 
DNA (50–100 nM) and loaded into capillaries.  
Assays were run on a Monolith NT.115 instrument (NanoTemper Technologies Gmbh) 
with MST power at 20% or 40% (infrared laser for heating, 1480 nm) and LED power at 
40–90% at ~25 ˚C or 18 ˚C. LED was set to blue (λex = 470 nm and λem = 520 nm) or 
Red (λex = 625 nm and λem = 680 nm) for samples using amine reactive labelling 
(RED-NHS).  
Relative fluorescence for each point of the titration was acquired using Monolith NT. 
Affinity Analysis software (NanoTemper Technologies GmbH). Normalised fluorescence 
was plotted as a function of protein concentration and data fitted to Equation 2.4 on the 
GraphPad Prism software. The reported KD for each experiment is the mean of 2 
experiments where data is available and errors are given as a range in the data, or as an 
error in fit when only one data set was collected. This information is provide for each 
data set. 
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In some cases comparison of binding curves is shown using fraction bound plotted as a 
function of protein concentration. Fraction bound for each point in the titration was 
calculated using Equation 2.5 and data fitted to Equation 2.6 on the GraphPad Prism 
software. 
 
2.14 ISOTHERMAL TITRATION CALORIMETRY 
2.14.1 General sample preparation 
Purified proteins and dsDNA oligonucleotides were dialysed overnight at 4 ˚C against 
several litres of corresponding isothermal titration calorimetry (ITC) buffer (Table 2.9) 
using SnakeSkin™ 3.5 kDa molecular weight cut-off tubing (Thermo Scientific) or 
CelluSep®H1 1 kDa cut-off dialysis membrane (Membrane Filtration Products, Inc.; 
        
         
  
  (Equation 2.5) 
Where Fbound is the fraction bound, Fnorm is the normalised fluorescence, M1 is the 
amplitude of the binding phase and t1 is the starting Fnorm.  
        
                     
  
 
 
(Equation 2.6) 
Where Fbound is the fraction bound, Fnorm is the normalised fluorescence,   is the 
concentration of the titrated binding partner, B is the concentration of the labelled binding 
partner, KD is the dissociation constant, M1 is the amplitude of the binding phase and t1 is 
the starting Fnorm.  
        
                     
  
        (Equation 2.4) 
Where Fnorm is the normalised fluorescence,    is the concentration of the titrated binding 
partner, B is the concentration of the labelled binding partner, KD is the dissociation 
constant, M1 is the amplitude of the binding phase and t1 is the starting Fnorm.  
CHAPTER TWO: MATERIALS AND METHODS 51 
 
Seguin, TX, USA). All samples were dialysed in the same reservoir and dialysis buffer 
from this reservoir used for dilutions and in control experiments.  
Table 2.9 ITC buffers 
Interaction Buffer composition  Temperature  
LMO-LDB1:Tal1-E12 
20 mM NaH2PO4 (pH 7.4), 150 mM NaCl and 1 mM 
DTT 
25 ˚C 
Gata1CF:DNA 20 mM Tris (pH 7.5), 150 mM NaCl and 1 mM DTT 18 ˚C 
 
2.14.2 ITC physical parameters  
All titration experiments were performed by injecting a high concentration sample 
(titrant) into a low concentration sample (titrand) using a MicroCal iTC200 isothermal 
titration calorimeter (MicroCal Inc.). The temperature (Table 2.9) was maintained as 
indicated and reference power set to 2 µcal s
-1
. Titrations consisted of a single 0.5 µL 
injection followed by injections of 2 µL at intervals of 4 s for ~20 injections. The data for 
the initial injection is discarded from fitting as it allows for small amounts of exchange 
across the tip of the injection syringe during equilibrium, although the amount of titrant is 
recorded and accounted for during curve fitting. Rapid mixing of the reactions was 
achieved by constant stirring of the cell. Changes in heat attributed to dilution of the 
titrant were measured by separate titrations of titrant into buffer and subtracted from 
experimental data. Data were analysed using the Origin 7.0 ITC data analysis software 
package (MicroCal Inc.) and a non-linear least-squares curve fitting algorithm was used 
to extract equilibrium association constants (KA), enthalpy of binding (ΔH), and 
stochiometric ratio (n). Changes in free-energy (ΔG) and entropy (ΔS) were determined 
indirectly using Equation 2.7.  
  
                      
(Equation 2.7) 
 C H A P T E R  T H R E E  
P R O D U C T I O N  O F  L M O - L D B 1 L I D  
F U S I O N  C O M P L E X E S  
3.1 INTRODUCTION 
The isolated LIM domains of LMO proteins tend to aggregate, often forming in inclusion 
bodies in bacteria. Protein engineering approaches have been employed to overcome 
these problems during recombinant LMO expression and purification. Fusion constructs 
have been generated in which LMO2 is tethered, by a flexible linker, to LDB1LID.
63,126,136
 
This technique was originally published in Deane et al. (2001),
136
 where the N-terminal 
LIM domains of LMO2 and LMO4 (LMO2LIM1 and LMO4LIM1) were each tethered to 
LDB1LID. Similar fusion constructs using both LIM domains of each protein 
(LMO2LIM1+LIM2 and LMO4LIM1+LIM2) and LDB1LID were generated and used to solve the 
structure of LMO2
126
 and LMO4,
127
 each in complex with LDB1LID, by X-ray 
crystallography. These fusion constructs are generically referred to as LMO-LDB1; 
however, in most cases the identity of the LMO protein in the construct is indicated as 
LMO2-LDB1, LMO4-LDB1, etc. 
Examination of the LMO2-LDB1 structure shows that LDB1 binds an extensive 
hydrophobic surface area on LMO2 (Figure 3.1). A similar phenomenon occurs for 
LMO4 and related LIM-homeodomain proteins in complex with LDB1LID (not shown). 
Exposure of this surface is a likely cause of aggregation associated with the production of 
isolated LMO proteins. That is, the LIM domains cluster in a non-specific way to bury 
hydrophobic surfaces. Binding to LDB1LID is thought to both provide stability through 
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the formation of extensive protein-protein interfaces, and minimise aggregation by 
burying hydrophobic surfaces (Figure 3.1B). 
Slightly different versions of LMO2-LDB1 and LMO4-LDB1 have been produced 
previously using this engineering approach. In this chapter modified versions of these 
constructs, as well as new LMO1-LDB1 and LMO3-LDB1 constructs were designed with 
consistent domain boundaries and tethers. The constructs generated were characterised 
using a range of biophysical and structural methods. 
 
 
Figure 3.1 Electrostatic potential map of LMO2-LDB1. A) LMO2 only and 
B) in complex with LDB1LID (magenta) from the LMO2-LDB1 structure (PDB 
accession code 2XJY; Omari et al. 2011). 
 
A 
B 
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3.2 DESIGN OF FUSION CONSTRUCTS 
Sequences for mouse proteins were selected for these new fusion constructs. Mus 
musculus and Homo sapiens have high sequence identity for LDB1 (100%) and 
LMOLIM1+LIM2 proteins (98–100%) (e.g. Figure 3.2). The roles of both mouse and human 
versions of LDB1 and LMO proteins, in their normal function
42,47
 and during 
oncogenesis,
22,137,138
 have been well studied. Both sequences have been independently 
used to solve the structures of LMO fusion constructs. Here we chose mice sequences as 
downstream biological studies will most likely be carried out in mouse models. 
 
For previous structural studies, constructs of the tandem LIM domains from LMO2 and 
LMO4 tethered to LDB1LID were designed to include flanking residues on either side.  
However, there has been some variation in the length of flanking regions from construct 
to construct. In particular, structures for some of the earlier constructs showed that a few 
residues in the non-native linker adjacent to the N-terminus of LDB1LID were structured, 
effectively extending the LIM-LID interface and suggesting that the native LID sequence 
should be longer. For example the constructs used to obtain the structure of LMO4-LDB1 
(1RUT and 2DFY) contains 1 or 2 residues, respectively, from the linker (Figure 3.3). 
Figure 3.2 Alignment of the recombinant construct region of LMO1. Sequence identity is indicated; 
identical (*), very similar (:) and slightly similar (.) residues. The alignment was made using Clustal W 
(Gasteiger et al. 2005). UniProtKB: Homo sapiens (Q924W9), Mus musculus (P25800). 
LMO1_Homo  GKQKGCAGCNRKIKDRYLLKALDKYWHEDCLKCACCDCRLGEVGSTLYTKANLILCRRDY 78 
LMO1_Mus   GKQKGCAGCNRKIKDRYLLKALDKYWHEDCLKCACCDCRLGEVGSTLYTKANLILCRRDY 79 
           ************************************************************ 
 
LMO1_Homo  LRLFGTTGNCAACSKLIPAFEMVMRARDNVYHLDCFACQLCNQRFCVGDKFFLKNNMILC 139 
LMO1_Mus   LRLFGTTGNCAACSKLIPAFEMVMRARDNVYHLDCFACQLCNQRFCVGDKFFLKNNMILC 139 
           ************************************************************ 
 
LMO1_Homo  QMDYEEGQLNGT 150 
LMO1_Mus   QVDYEEGHLNGT 151 
           *:*****:**** 
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Thus the length of LDB1 included in the design was extended from 336–366 to 331–375. 
Regions of LMO proteins used were also based on the structural data available and 
included equivalent regions of all four homologues for consistency between the different 
constructs (Figure 3.4). 
 
Figure 3.3 LMO4-LDB1 construct used for structure determination A) The construct is a fusion 
of the tandem LIM domains of LMO4 tethered to the LID domain of LDB1 via a flexible Gly/Ser 
linker. UniProtKB: LMO4 (P61969), LDB1 (P70662). B) The X-ray structure of this construct 
(1RUT). Red arrows indicate the residues from the Gly/Ser linker present in the structure. 
 
A 
B 
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3.3 RECOMBINANT FUSION CONSTRUCT PRODUCTION 
The protein sequences of the constructs designed (Appendix A.1) were reverse- translated 
into DNA sequences and optimised for expression in E. coli. These DNA sequences were 
obtained as synthetic genes from GENEWIZ, Inc.  
The genes were subcloned into the pGEX-2T vector allowing expression with an 
N-terminal GST-tag, as was used for previous LMO-LDB1 fusion constructs. The 
GST-tag was used to enhance soluble expression and enable GSH-affinity purification. A 
thrombin cleavage site between the tag and target protein facilitated subsequent removal 
of the GST-tag.  
All four LMO-LDB1 fusion constructs were expressed and purified using previously 
established protocols
136
. Figure 3.5 shows a sample of expression and purification for 
LMO1   ------MMVLDKEDGVPMLSVQPKGKQKGCAGCNRKIKDRYLLKALDKYWHEDCLKCACC 54 
LMO3   -----------------MLSVQPDTKPKGCAGCNRKIKDRYLLKALDKYWHEDCLKCACC 43 
LMO2   MSSAIERKSLDPSEEPVDEVLQIPPSLLTCGGCQQNIGDRYFLKAIDQYWHEDCLSCDLC 60 
LMO4   ------MVNPGSSSQPPPVTAG-SLSWKRCAGCGGKIADRFLLYAMDSYWHSRCLKCSCC 53 
                                .   *.**  :* **::* *:*.***. **.*  * 
 
LMO1   DCRLGEVGSTLYTKANLILCRRDYLRLFGTTGNCAACSKLIPAFEMVMRARDNVYHLDCF 114 
LMO3   DCRLGEVGSTLYTKANLILCRRDYLRLFGVTGNCAACSKLIPAFEMVMRAKDNVYHLDCF 103 
LMO2   GCRLGEVGRRLYYKLGRKLCRRDYLRLFGQDGLCASCDKRIRAYEMTMRVKDKVYHLECF 120 
LMO4   QAQLGDIGTSCYTKSGMILCRNDYIRLFGNSGACSACGQSIPASELVMRAQGNVYHLKCF 113 
        .:**::*   * * .  ***.**:****  * *::*.: * * *:.**.:.:****.** 
 
LMO1   ACQLCNQRFCVGDKFFLKNNMILCQVD-YEEGHLNGTFESQVQ---------- 156 
LMO3   ACQLCNQRFCVGDKFFLKNNMILCQTD-YEEGLMKEGYAPQVR---------- 145 
LMO2   KCAACQKHFCVGDRYLLINSDIVCEQDIYEWTKINGII--------------- 158 
LMO4   TCSTCRNRLVPGDRFHYINGSLFCEHD-RPTALINGHLNSLQSNPLLPDQKVC 165 
        *  *.:::  **::   *. :.*: *      ::     
 
Figure 3.4 Regions of LMO1–4 used in fusion design. Sequence identity is indicated; 
identical (*), very similar (:) and slightly similar (.) residues. The alignment was made using 
Clustal W (Gasteiger et al. 2005). UniProtKB: LMO1 (P25800), LMO2 (P25801), LMO3 
(Q8BZL8), LMO4 (P61969). 
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LMO2-LDB1. Similar data was obtained for all four constructs. SDS-PAGE analysis 
showed a band of the expected size (47 kDa) in the post-induction lane (Figure 3.5A).  
Following expression in E. coli, soluble fractions were bound to glutathione beads. To 
remove the GST-tag and allow elution of the fusion constructs, the immobilized proteins 
were incubated with thrombin. The elution samples were visualised using  SDS-PAGE, 
where a band migrating at the expected size of the cleaved fusion construct (~21 kDa) 
can be observed. These elution fractions were further purified by size-exclusion 
chromatography (Figure 3.5B). 
 
A 
B 
Figure 3.5 Purification of LMO2-LDB1 A) SDS-PAGE of overexpression and purification 
samples of GST-tagged LMO2-LDB1 fusion constructs; pre- and post-induction, soluble 
fraction, beads after binding, elutions 1–3 following cleavage from GST by thrombin, and size 
exclusion chromatography fractions that correspond to peak fractions in B) Size-exclusion 
chromatography elution profile. C) SDS-PAGE analysis of purified LMO-LDB1 fusion 
constructs. 
 
C 
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The size-exclusion chromatography elution profile contains four peaks. Analysis by 
SDS-PAGE shows that each peak contains the target protein. The early eluting fraction 7, 
in the void volume, (orange asterisk, Figure 3.5) probably contains aggregated fusion 
protein and contaminating proteins. The broad peak, around fraction 18 (red asterisk, 
Figure 3.5), may contain misfolded and/or small oligomeric forms of the target protein. 
The small peak, around fraction 61 (purple asterisk, Figure 3.5), may contain protein that 
has interacted with the column. The main peak, around fraction 32 (green asterisk, Figure 
3.5) was assumed to contain purified monomeric protein. The fractions within this main 
peak were combined and concentrated for further characterisation.  
3.4 CHARACTERISATION OF LMO-LDB1 FUSION 
CONSTRUCTS 
3.4.1 Size exclusion chromatography and multi-angle laser-light 
scattering  
To assess the oligomeric state and polydispersity of each of the new LMO-LDB1 fusion 
constructs in solution, samples were subjected to analytical size-exclusion 
chromatography (SEC) monitored by multi-angle laser-light scattering (MALLS). As the 
elongated shape of the fusion constructs would make their weight difficult to determine 
using sizing chromatography alone, MALLS was used to estimate solution molecular 
weights independent of shape and determine the oligomeric states present in solution by 
comparison to theoretical sizes.
132
 MALLS uses Rayleigh scattering to generate an 
estimate of the weight averaged molar mass of the species in the sample at the time of 
detection; the value calculated using this approach is generally considered to lie within 
~10% of the true value. This is checked by running monomeric BSA as a standard. 
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All the proteins eluted from the SEC column in two or three peaks (Figure 3.6), and 
estimates of molecular mass and oligomeric state were made for each peak. In each case, 
the smallest molecular weight species was the main peak. For LMO2-LDB1 and 
LMO4-LDB1, these clearly corresponded to monomers (Figure 3.7E). However, the 
estimates for LMO1-LDB1 and LMO3-LDB1 were higher than monomeric weights, 
which is most likely due to overlap with higher molecular weight peaks. Indeed, the 
calculated molecular weight slants up to the left, resulting in an overestimation of the 
monomer mass (Figure 3.6). The higher molecular weight peaks most likely correspond 
to dimers (all four proteins) and tetramers (only estimated for LMO1-LDB1 and 
LMO3-LDB1), although it is noted that the molecular weight estimates for these vary – 
again most likely because of overlap of peaks containing different molecular weight 
species.  
 
 
Figure 3.6 Initial SEC/MALLS of LMO-LDB1. Protein concentration in refractive index units (solid line) 
and the calculated molecular weights (·) of monomeric peaks for BSA and all four LMO-LDB1 fusion 
constructs. 
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Figure 3.7 SEC/MALLS analysis of LMO-LDB1 fusion constructs (initial injection). Protein 
concentration in refractive index units (solid line) and the calculated molecular weights (·) of monomeric, 
dimeric and tetrameric peaks for A) LMO1-LDB1, B) LMO2-LDB1, C) LMO3-LDB1 and D) 
LMO4-LDB1. E) MALLS data showing the theroretical molecular weight and the calculated experimental 
weight-averaged molecular weight of monomeric, dimeric and tetrameric species from A–D. 
 
 theoretical MALLS  MW (kDa)  
 MW (kDa) monomer dimer tetramer 
∎BSA 66.5 65.9   
∎LMO1-LDB1 20.7 28.9 52.9 100.7 
∎LMO2-LDB1 21.1 22.9 49.3  
∎LMO3-LDB1 20.8 26.6 48.4 82.0 
∎LMO4-LDB1 20.3 18.1 48.4  
 
A 
C 
E 
D 
B 
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A previous study has shown that LMO2-LDB1 behaves as a monomer in solution.
126
  In 
contrast, data for all four proteins here showed the presence of multiple oligomeric states. 
In order to test whether or not these multimers were purification artefacts or if the 
proteins were in exchange between monomeric, dimeric and tetrameric states, the 
samples from the monomeric peak were reinjected into the SEC/MALLS system 
(Figure 3.8) for analysis. In all cases the injected sample eluted as one major peak with 
molecular weights corresponding to monomers and estimates of polydispersity indicated 
that all proteins were still solely monomeric.  
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Notably, in the absence of contaminating dimeric species, the weight average molecular 
weights calculated for the reinjected samples were closer to the theoretical values 
(Figure 3.8B). Although a mixture of oligomeric species was present, analytical SEC was 
used to get a homogenous sample of monomeric protein (Figure 3.9). This indicates that 
dimeric and tetrameric species were artefacts of purification and that the proteins exist as 
monomeric species once fully purified. However, it was observed that although 
Figure 3.8 SEC/MALLS analysis of LMO-LDB1 monomeric peaks. A) Protein concentration in 
refractive index units (solid line) and the calculated molecular weight (·) of BSA and reinjected 
samples for all four LMO-LDB1 fusion constructs. B) MALLS data from A, showing the theoretical 
molecular weight, the calculated experimental averaged molecular weight and polydispersity of 
monomeric peaks. 
 
 theoretical MALLS 
 MW (kDa) MW (kDa) polydispersity 
∎BSA 66.5 65.9   
∎LMO1-LDB1 20.7 27.2 1.002 
∎LMO2-LDB1 21.1 21.1 1.001 
∎LMO3-LDB1 20.8 23.0 1.002 
∎LMO4-LDB1 20.3 21.8 1.000 
 
A 
B 
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reinjection of a fraction did not increase polydispersity, protein concentration via 
centrifugation did increase polydispersity (not shown). Unfortunately, based on the 
experience of others in the laboratory, this can be a common feature of concentration for 
many different proteins. 
 
3.4.2 Far-UV circular dichroism spectropolarimetry  
To determine if the fusion proteins were folded and contained equivalent levels of each 
type of secondary structure, they were subjected to far-UV circular dichroism (CD) 
spectropolarimetry. All of the proteins show spectra that are essentially identical and 
characteristic of LIM-LDB1 tethered complexes (Figure 3.10A) with a minimum at 
~205 nm and a shoulder at ~220 nm.
136
 
Estimates of secondary structure deconvolution were determined using the CDPro 
suite,
133
 which compares experimental data with spectra of proteins with known 
structures (Figure 3.10B). As this method is very sensitive to protein concentration, and 
Figure 3.9 SDS-PAGE of SEC/MALLS samples. Initial input 
and elution fractions from monomeric and dimeric peaks of 
LMO-LDB1 fusion constructs. 
CHAPTER THREE: PRODUCTION OF LMO-LDB1 FUSION 
CONSTRUCTS  64 
 
experience in the laboratory has shown that accurate concentration estimates of proteins 
are difficult to obtain, particularly in the presence of reducing agents, a concentration 
independent method was used (Figure 3.11). In this method data is normalized to the 
ellipticity at 207 nm and normalized ellipticity at 193 nm, 196 nm, 211 nm and 234 nm, 
are used to determine secondary structure content.
134
 The methods report slightly 
different values of secondary structure; however, both methods indicate a similar relative 
composition for each protein. As might be expected from the similarity of the spectra, the 
estimated levels of secondary structure are consistent across the set of proteins with 
moderate levels of helical, sheet and turn structure, and high levels of random coil 
structure, indicating the family having a common structure. This data is consistent with 
previous estimates for LIM-LDB1 fusion constructs.
136
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Figure 3.10 Far-UV CD of LMO-LDB1 fusion constructs. A) CD spectra for LMO-LDB1 
fusion constructs. Data were recorded at ~11 µM (20 mM Tris [pH 8.0], 150 mM NaF, 1 mM 
DTT) at 20 ˚C and are the sum of 3 scans that were buffer baseline corrected and smoothed using 
9 point adjacent averaging. B) Secondary structure deconvolution was determined using the 
CDPro suite given as percentages and determined as described in Section 2.8.2.
133
  
 
A 
B  helix sheet turn coil 
LMO1-LDB1 6 ± 6 30 ± 2 15 ± 5 48 ± 8 
LMO2-LDB1 11 ± 5 28 ± 4 16 ± 1 45 ± 14 
LMO3-LDB1 8 ± 2 32 ± 4 16 ± 1 45 ± 7 
LMO4-LDB1 7 ± 2 26 ± 1 16 ± 1 52 ± 3 
 
A 
B  helix sheet turn coil 
LMO1-LDB1 19  22 13 38 
LMO2-LDB1 33  15  13  35 
LMO3-LDB1 21 21 13  38 
LMO4-LDB1 14  25 13 39  
 
Figure 3.11 Normalised far-UV CD of LMO-LDB1 fusion constructs. A) CD spectra for 
LMO-LDB1 fusion constructs. Following buffer baseline correction and smoothing data was 
normalised to the MRE at 207 nm. B) Secondary structure deconvolution was determined using 
the Raussens’ analysis. Data was given as percentages and determined as described in 
Section 2.8.2.
134
 The error of this deconvolution approach is ~10%. 
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3.4.3 1D 
1
H NMR spectroscopy 
One dimensional 
1
H NMR spectra were recorded for all four LMO-LDB1 fusion 
constructs (Figure 3.12). The signals of all four spectra were very similar. The peaks are 
all well-dispersed, and are reasonably sharp for ~20 kDa proteins with an expected 
elongated structure. These features indicate the samples have a well packed tertiary 
structure. This in combination with MALLS and CD data indicate that all LMO-LDB1 
fusion constructs are greater than ~75% monomeric and folded.  
 
 
  
Figure 3.12 1D 
1
H NMR spectra of LMO-LDB1 fusion constructs. Showing the aliphatic region    
(~0–3 ppm) and the amide region (~5–10 ppm). The spectra were recorded at a concentration of ~100 µM  
in 20 mM phosphate (pH 7.0), 50 mM NaCl, 1 mM DTT, 5% (v/v) D2O 200 µM DSS,  and at 600 MHz. 
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3.5 COMPARISON OF FUSION DESIGN 
In order to further assess the physical characteristics of these newly designed 
LMO-LDB1 fusion constructs (Section 3.3), they were compared with an older 
LMO2-LDB1 fusion construct that was previously characterized in the laboratory. The 
portion of the LIM domain of LMO2 used in the older version of the fusion spanned 
residues 27–156, compared with 25–156 in the newer construct, and the LID domain of 
LDB1 spanned residues 336–366 compared with 331–375 in the newer designs 
(Figure 3.13).  
 
It was hoped that inclusion of additional residues that would contribute to structure might 
increase stability of the fusion construct. Both versions of the LMO2-LDB1 fusion were 
expressed and purified. At the level of expression and solubility, there were no significant 
differences between the two variants. However, an interesting difference was observed 
during purification. After the LMO2-LDB1 constructs were eluted from the GSH beads, 
following treatment with thrombin to remove the GST-tag, the samples were subjected to 
size-exclusion chromatography, during which a difference in oligomeric state could be 
observed (Figure 3.14B). The new version eluted mostly in one peak at ~75 mL, which 
Figure 3.13 Schematic of LMO2 and LDB1 regions used in old vs. new fusion constructs. UniProtKB: LMO2 
(P25801), LDB1 (P70662).  
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was previously determined to be monomeric (Section 3.3.2), with smaller amounts of 
protein eluting earlier, whereas for the older version a monomeric peak could still be 
observed at ~75 mL at a much smaller proportion of the overall protein.  
Analysis by SDS-PAGE indicates the earlier fractions for the new version contain 
contaminants and the later middle fractions contain small amounts of dimeric and/or 
higher order oligomers of the same protein (Figure 3.14A). The older version contained 
more contaminants by SDS-PAGE (Figure 3.14A, lane 2 vs. 4) and probably a large 
aggregate of the target protein in the early eluting peaks. Thus, the overall yields of the 
monomeric recombinant protein appear to be higher for the newly designed fusion 
construct. This indicates that the designed mutations did as they were theorised and 
increased stability of the constructs. 
 
Figure 3.14 Purification of old and new LMO2-LDB1 fusion constructs. A) SDS-PAGE of 
size-exclusion chromatography fractions of the old (LMO227–156LDB1336–366) and the new (LMO225–
156LDB1331–375) recombinant LMO2 fusion constructs.  Fractions correspond to peaks from the B) 
size-exclusion chromatography elution profile. 
 
A B 
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3.6 STRUCTURAL EVALUATION 
3.6.1 Crystallisation trials  
Structures of both LMO2 and LMO4 bound to LDB1LID have been solved using X-ray 
crystallography (see Chapter 1.4.1), but no similar structures exist for LMO1 and LMO3. 
Attempts were made to crystallise LMO1-LDB1 and LMO3-LDB1 for structure 
determination by X-ray crystallography.  
Initial screening of LMO1-LDB1 and LMO3-LDB1 (~10 mg mL
-1
) was carried out using 
commercial sparse-matrix crystallisation screens (Section 2.9). During set up using a 
Mosquito liquid-handling robot to dispense hanging drops for JCSG+ and PACT suites, 
the protein samples were sticking to the tips and not dispensing properly. This was 
thought to be due to high levels of unfolded protein creating a highly hydrophobic 
solution. These first screens did not produce any crystals, however, it was noted (data not 
shown) that the LMO1-LDB1 screens gave more promising results (increased levels of 
sperolytes) and therefore subsequent screening was restricted to LMO1-LDB1. 
The next round of screens of LMO1-LDB1 (10–20 mg mL-1) was carried out with the 
JCSG+, Classics, AmSO4 and PACT suites, in both hanging and sitting drop 
vapour-diffusion methods. These are conditions which have historically worked for 
similar proteins.
61
 The trays were incubated at room temperature and monitored for the 
appearance of crystals.  
Summaries of the first-round of trials are detailed in Table 3.1. Within a few days a small 
(~25 x 25 µm) plate crystal cluster (Figure 3.15A) and an amorphous crystal (not shown) 
appeared from the AmSO4 screen. The amorphous crystal was too small to be checked for 
diffraction but was considered to be less promising for structure determination, and the 
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plate crystal disintegrated during handling for diffraction testing. Although the crystals 
could not be checked for diffraction, the fragility of the plate crystal indicated that it was 
more likely to be protein than a salt crystal, which tend to be robust. 
Optimisation of crystal growth was carried out around the two conditions that produced 
crystals in the AmSO4 suite (conditions E2 and G12, Table 3.1). Here, LMO1-LDB1 
(10 mg mL
-1
) was tested in fractional screens that contained either 0.1 M MES (pH 6.3–
6.7) or 0.1 M citric acid (pH 4.8–5.2) with varying concentrations of ammonium sulfate 
(0.6–2.2 M). This screen used a 24-well plate format with hanging drops made from 
manually mixing (1:1) sample and reservoir solutions to a total volume of 2 µL. 
Unfortunately, these optimisation screens resulted in only one amorphous crystal that did 
not diffract in-house. 
The first-round trials were re-checked 12 months after being set up (Table 3.1) and 
crystals were found in three conditions (Figure 3.15) from the JCSG+ suite. A brick 
crystal (~200 µm) was found in condition D7. However, there were similar looking 
crystals in the reservoir, and the crystal gave salt-like patterns of diffraction.  
For each reservoir solution there were two protein drops (made with 10 mg mL
-1
 and 
20 mg mL
-1
 protein). Condition F12 produced crystals in each drop. The 10 mg mL
-1
 
drop held a plate crystal (~200 x 150 µm) whereas the 20 mg mL
-1
 drop held a crystal 
cluster. The plate crystal did not diffract, while the crystal cluster gave salt-like 
diffraction patterns.  
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Table 3.1 Summary of first-round crystal screens of LMO1-LDB1. LMO1-LDB1 at 10 mgmL
-1
  for all 
screens and 20 mg mL
-1
 for sitting drop screens in 20 mM Tris pH 8.0, 150 mM NaCl, 1 mM DTT. 
Suite Drop Result Diffraction 
PACT Sitting No crystal was observed  
JCSG+ Sitting After 12 months crystals formed in drops F12 and D7 
D7 =  0.2 M lithium sulfate, 0.1 M Tris pH 8.5, 40 % (v/v) PEG 400 
F12 = 0.1 M HEPES pH 7.0, Jeffamine M-600  
10 mg mL-1 
20 mg mL-1  
 
 
Salt 
 
No diffraction 
Salt 
AmSO4 Hanging In three days very small crystals formed in drops E2 and G12 
E2 = 0.1 M citric acid pH 5.0, 0.8 M AmSO4  
G12 = 0.1 M MES pH 7.5, 1.8 M AmSO4 (no picture) 
Not 
checked 
Classic Hanging No crystal was observed  
 
 
Three more commercial sparse-matrix crystallisation screens were trialled with 
10 mg mL
-1
 LMO1-LDB1: Anions, Cations and PEGs, all in hanging drop format. The 
PEGs suite was included as crystals used for structure determination of LMO2-LDB1 
(PDB: 2XJY) were formed in the presence of PEG. In addition, the JCSG+ was screened 
a second time; however, this time in hanging drop rather than sitting drop format.  
Figure 3.15 Crystals from first-round screens of LMO1-LDB1. A) Plate crystal cluster formed in 
drop E2 from the AmSO4 suite B) Brick crystal formed in D7 drop from the JCSG+ suite. C) Plate 
crystals from the JCSG+ suite drop F12 using protein at 10 mg mL
-1
. D) Crystal cluster from the JCSG+ 
suite drop F12 using protein at 20 mg mL
-1
. White bar is 50 µm. 
C D A B 
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Summaries of this round of screening are detailed in Table 3.2. Crystals were generated 
from the JCSG+, Anions and Cations suites, and were checked for diffraction. Crystal 
plates found in the JCSG+ suite (Figure 3.16A) and numerous cuboid crystals 
(Figure 3.16C) from the Cations suite gave rise to salt-like diffraction patterns. The most 
promising result came from micro-crystals found in the Anions suite (Figure 3.16B). 
These crystals gave rise to an ice ring in the diffraction pattern (not shown), indicating 
poor cryo-protection, but did not give salt-like diffraction patterns, indicating they were 
potentially protein and worth pursuing further.  
Table 3.2 Summary of second-round crystal screens of LMO1-LDB1. LMO1-LDB1 at 10 mg mL
-1
 in 
20 mM Tris pH 8.0, 150 mM NaCl, 1 mM DTT. 
Suite Drop Result Diffraction 
PEGs Hanging Crystals formed in drop B9 (no picture)  
JCSG+ Hanging Crystals formed in drop C8 
C8 =  0.1 M Tris pH 8.5, 20 % (v/v) Ethanol  
 
Salt 
 
Anions Hanging Crystal formed in drop A8 
A8 = 0.1 M MES pH6.5, 1.25 M Sodium acetate 
No 
diffraction 
Cations Hanging Crystals formed in drops A5 and A6  
A5 = 0.1 M Sodium acetate pH 4.6, 1.55 M Magnesium chloride 
A6 = 0.1 M Sodium acetate pH 4.6, 0.75 M Magnesium chloride 
 
Salt 
Salt 
 
 
Figure 3.16. Crystals from second-round screens of LMO1-LDB1. A) Plate crystals formed in 
drop C8 from the JCSG+ suite.  B) Micro-crystals formed in A8 drop from the Anions suite. C) 
Cuboid crystal formed in drop A6 from the Cations suite. White bar is 50 µm. 
C A B 
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3.7 DISCUSSION 
In order to produce stable recombinant versions of LMO1-4 for interaction studies and 
structural analysis, fusion constructs of each LMO protein with the LIM-interacting 
domain (LID) of LDB1 were engineered. Similar fusion constructs of LMO2 and LMO4 
members had been previously engineered for structure determination; however, that 
structural data indicated potential improvements to design. The portion of the LDB1 used 
in the fusion constructs was extended to include residues from the N-terminus of LID that 
were likely to be structured in the LIM-LID complexes. Data suggests that this extension 
improved monomeric stability and decreased the potential for aggregation.  
Based on comparison of LMO2-LDB1 constructs it appears that these newly designed 
LMO-LDB1 fusion constructs produce higher yields of monomeric protein compared to 
older versions. This could be due to reduced propensity for aggregation.  
Data in this chapter was able to show that all four LMO-family member fusion constructs 
designed were reasonably stable, folded, largely monomeric and structured. Sufficient 
amounts of protein were able to be generated for structural determination and biophysical 
experiments.  
Initial crystallisation screens did not yield good quality, diffracting crystals for either 
LMO1 or LMO3. From LMO1 crystallisation trials, however, there were a couple of 
conditions that produced crystals that are worth pursuing. The micro-crystals produced in 
the Anions suite (Figure 3.16B), despite not diffracting using the in-house X-ray source, 
were more likely to be protein than salt and therefore it could be worth screening around 
this condition [0.1 M MES pH6.5, 1.25 M sodium acetate]. 
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Table 3.3 lists the crystallisation conditions that were successful in structure 
determination of LMO2-LDB1 and LMO4-LDB1.  The presence of ammonium sulphate 
in two conditions is noteworthy. Interestingly, ammonium sulphate was in a condition for 
LMO1-LDB1 (Section 3.6.1) that produced a crystal, which was likely to contain protein. 
Although optimisation around this condition failed to replicate the crystal, it could be 
worth further pursuing this or similar conditions containing ammonium sulphate.  
The conditions used to crystallise LMO proteins for published structural determination 
used incubation temperatures of 23–25 ˚C, which are slightly higher than that used in the 
screens described in this chapter (18 ˚C). Optimisation of temperature could also be 
worth pursuing in future.  
Table 3.3 Summary of conditions used for the production of crystals in the structural determination 
of LMO1-LDB1 homologues. 
Homologue PDB Condition 
LMO4-LDB1 1RUT 1.0 M ammonium sulfate, 0.1 M MES, pH 6.7, vapor 
diffusion, hanging drop, 25 ˚C 
LMO4-LDB1 2DFY 1.0 M ammonium sulfate, 0.1 M Tris, 15 % glycerol, pH 8.5, 
vapor diffusion, hanging drop, 23 ˚C  
LMO2-LDB1 2XJZ 1.6 M NaCl, 100 mM MES pH 5.0, 1 mM DTT, 25 ˚C 
LMO2-LDB1 2XJY 25 % PEG 1500, 100 mM SPG, pH 4.0, 25 ˚C 
LMO2 = 2XJY/2XJZ and 2YPA (with Tal1E47 and DNA) 
LMO4 = 2DFY, 1RUT 
 
 
 C H A P T E R  F O U R  
L y l 1  P R O D U C T I O N  
4.1 INTRODUCTION  
4.1.1 bHLH proteins 
Basic helix loop helix (bHLH) proteins are involved in many developmental 
processes.
66,139
  The bHLH domain forms dimers that bind DNA at E-box sites.
67
 The 
dimers, which can be homo- or heterodimers, form a four-helix parallel bundle.
68
 Two 
homologous class II bHLH proteins, Tal1 and Lyl1, are implicated in T-ALL.
16,118,140
 It is 
thought that oncogenesis in developing T-cells arises when these proteins heterodimerise 
with class I bHLH proteins from the E2a gene, E12 or E47,
71
 and that this effect can be 
exacerbated by interactions with LMO proteins.
101,108,141,142
  Further details of the bHLH 
proteins were given in Chapter 1.  
Co-expression and purification of the bHLH domains of Tal1 and E2a proteins (E12 and 
E47) yield pure, stable protein in reasonable quantities
143
. In the expression protocol for 
these proteins, the pETDUET vector, which has two multiple cloning sites, is utilised to 
co-express Tal1 carrying an N-terminal HIS tag and untagged E12 or E47 (Figure 4.2A, 
sequences in Appendix A.2). Batch cation-exchange chromatography followed by 
Ni-NTA-affinity chromatography is then used to co-purify HIS-Tal1/E2a complexes. As 
Lyl1 is a homologue of Tal1 with 85 % identity in bHLH domain (Figure 4.1) it was 
assumed that similar expression and purification protocols could be used to generate 
Lyl1-E2a protein complexes. Unfortunately, as described in the following section, this 
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proves not to be the case. Thus, this chapter describes the more extensive work that was 
required to generate Lyl1 for further study. 
 
4.1.2 Lyl1 instability during overexpression and purification  
Initial attempts to purify HIS-Lyl1/E2a heterodimers, were carried out in parallel with 
HIS-Tal1/E2a heterodimers as part of an honours project.
143
 The successful co-expression 
of HIS-Tal1 and E12 was observed (Figure 4.2b). The appearance of bands at ~9 kDa and 
~7 kDa, in the post-induction sample, correspond to HIS-Tal1 and E12, (theoretical 
molecular weights of 8.9 kDa and 7.8 kDa, respectively). However, although 
co-expression of HIS-Lyl1 and E12 gave an intense E12 band (~7 kDa), the HIS-Lyl1 
band (theoretical molecular weight of 8.9 kDa) is much less intense than that observed for 
HIS-Tal1. This observation suggested that Lyl1 was not expressing as well, or was not as 
stable, as Tal1.  
Following cation-exchange chromatography, most contaminating proteins are purified 
away from the heterodimers (Figure 4.2C). Both sets of heterodimers eluted with 
reasonable purity at 600 mM NaCl, but the band representing HIS-Lyl1 was further 
decreased in intensity when compared to HIS-Tal1. This reduction in HIS-Lyl1 is even 
more pronounced after Ni-NTA-affinity chromatography (Figure 4.2D), where HIS-Lyl1 
Figure 4.1 bHLH domains of Tal1 and Lyl1. Alignment of the amino acid sequence of the bHLH 
domains of Tal1 and Lyl1. Sequences are from Mus musculus and their GenBank accession numbers 
are Tal1 (P22091) and Lyl1 (P27792). 
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was not evident in any of the fractions. Consequently, the E2a proteins, which do not 
contain a HIS-tag, were eluted during the wash steps.  
The low levels of HIS-Lyl1 during expression and its loss throughout purification was 
thought to be due to the instability of the protein construct and subsequent proteolytic 
degradation and/or non-specific binding of protein to surfaces following exposure of 
hydrophobic regions. Preliminary attempts to resolve this instability were made during 
my honours year by optimisation of expression conditions and utilisation of various 
tag-fusion constructs with no success.
143
 Attempts were made to improve expression 
levels and stability as part of this thesis by modifying the design of the constructs. 
 
A B 
Figure 4.2 bHLH heterodimer expression and purification. A) pETDUET vector with Tal1 
gene in MCSI and E12 in MCSII. B) The expression gel of Tal1 and E12 or Lyl1 and E12 
showing pre– and post–induction samples. Expression was performed in BL21(DE3) E. coli. at 
22 ˚C for ~15 h. C) Cation-exchange chromatography. E1–E4 fractions eluted with increasing 
concentrations of NaCl (150, 250, 375, 475, 600 mM, respectively) and E5–E9 are fractions 
eluted with 600 mM NaCl. D) Ni-NTA-affinity chromatography. E1–E4 fractions eluted with 
increasing imidazole concentrations (0–250 mM imidazole) and E5–E8 fractions eluted with 
250 mM imidazole. The asterisk (*) indicates lysozyme (14.4 kDa) added during lysis.
143
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4.2 IMPROVED EXPRESSION BY EXTENDING CONSTRUCT 
TERMINI 
4.2.1 Design of extension constructs 
It was possible that the Lyl1 constructs used initially might be too short. Indeed, based on 
structure prediction analysis, there is likely alpha helical content in region flanking the 
bHLH domain at its C-terminus (Figure 4.3A). Therefore, three new constructs were 
designed and cloned where the N-terminus, C-terminus, or both were extended by five 
residues (Figure 4.3B, Appendix A.2.2).144  
 
Figure 4.3 Lyl1 extension constructs. A) Structure prediction analysis of bHLH domain and flanking 
regions of Lyl1; random coil (purple strokes), extended strands (red strokes) and alpha helices (blue 
strokes). Structural prediction was performed using Network Protein Sequence Analysis
144
 B) 
Alignment of the amino acid sequence of the original and three new  constructs of the bHLH domain 
of Lyl1. These constructs are termed Lyl1(1)–(4).  Construct dimensions and bHLH regions indicated; 
basic (green fill), helix-loop-helix (yellow fill), original construct (1) 136–196, N-terminal extension 
from 131 and C-terminal extension to 201. 
 
B 
A 
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4.2.2 Expression trials  
Attempts were made to express all four Lyl1 constructs (the three new extension 
constructs, Lyl1(2)–(4), and the original, Lyl1(1)) with an N-terminal HIS-tag in a 
pRSET vector. In Figure 4.4 the overexpression of the positive control, HIS-Tal1, can be 
observed as an intense band in the post induction sample; however, for all Lyl1 
constructs, no equivalent overexpression band can be seen.  
These constructs were then cloned into pGEX-6P for expression with an N-terminal 
GST-tag. Overexpression trials of these proteins resulted in observable bands (~28 kDa) 
correspond to a size smaller than full length GST-tagged Lyl1 constructs (~34 kDa) in 
post induction samples for Lyl1(3)–(4), but not for Lyl1(1)–(2) ( Figure 4.5A). However, 
it should be noted that these were bigger than GST alone. 
To confirm the identity of these bands, a western blot using anti-GST antibodies as the 
primary antibody was carried out. The overexpression band did show up on the western 
blot. However, so did two other bands of lower molecular weight. As these bands are 
more prominent in samples where overexpression was observed, these bands likely 
correspond to truncation products of the tagged protein, including GST (26 kDa). Overall, 
however, these expression trials indicated that the two constructs with extended C-termini 
appear to exhibit higher levels of expression, suggesting that, as predicted (Figure 4.3), 
the structured component at the C-termini of the bHLH domain continues past that used 
in the original construct, Lyl1(1).  
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4.2.3 Purification trials  
GST-Lyl1(3) was selected for further expression and purification studies as it was the 
construct with the smallest extension that was still able to produce increased expression 
yields. Two methods of purification were trialled; GST-affinity purification and 
cation-exchange chromatography (Figure 4.5B). These were tested by binding the soluble 
fraction of GST-Lyl1(3) cell lysates to either reduced glutathione (GSH) or SP Sepharose 
resin. 
In the case of cation-exchange chromatography, there was no obvious enrichment of a 
target GST-Lyl1 protein; many proteins were retained on the resin following the wash 
step (Figure 4.5B). A band that may correspond to GST-Lyl1 comes off mostly in the 
flow-through fraction, not binding the resin at all. In contrast, two bands appear to be 
enriched on the GST-resin, although both run at a lower molecular weight than the 
putative fusion band from the soluble fraction. According to the size of the bands, these 
were predicted to be a GST-Lyl1(3) truncation and the GST-tag alone. 
Figure 4.4 SDS-PAGE analysis of small scale expression trials of HIS-Lyl1(1)–(4) in pRSET. 
The expression gel of extension constructs of Lyl1bHLH showing pre- and post-induction samples. 
Expression was performed in BL21(DE3) E. coli. at 22 ˚C for ~15 h.  
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An additional sample of the proteins immobilised on the GSH resin was further analysed 
by SDS-PAGE under conditions that would allow further separation of bands. In this 
analysis four bands are observed, running at molecular weights of ~32, ~28, ~26 and 
~23 kDa (Figure 4.6A). The bands were excised and subjected to sequence analysis by 
in-gel tryptic digestion and mass spectrometry (Figure 4.6B). This analysis suggests that 
these bands represent a series of C-terminal degradation products, and no full length Lyl1 
protein was obtained.  
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A B 
Figure 4.5 GST-Lyl1 extension construct trial expression and purification. A) The expression gel of 
GST-Lyl1(1)–(4) showing pre- and post-induction samples. Expression was performed in BL21(DE3) E. coli. at 
22 ˚C for ~15 h. Purified  GST was used as a control for size comparison. The gel was Coomassie-stained (top 
panel) and subjected to western blot using an antiGST antibody (bottom panel) B) Trial binding to GSH resin 
and Sepharose beads.  GST-affinity and cation exchange was performed in PBS (pH 7.0). Lysozyme was used 
during GST-affinity chromatography trials.  
Figure 4.6 Mass spectrometric analysis of protein bands from GST-affinity chromatography. A) 
SDS-PAGE of GSH resin following binding of bacterial cell lysate containing overexpressed Lyl1(3). The three 
bands indicated were subjected to in-gel tryptic digestion and mass spectrometry. B) The sequence of 
GST-Lyl1(3) showing tryptic peptides from mass spectrometry analysis. Predicted peptides are indicated and 
coloured according to the sample of the tryptic digested band in which they were observed. The thrombin 
cleavage site between the GST-tag and the Lyl1 construct is indicated with a magenta border.  The sequence is 
coloured by the minimum possible sequence for each band, according to mass spectrometry data. 
A B 
CHAPTER FOUR: Lyl1 PRODUCTION 83 
 
4.3 Lyl1 TO Tal1 POINT MUTANT TRIALS 
4.3.1 Mutant design 
Despite the high levels of sequence identity (and homology) in their bHLH domains 
(Figure 4.1), the apparent stability and subsequent yield of recombinant Tal1 were 
consistently higher than those of Lyl1. With few sequence differences in the bHLH 
domain, it was thought that one or several amino acid differences were responsible for the 
difference in stability during expression and purification.  
A series of point mutants, in which Lyl1 residues were changed to Tal1 residues, were 
generated and tested for increased stability. Five sites in the bHLH domain were chosen 
for mutation where Lyl1 contained an amino acid not conserved in Tal1 (Figure 4.7). 
 
Figure 4.7 Lyl1 point mutant design. A) Aligned sequence of the bHLH domains of Tal1 and Lyl1 showing 
flanking regions included in original constructs. Black dots indicate conserved sequence. Open circles indicate 
positions where Lyl1 was mutated to the native Tal1 sequence.  B) Homology model of Tal1-E12 on DNA. 
Residues of Tal1 (red) that are not conserved in Lyl1 are in spheres and those chosen for Lyl1 point mutants 
are lightened.  
A 
B 
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4.3.2 Trial expression and purification 
The co-expression of HIS-Lyl1/E12 from a pETDUET vector was compared with that of 
HIS-Tal1/E12 as a preliminary assessment of stability of the Lyl1 mutants. It should be 
noted that preliminary studies (data not shown) indicated no significant difference 
between Lyl co-expressed with E12 and its splice variant E47, therefore E12 was chosen 
for further exploration for simplicity. These two splice varients have high levels of 
sequence identity in their bHLH region (Appendix A.2.6). Expression levels were 
assessed by SDS-PAGE (data not shown), which suggested that the V57I and R73N 
mutants had no improved expression compared to wild type Lyl1/E12, but H31N, L43I 
and G66N all showed modest improvement in expression levels, albeit still less than seen 
for Tal1/E12.   
All five mutants were purified using the protocol previously established for Tal1/E12— 
cation-exchange chromatography followed by Ni-NTA-affinity chromatography. Note 
that it was during Ni-NTA affinity chromatography that most losses of Lyl1 were 
observed previously (Figure 4.2). During cation-exchange chromatography, little R73N 
was visible, levels of H31N approached that of Tal1, and wild type Lyl1, G66N, L43I and 
V57I were present at intermediate levels (Figure 4.8). 
SDS-PAGE of samples from Ni-NTA-affinity chromatography (Figure 4.9) show Lyl1 
wild type and mutants eluting at lower yields than Tal1. However, two mutants, H31N 
and G66N, showed improved yields compared to wild type Lyl1.  
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Extensive experience with the expression of bHLH proteins in the laboratory tells us that 
protein yield varies considerably between preparations. Therefore, the trial expression 
and purification of H31N and G66N was repeated (Figure 4.10). In this preparation lower 
yields of wild type Lyl1 than Tal1 were seen, as observed previously. However, the 
difference here was less than previously encountered, and H31N and G66N yielded levels 
similar to wild type Lyl1.  
 
Figure 4.8 Cation-exchange chromatography of Lyl1 mutants. Showing pre- and 
post-induction samples, insoluble and soluble fractions of whole cell lysate, the flow through and 
wash samples and beads after binding. E1-E4 fractions eluted with increasing concentrations of 
NaCl (150, 250, 375, 475, 600 mM, respectively) and E5-E6 are fractions eluted with 600 mM 
NaCl. 
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Figure 4.9 Ni-NTA-affinity chromatography of Lyl1 mutants. Showing the sample loaded 
from cation-exchange, flow through, wash and beads after binding. E1-E4 fractions eluted with 
increasing imidazole concentrations (0–250 mM imidazole) and E5-E8 fractions eluted with 
250 mM imidazole. 
 
Figure 4.10 Ni-NTA-affinity chromatography of Lyl1 G66N and H31N mutants. Showing  
flow through, beads after binding. E1-E3 eluted with increasing imidazole concentrations (62.5–
187.5 mM imidazole) and E4–E7 fractions eluted with 250 mM imidazole. 
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4.3.3 Mutants maintain the ability to complex LMO fusion 
constructs 
The abilities of the mutants to bind LMO2-LDB1 were tested using GST-pulldown 
experiments. These assays showed that Lyl1 WT, H31N and G66N were all able to be 
pulled down by GST-LMO2-LDB1, but not the GST-only control (Figure 4.11). Thus 
mutations did not affect the ability of Lyl1/E12 to bind LMO2-LDB1. Notably, the levels 
of H31N and G66N protein bound by GST-LMO2-LDB1 appear higher than wild type 
Lyl1, and are similar to levels seen in the Tal1/E12 control.  
 
A similar experiment was carried out to test binding of all LMO family members to wild 
type Lyl1/E12 and G66N/E12 and Tal1/E12 (Figure 4.12). LMO1–3, but not LMO4, 
showed apparently similar levels of binding to all bHLH heterodimers. Note that any 
differences in binding between the bHLH heterodimers were negligible. 
Figure 4.11 GST-pulldown assays 
trialling GST-LMO2-LDB1 binding to 
Lyl1 mutants. GST-LMO2-LDB1 and 
GST were separately immobilised onto 
GSH beads from soluble fractions of 
whole cell lysates. The washed beads 
were incubated with bHLH heterodimers, 
from soluble fractions of whole cell 
lysates. Following a wash step, beads 
were analysed by SDS-PAGE. 
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4.4 DISCUSSION 
It was hoped that the experiments in this chapter would result in the generation of more 
stable recombinant Lyl1 for biophysical and structural experiments. Modifying the Lyl1 
construct by extension of the bHLH domains flanking regions resulted in increased levels 
of soluble proteins during expression for GST-tagged C-terminally extended constructs 
Lyl1(3) and Lyl1(4). Unfortunately, however, western blots (Figure 4.5A) indicated that 
these protein constructs were prone to degradation. The persistence of degradation 
through purification of Lyl1(3) meant that no full length protein was retained.  
Attempts to generate more stable variants of Lyl1 by making point mutations to the 
equivalent Tal1 residues were met with limited success. Two mutants, H31N and G66N, 
showed slight improvements in stability throughout expression and purification. This 
apparent improved stability, however, did not result in higher levels of protein overall, as 
protein yields varied from batch to batch.  
Figure 4.12 GST-pulldown assays trialling LMO1–4 binding to Lyl1 G66N. 
GST-LMO-LDB1 and GST proteins were separately immobolised onto GSH resin from 
soluble fractions of whole cell lysates. The washed beads were incubated with bHLH 
heterodimers from soluble fractions of whole cell lysates. Following a wash step, beads 
were analysed by SDS-PAGE.  
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Due to high levels of identity between Tal1 and Lyl1, and the small effects Lyl1 to Tal1 
point mutants have made on stability, it seems likely that differences between Tal1 and 
Lyl1 stability are due to dimer formation rather than inherent structural effects. The 
recently published structure
124
 of Tal1 bound to E47 provides some possible explanations 
for these differences. 
H31N and G66N are hydrophilic residues which lie at the Tal1:E47 interface. Such 
residues are generally less conserved than hydrophobic interface residues in bHLH 
proteins, prompting the suggestion that they play a role in heterodimerisation 
specificity.
124
 These hydrophilic interface residues could account for a disparity in the 
abilities of Tal1 and Lyl1 to both heterodimerise with E12 and E47 and homodimerise. 
Note that Tal1, but not Lyl1, homodimers have been described previously.
71
 If Lyl1 is 
unable to homodimerise, or forms less stable heterodimers, it will be more prone to 
degradation than Tal1. Homology modelling of a Lyl1 homodimer indicates that the 
positively charged and bulkier hydrophilic interface residue histidine 31 creates an 
unfavourable environment for the positive lysine 54 of the adjacent Lyl1 molecule 
(Figure 4.13). In H31N mutants, replacement of histidine with a smaller neutral 
asparagine residue would be more conducive to homodimerisation, as seen for equivalent 
residues in Tal1.  
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It is possible that any increases in LMO2 binding in pulldown experiments (e.g., 
Figure 4.11) could be affected not just by increases in bHLH stability, but through 
changes in the binding interface. The structure of LMO2 bound to Tal1:E47 shows that 
only one mutant tested in these experiments lies at the LMO2 interface, L43I 
(Figure 4.14). In contrast, the two mutants that showed some evidence of tighter binding 
to LMO2-LDB1, H31N and G66N, lie well away from the LMO2-LDB1 interface. Thus 
any apparent increase in protein pulled down relative to wild type Lyl1 likely arises from 
increases in bHLH heterodimer stability.  
Figure 4.13 Hydrophilic interface residues may create specificity. Homology models of 
Tal1 and Lyl1 homodimers (red/salmon) derived from PDB:2YPB with two hydrophilic 
interface residues shown as sticks; a highly conserved Lysine (K54) and a non-conserved 
histidine/asparagines (magenta). 
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The structure indicates that Tal1-E47 forms a salt bridge between R606 of E47 and E247 
in Tal1. The homology model of Lyl1 based on this structure (Figure 4.15) shows that the 
alanine residue at this position (A76) cannot participate in this interaction and would 
likely result in reduced binding of Lyl1-E47 relative to Tal1-E47. The Tal1 construct 
used here ends at residue 246, so this salt bridge cannot form, nor account for differences 
in stability. However, it does suggest a potential improvement for Tal1 constructs as 
detailed in Chapter 6. Note that the alternative protein engineering approach used to 
increase the stability of Tal1 heterodimers in Chapter 6 could be trialled to generate more 
stable forms of Lyl1-E2a heterodimers. 
Figure 4.14 Mutants effect on LMO2-LDB1 binding. Structure of LMO2-LDB1 (cyan spheres) bound 
to Tal1-E47 (red and orange respectively). Tal1 residues used for Lyl1 mutants are indicated as red 
spheres. 
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Figure 4.15 Loss of salt bridge in Lyl1:E47. Structure of Tal1 (red) bound to 
E47 (grey) with salt-bridge indicated by a dotted line. A homology model of 
Lyl1 (salmon) is imposed onto the structure. (PDB:2YPB; El Omari et al. 
2013). 
 C H A P T E R  F I V E  
b H L H  H I G H E R  O R D E R  C O M P L E X  
F O R M A T I O N  
5.1 INTRODUCTION 
This chapter investigates the feasibility of transcriptional complex formation by LMO 
proteins other than LMO2 and bHLH proteins other than Tal1/E2a at E-box sites on 
DNA. 
5.1.1 Tal1 binds to LMO2 and E-box sites on DNA 
As covered in more detail in Section 1.2 and 1.3.1, it is known that Tal1, when 
heterodimerised with E2a proteins, can simultaneously bind LMO2 and DNA at E-box 
sites.
20,22,145
 LMO2 and Tal1 have been found in complexes, both in association with their 
normal roles as developmental regulators of haematopoiesis, and their oncogenic roles in 
T-ALL. In the latter case LMO2 and Tal1 have shown synergistic effects. LMO2-Tal1 
double transgenic mice have a faster onset of T-ALL development when compared to 
LMO2-only or Tal1-only transgenic mice.
108,141
 LMO1, a homologue of LMO2 also 
interacts with and shows synergistic effects with Tal1 in leukaemic T-cells.
21,115,116
 
There are many additional cases where LMO proteins and other Class II bHLH proteins 
are thought to have common roles in both normal development and the onset of 
oncogenesis (e.g. see Section 1.3). The sequences of LMO3 and LMO1 are almost 
identical, and the two appear to have overlapping roles in neuronal development
47
 and 
neuroblastomas (also see Section 1.2).
34,96
 The Class II bHLH protein HEN2 has been 
found to interact with all LMO family members through immunoprecipitation 
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experiments.
34,146
 Its interaction with LMO1 is associated with neuroblastomas
34,147
 and 
interactions with LMO2 and LMO4 in neuronal development.
146
 It is therefore likely that 
LMO proteins and HEN2 take part in transcriptional complexes similar to that described 
for LMO2/Tal1/E2a. 
5.1.2 Lyl1 complexes with LMO1 and LMO2 
Only a small number of bHLH proteins have been investigated to date as possible 
components of LMO containing complexes in T-ALL. Lyl1, a homologue of Tal1, was 
found to be expressed at high levels in combination with LMO2 in leukaemic T-cells.
101
 
Lyl1 has also been found to interact with both LMO1 and LMO2 in two hybrid 
experiments, although these interactions were apparently weaker than those involving 
Tal1.
41
 The high sequence identity between Tal1 and Lyl1 in conjunction with their 
LMO-associated roles in T-ALL, indicate a functional overlap in oncogenesis.  
5.1.3 E-box DNA sites targeted by Tal1 and Lyl1 complexes 
bHLH dimers bind sequence-specific DNA sites, known as E-box motifs, which have the 
following consensus sequence: NNCANNTGNN.
67,148
 Different partners in the dimer 
recognise independent half sites of the E-box. For example, Tal1-E2a heterodimers were 
found to bind the sequence AACAGATGGT, with the E2a subunit preferentially binding 
the AACAG half site and Tal1preferentially binding the ATGGT half sites.
70
 
The pentameric complex contains two DNA binding features, Tal1 heterodimers and 
Gata1 and the complex was shown to preferentially bind a bipartite E-box-GATA 
consensus site in which the E-box motif (CAGGTG) lay 9 bp upstream of a GATA site 
during CASTing experiments
20
. Interestingly, although both Tal1 and E2a proteins were 
confirmed to be present in the complex bound by this new consensus sequence, the E-box 
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motif defined had previously been identified as being preferentially bound by E47 
homodimers.
23,70,149
 
Lyl1 containing heterodimers preferentially bind a motif similar to that preferred by 
Tal1-E2a: AACAGATG[T/g]T.
23
 Some EMSA experiments indicate that although the 
CAGATG E-box motif was identified as the preferred binding site for Tal1 and Lyl1 
containing heterodimers, E2a homodimers are also able to bind this sequence with similar 
affinity.
23,70
 Regardless, the E2a homodimer E-box (CAGGTG) was reported to be more 
specific for the homodimer.
23
 
5.2 LMO-LDB1 INTERACTIONS WITH bHLH 
HETERODIMERS 
5.2.1 Tal1 and Lyl1 heterodimers bind LMO1–3  
GST-pulldown experiments were initially used to assess interactions between 
Tal1/Lyl1-E12 heterodimers and all LMO proteins. Here, GST-tagged LMO-LDB1LID 
fusion proteins were immobilised onto GSH resin and washed with whole bacterial cell 
lysates containing either co-expressed HIS-Tal1/E12 or HIS-Lyl1/E12.  
GST-LMO1–3-LDB1LID constructs were able to pulldown both Tal1 and Lyl1 
heterodimers, as shown by the low molecular weight bands corresponding to those 
proteins by Coomassie-stained SDS-PAGE in the pulldown lanes (Figure 5.1). Bands 
corresponding to the bHLH proteins were clearly enriched in the pulldown lanes 
compared to the cell lysate input. In contrast, no binding was observed for 
GST-LMO4-LDB1LID and the GST negative control.  
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It was noted that for the experiments involving GST-LMO1–3, where bHLH 
heterodimers were present, substantial amounts of other proteins could be observed, 
which were not present in GST-LMO4 and GST lanes. These bands, which likely 
correspond to bacterial proteins, were not present in samples of beads before incubation 
with lysate containing prey proteins (data not shown). It is possible that these bands are 
bacterial proteins that bound non-specifically to either the bHLH proteins or the larger 
bHLH-LMO-LDB1LID complex. Alternatively, non-specific binding could be mediated 
through DNA. bHLH proteins likely bind to fragments of bacterial DNA, which in turn 
could bind a myriad of bacterial DNA binding proteins. Based on past experience in the 
laboratory of mammalian transcription factors binding to host DNA during purification, 
this is the most likely explanation for the presence of the additional bands.  
Figure 5.1 GST-pulldown assays testing LMO1–4 binding to 
Tal1-E12 and Lyl1-E12 heterodimers. GST-LMO-LDB1 proteins 
and GST alone were immobilised on GSH beads from soluble 
fractions of whole cell lysates. Washed beads bound to GST-fusions 
were incubated with soluble fractions of whole cell lysates 
overexpressing bHLH heterodimers (input). Following a wash step 
beads were analysed by SDS-PAGE. Data previously shown in 
Figure 4.12. 
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These observations support previous experiments showing that LMO1 and LMO2 can 
interact with both Tal1 and Lyl1 heterodimers
41
. These data also show that LMO3 can 
bind both heterodimers, as might be expected from high sequence similarity between 
LMO1 and LMO3. However, LMO4 showed no evidence of binding either bHLH 
heterodimer tested, which is consistent with the fact that LMO4 has never been 
implicated in binding to Tal1 or Lyl1. 
5.2.2 Tal1 heterodimers can complex with DNA and LMO1–3 
EMSA experiments were used to further investigate the ability of Tal1 to bind LMO 
family members. First co-purified Tal1-E12 heterodimers were titrated into fluorescently 
labelled DNA oligonucleotides containing the E-box sequence that is preferentially 
bound by Tal1-E12: AACAGATGGT (Figure 5.2, sequence in Appendix B). This 
titration resulted in two mobility shifted bands. Incubation of sample with 3 µM Tal1-E12 
(the most concentrated sample in the titration series) and an anti-HIS antibody (i.e., 
super-shifting) resulted in the disappearance of the higher of the two bands but retention 
of the lower band. As only Tal1 carries a 6  HIS (HIS) tag, and Tal1 homodimers are 
not thought to bind DNA,
71
 it was inferred that the lower band corresponded to E12 
homodimers bound to DNA and the higher band corresponded to a Tal1-E12:DNA 
complex. Note that during co-purification Ni-NTA-affinity chromatography selects for 
HIS-Tal1 containing complexes, and the formation of heterodimers is biased by the 
preference of Tal1 and E2a to heterodimerise over homodimerisation, in the absence of 
DNA.
71
 This process should favour a ~1:1 ratio of Tal1 and E2a proteins, with high 
proportion of heterodimer in solution. Despite purification of these proteins as 
heterodimers, the EMSA clearly shows that E12 homodimers have formed. This is likely 
a result of the bHLH proteins taking part in multiple interactions. In the absence of DNA 
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they undergo exchange between dimers and monomer in solution and with the addition of 
DNA the equilibrium is shifted because E2a homodimers (but not Tal1 homodimers) can 
bind E-boxes (Figure 5.3).  
 
To confirm the ability of Tal1-E2a to simultaneously bind LMO2 and DNA, the 
LMO2-LDB1 fusion construct was titrated onto constant concentrations of Tal1/E12 and 
DNA (Figure 5.2). The concentration of Tal1-E12 (0.3 µM) was selected based on the 
initial titration, and represented a point about mid-way through the titration where the 
gel-shifted bands were clearly visible, but some free DNA was also present. These 
conditions ensured maximal DNA-binding and low levels of free Tal1-E12. This titration 
resulted in further shifting of the highest band. This new shifted band was assigned as 
Figure 5.2 EMSA analysis of Tal1-E12 heterodimers binding DNA in the presence or absence 
of LMO2-LDB1. Fluorescently labelled E-box dsDNA oligonucleotides (100 nM) were incubated 
with increasing concentrations of co-purified HIS-Tal1/E12 (0, 0.02, 0.05, 0.3, 0.5, 0.8, 1, and 
3 µM) (left) or a constant concentration of HIS-Tal1/E12 (0.3 µM) and increasing concentrations of 
purified LMO2-LDB1 (0, 0.025, 0.05, 0.15, 0.6, 3 and 8 µM) (right). In the last lane of each titration 
incubation was performed at the highest concentration of the titration in the presence of anti-HIS 
antibody.  
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corresponding to LMO2-LDB1-Tal1-E12-DNA. Super-shifting with anti-HIS antibody 
confirmed the presence of Tal1 in the complex. As expected from previous 
experiments,
71
 LMO2-LDB1 did not bind the E12 homodimer, as the lower band did not 
shift upon titration with LMO2-LDB1.  
 
A similar experiment was carried out in which Lyl1-E12 heterodimers were tested for 
their ability to bind the same E-box site on DNA (AACAGATGGT), either alone, or with 
increasing concentrations of preformed Lyl1-E12-LMO2-LDB1 complex. Under the 
conditions of this experiment there was no evidence of Lyl1-E12 heterodimers binding to 
DNA in the absence of LMO2-LDB1. Only one shifted band was observed, which is 
presumed to correspond to E12 homodimer bound to DNA (Figure 5.4C); this band was 
not super-shifted upon the addition of anti-HIS antibody. However, in the presence of 
LMO2-LDB1 (Figure 5.4D), a higher order complex was observed. This band does 
undergo a super-shift with the addition of anti-HIS antibody, confirming the presence of 
HIS-Lyl1 in the complex. This band is assumed to correspond to Lyl1-E12-LMO2-LDB1 
bound to DNA.  
Figure 5.3 bHLH proteins are in exchange between monomer and dimer. A) The stability 
of heterodimer is greater than either homdimer, and E2a-E2a is a relatively weak interaction. 
B) Heterodimers and E2a homodimers, but not Tal1 homodimers, can bind E-box DNA. 
 
 
B A 
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Similar titrations were carried out with all LMO family members (Figure 5.5). Fusion 
constructs of LMO1–3 resulted in shifting of the band corresponding to Tal1-E12-DNA 
(but not the E12 homodimer-DNA complex) to form a further shifted band. Consistent 
with the GST-pulldown experiment, LMO4 showed no evidence of binding to the 
Tal1-E12-DNA complex.  
In these experiments, LMO1 was able to shift the complex at similar concentrations to 
LMO2 (mid-point of titration at ~50–150 nM) indicating that the two have a similar 
affinity for the TAL1-E12-DNA complex. In contrast, LMO3 shifted the complex at a 
higher concentration (~0.6 µM) suggesting a slightly weaker affinity for the complex.  
 
Figure 5.4 EMSA experiments of Tal1/Lyl1-E12 alone or in complex with LMO2-LDB1. 
Fluorescently labelled E-box dsDNA oligonucleotides (6 nM) incubated with increasing 
concentrations of co-purified A) HIS-Tal1/E12 or C) HIS-Lyl1 / E12 alone (0, 0.05, 0.5 and 
1 µM) or B) HIS-Tal1/E12 or D) HIS-Lyl1/E12 in complex with LMO2-LDB1 (0, 0.05, 0.5, and 
1 µM). The right hand lane of each titration corresponds to the same protein concentrations as 
the previous lane in each case, with the addition of anti-HIS antibody. 
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5.2.3 LMO1–3 increases the affinity of Tal1-E12 for E-box sites  
The EMSA experiments of Tal1-E12 titrations presented to date were generally designed 
to have a molar excess of heterodimer to DNA (3:1 or higher by the end of the titration). 
However, in practice, there remained significant amounts of unbound DNA and the 
concentrations of the components used resulted in relatively high levels of E12-DNA 
complex formation. However, as reported by Beltran et. al. (2005)
150
, the E-box 
consensus used here has a ~10 fold higher affinity for Tal1-E12-heterodimers over 
E12-homodimers. Thus, by limiting the concentration of DNA, it should be possible to 
shift the equilibria to favour Tal1-E12 heterodimer formation. This was observed to some 
degree in Figure 5.4, where DNA was used at a constant concentration of 6 nM. Similarly 
in Figure 5.6, the DNA concentration was dropped from 100 nM to 8 nM, and the higher 
heterodimer band is more prominent. The E12-homodimer band is still present, but at 
much lower intensity.   
Figure 5.5 EMSA experiments testing the ability of LMO-LDB1 fusion constructs to bind Tal1-E12 
and DNA. Fluorescently labelled E-box dsDNA oligonucleotides (100 nM) incubated with co-purified 
HIS-Tal1 and E12 (0.3 µM) and increasing concentrations of purified LMO-LDB1 (0, 0.025, 0.05, 0.15, 
0.6, 3 and 8 µM). 
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When LMO2-LDB1 was titrated into the Tal1-E12:DNA complex, a shift of the 
heterodimer-DNA band to a higher order complex was observed (Figure 5.6). However, it 
was also observed that the E12-homodimer-DNA band disappeared with increasing levels 
of LMO2-LDB1. A similar phenomenon was noted for Lyl1 in Figure 5.4, where low 
concentrations of DNA are used (6 nM). Here, not only does the presence of 
LMO2-LDB1 introduce a higher order complex involving Lyl1-E12, where there was no 
visible Lyl1-heterodimer-DNA complex in the absence of LMO2-LDB1, but the 
E12-homodimer band is reduced in intensity in the presence of LMO2-LDB1. This 
suggests that LMO2-LDB1 significantly stabilises the Tal1-E12/DNA and 
Lyl1-E12/DNA complexes. The changed equilibria, achieved by reducing the available 
DNA, makes these shifts easier to observe than was the case in Figure 5.2. 
 
Figure 5.6 EMSA experiments with limiting E-box oligonucleotide. Fluorescently labelled E-box 
dsDNA oligonucleotides (8 nM) was incubated with increasing concentrations of co-purified 
HIS-Tal1 and E12 (0, 0.02, 0.05, 0.3, 0.5, 0.8, 1 and 3 µM) (left) or with a constant concentration of 
HIS-Tal1/E12 (0.5 µM) and increasing concentrations of purified LMO2-LDB1 (0, 0.05, 0.2, 0.8, 
1.5, 4, 8 and 16 µM) (right). The last lane was at the highest concentration of the titration in the 
presence of anti-HIS antibody.  
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A similar effect was seen for titrations with LMO1/3-LDB1 (Figure 5.7). Initially 
heterodimer and homodimer bands were observed; however, upon titration of LMO1–
3-LDB1, the E12-homodimer-DNA complex disappears.  
 
5.3 THE SPECIFICITY OF Tal1-E2a FOR LMO1–3 
5.3.1 Structural rationalisation of LMO1–3 specificity 
To try and understand why Tal1-E2a binds LMO1–3 but not LMO4, a structure based 
sequence comparison was carried out, with particular attention to the structures of 
LMO2
126
 alone and in complex with Tal1-E47.
124
 In the latter structure, numerous 
residues from LMO2 were identified as being important for the interactions
124
. These 
include residues that form hydrogen bonds (C60 and R86), salt bridges (R77, R100 and 
Figure 5.7 EMSA experiments of LMO-LDB1 fusion constructs complexing Tal1-E12 and 
radiolabelled DNA.  E-box dsDNA oligonucleotides (7 nM) labelled with 
32
P and incubated with co-purified 
HIS-Tal1 and E12 (0.3 µM) and varying concentrations of purified LMO1-LDB1, LMO3-LDB1, 
LMO4-LDB1 (0–8 µM), or LMO2-LDB1 (0–20 µM). In the last lane of each titration incubation was 
performed in the presence of anti-HIS antibody.  
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R102) and those stabilising the hydrophobic interface (L59, L79, L87 and F88) 
(Figure 5.8).  
 
Of these residues, two-hybrid luciferase reporter assays showed that R77 and R86 are 
particularly important to the interaction.
124 As R86 is fully conserved in the LMO family 
(Figure 5.8B), it is unlikely to be responsible for binding specificity. In contrast, R77, is 
unique to LMO2 where it forms a salt bridge with Tal1-D245 (Figure 5.8B). The 
 30 40 50 60 70 80 90 
LMO2   PSLLTC GGCQQNIGDR YFLKAIDQYW HEDCLSCDLC GCRLGEVGRR LYYKLGRKLC RRDYLRLFGQ 
LMO1   GKQKG- A--NRK-K-- -L---L-K-- -----K-AC- D-------ST --T-ANLI-- ---------T 
LMO3   TKPKG- A--NRK-K-- -L---L-K-- -----K-AC- D-------ST --T-ANLI-- ---------V 
LMO4   L-WKR- A--GGK-A-- FL-Y-M-S-- -SR--K-SC- QAQ--DI-TS C-T-S-MI-- -N--I----N 
 
 100  110 120 130 140 150                                
LMO2   DGLCASCDKR IRAYEMTMRV KDKVYHLECF KCAACQKHFC VGDRYLLINS DIVCEQDIYE WTKING 
LMO1   T-N--A-S-L -P-F--V--A R-N----D-- A-QL-NQR-- ---KFF-K-N M-L-QV---- EGHL-T 
LMO3   T-N--A-S-L -P-F--V--A K-N----D-- A-QL-NQR-- ---KFF-K-N M-L-QT---- EGLMKE 
LMO4   S-A-SA-GQS -P-S-LV--A QGN----K-- T-ST-RNRLV P---FHY--G SLF—H--RPT AL---H 
 
Figure 5.8 Residues from LMO2 involved in binding to Tal1-E47. A) Structure of LMO2-LDB1 (cyan) 
bound to Tal1-E47 (red and yellow respectively) showing residues involved in the interaction. PDB: 2YPA 
B) A sequence alignment of LMO2 with LMO1, LMO3 and LMO4. Residues identical to LMO2 are 
indicated (-), surface-exposed hydrophobic residues from LMO2 that stabalise the Tal1-E47 interface are 
coloured green. Residues from LMO2 that form hydrogen bonds (blue), salt bridges (red) and other highly 
charged packing (orange) with Tal1-E47 are also shown. UniProtKB: LMO1 (P25800), LMO2 (P25801), 
LMO3 (Q8BZL8), LMO4 (P61969). 
A 
B 
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equivalent residue is a leucine in LMO1/LMO3 and a methionine in LMO4, neither of 
which could form an equivalent salt bridge.  
Similarly R100 and R102 are unique to LMO2 (Figure 5.8B) and should prevent salt 
bridge formation for each of the other LMO proteins (Figure 5.9), making it unlikely that 
either is responsible for selectivity. Indeed mutational analysis confirms that when these 
residues in LMO2 are mutated to alanine, the Tal1-E47 interaction is maintained.
124
  
 
From this initial structural analysis, it was not obvious why LMO1–3 can bind Tal1-E2a 
but LMO4 cannot. Thus, a more extensive structure-based sequence analysis was carried 
out. All LMO2 residues at the interface with Tal1 were identified (Figure 5.10). Residues 
that are identical or homologous among LMO1–3, but are different in LMO4 were 
selected for further consideration. Based on this analysis, two sets of residues from 
LMO2 were identified as candidates for providing binding specificity.   
Figure 5.9 LMO4 vs. LMO2 residues involved in Tal1-E47 binding. 
The crystal structures of LMO2-LDB1 (cyan) bound to Tal1-E47 (red and 
yellow, respectively) (PDB: 2YPA) overlayed with the structure of LMO4 
(magenta) (PDB: 1RUT) showing residues involved in the interaction. 
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The first set comprises three surface exposed residues that are hydrophobic in LMO2 but 
are polar in LMO4. Residues L59, L75 and Y104 correspond to C52, S68 and S97 
respectively in LMO4 (green, Figure 5.10B). Together the loss of these hydrophobic 
residues may reduce binding to Tal1-E47. It should be noted that the equivalent residues 
in LMO1 and LMO3 are not necessarily identical to those in LMO2, but hydrophobicity 
is conserved. In LMO1/LMO3 L75 and Y104 are A69/58 and F98/87, respectively. As 
was the case for LMO4, the LMO2-L59 equivalent in LMO1 and LMO3 is a cysteine 
residue, but the preceding residue in LMO1 and LMO3, but not LMO4, is hydrophobic 
(A52/41) compared with the negatively charged D58 from LMO2 and polar S51 from 
LMO4. That is, positions 58 and 59 from LMO1–3 have one hydrophobic residue 
present, whereas LMO4 has none.  
The second set consists of a single large bulky arginine residue in LMO2, R82, which is 
buried in what would otherwise be a cavity in the LMO2:Tal1-E2a interface. This residue 
is conserved in LMO1 and LMO3, corresponding to R76/65, but in LMO4 this position is 
occupied by the smaller N75. 
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  30 40 50  70 80 90 
LMO2   PSLLTC GGCQQNIGDR YFLKAIDQYW HEDCLSCDLC GCRLGEVGRR LYYKLGRKLC RRDYLRLFGQ 
LMO1   GKQKG- A--NRK-K-- -L---L-K-- -----K-AC- D-------ST --T-ANLI-- ---------T 
LMO3   TKPKG- A--NRK-K-- -L---L-K-- -----K-AC- D-------ST --T-ANLI-- ---------V 
LMO4   L-WKR- A--GGK-A-- FL-Y-M-S-- -SR--K-SC- QAQ--DI-TS C-T-S-MI-- -N--I----N 
 
 100  110 120 130 140 150                                
LMO2   DGLCASCDKR IRAYEMTMRV KDKVYHLECF KCAACQKHFC VGDRYLLINS DIVCEQDIYE WTKING 
LMO1   T-N--A-S-L -P-F--V--A R-N----D-- A-QL-NQR-- ---KFF-K-N M-L-QV---- EGHL-T 
LMO3   T-N--A-S-L -P-F--V--A K-N----D-- A-QL-NQR-- ---KFF-K-N M-L-QT---- EGLMKE 
LMO4   S-A-SA-GQS -P-S-LV--A QGN----K-- T-ST-RNRLV P---FHY--G SLF—H--RPT AL---H 
 
Figure 5.10 LMO2 contact residues at Tal1-E47 interface. A) Structure of LMO2-LDB1 (cyan) bound to 
Tal1-E47 (red and yellow respectively) showing residues involved in the interaction (black spheres). PDB: 2YPA 
B) LMO2 aligned to LOM1, LMO3 and LMO4. Sequence identical to LMO2 is indicated (-). LMO2 contact residues 
at Tal1-E47 interface are blackened. Two sets of residues that are homologous in LMO1–3 but different in LMO4 
are illustrated.  These correspond to a loss of hydrophobicity (green) or loss cavity filling residue (orange) in 
LMO4.  UniProtKB: LMO1 (P25800), LMO2 (P25801), LMO3 (Q8BZL8), LMO4 (P61969). C) Residues D58 and 
L59 of LMO2 mutated to LMO1/3 and LMO4 residues. PDB:2YPA 
A 
B 
C 
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5.3.2 Tal1-E12 binding by LMO2-LDB1 mutants 
Based on the above observations, a series of mutants were generated in LMO2-LDB1 
including hydrophobic mutations in various combinations (Figure 5.10B, green) and a 
single mutation resulting in the loss of a bulky side group (Figure 5.10B, orange). Each of 
the mutations changed the LMO2 residue to the corresponding residue in LMO4 
(Table 5.1). 
 
These mutants were tested for Tal1-E12 binding using GST-pulldown experiments. 
Immobilised GST and GST-fusion constructs of wild type LMO2-LDB1, the mutants and 
LMO4-LDB1 were incubated with whole cell lysate from E. coli containing 
overexpressed HIS-Tal1-E12 (Figure 5.11). Wild type GST-LMO2-LDB1 was able to 
pulldown Tal1-E12, but GST-LMO4-LDB1 and the GST-only negative control did not. 
All mutants pulled down Tal1-E12 at the same levels as wild type LMO2-LDB1; any 
small differences in band intensity appear to be due to small differences in the amounts of 
bait protein used.  
Mutant name Number of mutations LMO2 mutations 
∎  DL 2 
D58S 
L59C 
∎  L75S 1 L75S 
∎  DLL 3 
D58S 
L59C 
L75S 
∎  R82N 1 R82N 
∎  Y104S 1 Y104S 
 
Table 5.1 Summary LMO2-LDB1 to LMO4 mutations. 
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5.4 DISCUSSION 
In this chapter it was demonstrated that each of LMO1–3 can bind Tal1-E2a heterodimers 
and that these sub-complexes can bind to DNA at E-box sites. Although Lyl1-E12 
heterodimers showed no evidence of binding to DNA in the absence of LMO2-LDB1, 
they were able to bind DNA as part of higher order Lyl1-E12-LMO2-LDB1 complexes. 
The evidence that Lyl1-E12, like Tal1-E12 heterodimers, can simultaneously bind LMO2 
and DNA supports the hypothesis that Lyl1 and Tal1 have overlapping roles in 
transcription factor complex formation, in both normal and disease states. 
5.4.1 LMO1–3 specificity for Tal1-E2a  
The GST-pulldown experiments (Figure 5.11) indicated that none of the residues tested 
have a key role in defining the specificity of LMO/Tal1-E2a binding. It may be that 
multiple residues must be mutated to significantly affect binding, and given that the 
reported dissociation constant for the LMO2-LDB1/Tal1-E2a interaction is fairly tight 
Figure 5.11 GST-pulldown assays testing LMO2 to LMO4 mutants binding to Tal1-E12 
heterodimers. GST fusions of wild type LMO2-LDB1, LMO2 mutants, LMO4-LDB1 and GST 
alone were immobilised on GSH resin from soluble fractions of whole cell lysates. Beads bound 
to GST-fusions were incubated with soluble fractions of whole cell lysates overexpressing 
Tal1-E12 (input). Following a wash step beads were run on SDS-PAGE gel. 
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(KD ~ 10
8
 M),
71
 small differences in affinity may not be picked up in the assay. Although 
a triple hydrophobic mutant (DLL) was tested with little effect on binding, it might be 
worth testing either a quadruple (DLLY) or quintuple mutant (DLLYR), which may show 
a bigger effect. A more quantitative assay, such as isothermal titration calorimetry or 
microscale thermophoresis may also discern more subtle differences in binding. 
An alternative explanation for the differences in binding between LMO1–3-LDB1 and 
LMO4-LDB1 lies not in a small number of sequence differences but to gross structural 
differences. It has been proposed that conformational flexibility of LMO2-LDB1 around 
the hinge (Section 1.1.2) is crucial to Tal1-E2a binding.
126
 It is possible that 
LMO4-LDB1 is less flexible at this point, and/or cannot adopt the correct conformation 
for binding to bHLH heterodimers. In support of this hypothesis, although the complexes 
themselves appear to adopt similar topological conformations, extant crystal structures 
for LMO2-LDB1 complexes show differences in relative orientation of the two LIM 
domains,
124,126
 whereas LMO4-LDB1 structures do not.
127,151
 However, although several 
tandem LIM-domain-LDBLID complexes show direct evidence of flexibility through 
small angle X-ray scattering studies,
152-154
 similar experiments have not been carried out 
for LMO2-LDB1 and LMO4-LDB1. Given that the mutational study here did not show 
any results, it would also be worth carrying out those experiments to determine if 
variations of flexibility affect binding.  
5.4.2 LMO proteins switch bHLH dimer preference  
Unlike Tal1-E2a heterodimers, Lyl1-E2a heterodimers showed no evidence of binding to 
the E-box sequence used here (AACAGATGGT) (Figure 5.4). This lack of binding could 
indicate that Lyl1 is more dependent than Tal1 on the formation of higher order 
complexes, or that Lyl1 heterodimers preferentially bind a different consensus sequence. 
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The sequence used here was identified using site-selection experiments with Lyl1-E12 
heterodimers,
155
 but genome wide binding studies in blood progenitor cells report a 
slightly different consensus sequence for both Tal1 and Lyl1; 
TGC(A/T)GCTGC(t/a)(g/c), where the underlined bases are more important
10
. It could be 
that, as has been described for Tal1,
156
 Lyl1 activates genes through associating with 
different complexes, and its dependence on these interactions for DNA binding is greater 
than that observed for Tal1. 
EMSA experiments in this chapter have revealed that bHLH binding partners, LMO1–3 
fused to LDB1LID, have a significant effect on bHLH dimer formation. In particular, 
Tal1-E12 heterodimers sequester E12 to a greater extent in the presence of LMO1–
3-LDB1, than in their absence (Figures 5.6 and 5.7). This was especially noticeable in 
super-shifts of Tal1-containing complexes, where, in the absence of LMO2, more E12 
was directed towards E12 homodimers as a result of the bHLH protein monomer/dimer 
exchange described earlier (Figure 5.3). However, in the presence of LMO2 the whole 
complex appeared to be super-shifted, consistent with LMO2-LDB1 binding to Tal-E12 
and locking these proteins into a heterodimer conformation by further shifting the 
monomer/dimer equilibria (Figure 5.12). 
Sequestering of E2a by bHLH and LMO proteins has been implicated in T-ALL. 
LMO/Tal1-induced oncogenesis is thought to be brought about via multiple gene 
inhibitory and activation mechanisms, described in Chapter 1, including block of T-cell 
differentiation through inhibition of E2a activated genes. Here it was shown that LMO1 
and LMO3 proteins can also push the bHLH equilibrium toward Tal1-E2a heterodimers, 
thereby sequestering E2a proteins from DNA-bound homodimers (Figure 5.7). 
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In the case of Lyl1, only E12 homodimers are seen bound to DNA E-box sites; however, 
when LMO2 is incubated with the sample we observe the formation of a higher order 
complex, which contains Lyl1-E12 heterodimers (Figure 5.4). This mirrors the 
phenomenon observed for Tal1 but the overall effect is much more dramatic, as the 
presence of LMO-LDB1 sub-complexes not only drives an equilibrium shift, but is 
necessary for the Lyl1 heterodimer to bind DNA with a sufficiently high affinity for 
detection by EMSA. This apparent stabilisation of Lyl1-E12 heterodimers supports the 
proposal that Lyl1 heterodimers are much less stable than Tal1 heterodimers, leading to 
problems with degradation and purification described in Chapter 4.   
Figure 5.12 LMO-LDB1 effects monomer/dimer exchange in bHLH proteins. LMO-LDB1 
tightly binds A) Tal1-E2a or B) Lyl1-E2a to shift the equilibrium to lock the bHLH proteins into 
heterodimer conformations within the higher order complex and thereby reduce the ability of those 
proteins to form monomers. The equilibrium that is affected is highlighted in yellow. 
 
A 
B 
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The more dramatic shifts in Lyl1 binding in the presence of LMO2 compared to Tal1 
may explain reports that Lyl1 is more important for some LMO2-induced leukaemias 
than Tal1.
157
 The overexpression of LMO2 in the presence of Lyl1 should cause a bigger 
shift in the formation of Lyl1- and E2a-containing transcription factor complexes over 
Tal1- and E2a-containing transcriptional factor complexes. These changes in composition 
of transcription complexes will subsequently influence gene expression in affected cells. 
Future work in this area could include testing if LMO proteins other than LMO2 also 
bind Lyl1. 
 C H A P T E R  S I X  
D E T E R M I N I N G  L M O - L D B 1 / b H L H  
B I N D I N G  A F F I N I T I E S  
6.1 INTRODUCTION 
Pulldown and EMSA experiments (Chapter 5) have shown that Tal1-E2a heterodimers 
can bind LMO1–3-LDB1 but not LMO4-LDB1 fusion constructs. EMSA experiments 
indicated that the LMO1 and LMO2 constructs may have slightly tighter binding 
compared to the LMO3 construct, as they shift the Tal1-E2a-DNA complex at lower 
concentrations of fusion protein (Figure 5.5). However, any differences in binding 
affinities should be validated with a more quantitative measure of binding affinity. To 
date, the interaction with LMO2 has been most thoroughly investigated and an estimate 
of binding affinity from isothermal titration calorimetry experiments indicated that the 
binding is strong (KA = 1.8 x 10
8
 M
-1
).
71
 
This chapter attempts to determine the binding affinities of Tal1-E47 to all 
LMO-LDB1LID protein constructs. The difficulties associated with measuring binding of 
a dimeric complex that is in exchange with monomeric and other dimeric species is 
addressed.  
6.2 LMO-LDB1/Tal1-E2a BINDING DATA 
6.2.1 Microscale thermophoresis 
Microscale thermophoresis (MST, as described in Section 2.13) was used to estimate 
binding affinities for interactions between Tal1-E2a heterodimers and LMO1–4-LDB1 
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fusion constructs in the absence of DNA. These experiments have not been repeated and 
should be regarded as preliminary.  
LMO-LDB1 constructs were labelled with amine reactive dye using the Monolith™ 
Protein Labelling Kit RED-NHS. Tal1-E12 was serially diluted (final concentrations of 
15 nM–35 µM) into the labelled LMO-LDB1 (100 nM).  Control scans showed sharp 
peaks of fluorescence for each capillary at similar intensities within the workable range 
(200–2000 counts), indicating that there was no aggregation or sign of protein sticking to 
the capillaries.  
The data for the LMO1–3 constructs are characteristic of full binding curves where 
binding appears to saturate at the highest concentrations of Tal1-E12. These binding 
curves were fitted by a 1:1 binding isotherm (Equation 2.4) which gave KA values of 
moderate affinity (Figure 6.1). In these experiments LMO2 appears to have a slightly 
higher affinity for Tal1-E12 than LMO1 and LMO3; KA ~8.9 x 10
5
 M
-1
 versus ~3.1 x 10
5
 
M
-1
 and ~2.9 x 10
5
 M
-1
 respectively.  
Saturation was not reached for LMO4-LDB1 with the concentrations of proteins used, 
consistent with the apparently weaker binding of LMO4-LDB1. This means that curve 
fitting for LMO4-LDB1 was not meaningful and is not presented.  
Although the MST binding curves look reasonable, published data indicates 
LMO2-LDB1/Tal1-E12 binding is much tighter. Ryan et al. (2008)
71
 reported affinities 
of ~1.8  108 M-1 for the interaction between Tal1-E12 and LMO2-LDB1 based on 
isothermal titration calorimetry data. One reason why MST might underestimate affinities 
relates to protein labelling. For detection of interactions in thermophoresis experiments, 
one partner (the titrand) must carry a fluorescent label. Here this was achieved by 
covalent attachment of a fluorophore to primary amine residues on lysine side-chains and 
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the N-terminus, which could interfere with the interaction. Although the temperatures 
were the same (25 ˚C), it is possible differences in the buffers used in the two types of 
experiments (20 mM Tris, pH 8.0 in MST; 20 mM NaH2PO4, pH 7.4 in ITC) also 
contributed to the differences in the estimated binding affinities.
71
 
Overall this data is consistent with GST-pulldown and EMSA experiments from the 
previous chapter showing that LMO4-LDB1 binding to Tal1-E12 is significantly weaker 
than for LMO1–3-LDB1. Although these data also suggest that LMO1-LDB1 and 
LMO3-LDB1 bind Tal1-E12 with moderate affinity (KA ~3  10
5
 M
-1
), with LMO2 
binding being slightly stronger (KA ~9  10
5
 M
-1
), the much lower affinities obtained by 
MST compared with previous experiments for LMO2 constructs were of concern. Rather 
than persisting with MST, it was decided to use an alternative method to estimate binding 
affinities.  
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Figure 6.1 MST binding curves for Tal1-E12 titrated into LMO-LDB1. Tal1-E12 was titrated (up 
to 35 µM) into fluorescently labelled LMO-LDB1 (100 nM). Normalised fluorescence was plotted as 
a function of A) LMO1-LDB1, B) LMO2-LDB1, C) LMO3-LDB1 or D) LMO4-LDB1 concentration. 
Experiments were performed at 25 ˚C in 20 mM Tris (pH 8), 100 mM NaCl and 1 mM DTT. E) 
Summary table of fitted dissociation constants and corresponding calculated association constants, 
where errors are standard errors of the fit.  F) Fraction bound is plotted as a function of LMO1–3 
concentration. Fraction bound was calculated from the fitted change in fluorescence compared to the 
initial fluorescence. Note: insufficient binding was observed LMO4-LDB1 to allow meaningful curve 
fitting or obtain good estimates of fraction bound. 
 
A B 
C D 
E  KD (µM) KA (M
-1) R2 
LMO1-LDB1 3.2 ± 0.6 (3.1 ± 0.6)   x 105 0.986 
LMO2-LDB1 1.1 ± 0.08 (8.9 ± 0.7) x 105 0.998 
LMO3-LDB1 3.4 ± 0.6 (2.9 ± 0.5) x 105 0.988 
 
F 
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6.2.2 Isothermal titration calorimetry 
Binding affinities for LMO2-LDB1/Tal1-E12 and Tal1-E47 were estimated using ITC. 
Note that for these experiments, LMO2-LDB1 was titrated into a fixed concentration of 
bHLH heterodimer. The buffer conditions were identical to those used previously.
71
 
Preliminary ITC experiments (Figure 6.2) gave good binding isotherms for both 
interactions and data were fitted to a 1:1 model of binding. The binding affinities of 
Tal1-E12 and Tal1-E47 for LMO2-LDB1 were very similar (both KA ~10
7
 M
-1
; the 
estimated values are unlikely to be significantly different) and are higher than those 
determined by MST with the titration in the opposite orientation. However, these values 
are still about at least an order of magnitude lower than those estimated previously 
(KA ~2  10
8
 M
-1
).  
CHAPTER SIX : DETERMINING LMO-LDB1/bHLH BINDING AFFINITIES 119 
 
 
In these binding curves the N value indicated ~2:1 binding (LMO2:Tal1-E2a), but it is 
known that binding is 1:1 from MALLS and X-ray crystallography data.
71,124
 This 
difference is likely due to difficulties in accurately estimating protein concentrations for 
Tal1-E2a. Thus, the data for LMO2-LDB1/Tal1-E12 was re-fitted with the assumption 
that Tal1-E12 concentration was ~2-fold higher than originally estimated (i.e., the 
concentration corresponding to a 1:1 stoichiometry). This treatment gave identical 
estimates of KA (Figure 6.3).  
Figure 6.2 ITC data for LMO2-LDB1 titrated into Tal1-E2a. LMO2-LDB1 (~130 µM) was 
titrated into Tal1 heterodimerised with E2a splice variants, A) E12 and B) E47 (~10 µM). 
Experiments were performed in 20 mM NaH2PO4 (pH 7.4), 150 mM NaCl and 1 mM DTT at 
25 ˚C.  Baseline data were measured by titration of the LMO2-LDB1 into buffer, and subtracted 
from experimental data. Integrated heats were plotted as a function of [LMO2-LDB1]/[Tal1-E2A] 
molar ratio. C) Data were analysed for single titrations using the Origin 7.0 ITC Data analysis 
software package (MicroCal) to generate estimates of association constants, changes in enthalpy 
and stoichiometry (N), where errors are standard errors of the fit.  
 
 
A B 
C 
 KA (M
-1) ΔH (kcal mol-1) N 
Tal1-E12 (4.3 ± 0.8) x 107 -9710 ± 80 1.86 ± 0.01 
Tal1-E47 (2.7 ± 0.7) x 107 -13800 ± 200 2.19 ± 0.02 
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6.2.3 The problem with the current method for determining 
binding affinities  
In methods used for the determination of LMO/bHLH heterodimer binding affinities, 
described in this chapter and used for published data, bHLH proteins were purified as 
heterodimers. It was assumed that heterodimerisation was maintained throughout 
experimentation because the concentrations of proteins used were generally well above 
the KD estimated for heterodimer formation (KD ~10
-8
 M). Accordingly, data were fitted 
assuming a 1:1 binding model (Figure 6.4A). However, this set of proteins can form both 
Figure 6.3 ITC data for LMO2-LDB1 titrated into Tal1-E12 with adjustments to Ta1-E12 
concentration. LMO2-LDB1 (~130 µM) was titrated into Tal1-E12. The experiment was the same as 
in Figure 6.2 with the exception that data analysis was made with the assumption that Tal1-E12 
concentration was ~20 µM. B) Data was analysed using the Origin 7.0 ITC Data analysis software 
package as in Figure 6.2. 
 
 
A 
B 
KA (M
-1) ΔH (kcal mol-1) N 
(4.3 ± 0.8) x 107 -9710 ± 80 0.97 ± 0.004 
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homodimers and heterodimers (Figures 5.2 and 5.3). Therefore, the actual binding model 
is more complicated (Figure 6.4B).  
 
It is possible that this more complex model accounts for differences in binding from 
different experiments – from both method to method and batch to batch variation. For the 
MST experiments in particular the titration (~15 nM–35 µM) starts very close to the KD 
estimated for heterodimer formation (KD ~10
-8
 M). It was decided therefore, to take a 
Figure 6.4 Tal1-E2a binding equilibria. A) Schematic of assumed 1:1 
LMO-LDB1/Tal1-E2a binding. B) Schematic showing the competition equilibria 
involving Tal1-E2a monomer/dimer exchange.  
 
 
A 
B 
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strategy in which heterodimer formation is further favoured, before attempting to obtain 
additional binding data. A protein engineering approach was taken to achieve this goal.  
6.3 bHLH TETHERED COILED-COILS 
6.3.1 Design of bHLH tethered coiled-coils 
The design strategy was to tether each member of the Tal1-E2a heterodimer to one 
subunit from a different heterodimer that cannot form homodimers. It was hoped that this 
strategy would favour heterodimer formation through synergistic or cooperative binding 
effects, and thereby minimise 
homodimer formation (Figure 6.5). 
Litowski et. al. (2002)
158
 described the 
design of two-stranded α-helical coiled 
coils that specifically form 
heterodimers. Heterodimerisation was 
favoured by rearrangement of charged 
residues at strategic points in the 
heptad repeats of typical coiled-coils. It 
was thought that these helical peptides 
could act as simple extensions of Tal1/E47 bHLH domains, which themselves have a 
coiled-coil structure at their C-termini. By extending the helices with these sequences, it 
was hoped that structural integrity would be maintained. Of the numerous heterodimers 
described, the smallest of the artificial coiled-coils with the highest affinity to 
heterodimerise (IAAL E3/K3) were selected.
158
 IAAL E3 and K3 (naming convention as 
designated in the original paper) describes two peptides with a sequence which converge 
Figure 6.5 Tethering of bHLH proteins to bias 
heterodimer formation. By tethering the bHLH 
proteins to partners that cannot homodimerise we 
hope to increase the affinity of heterodimerisation 
and therefore bias heterodimer formation and 
maintenance. 
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to complementing coiled coils. These contain a seven amino acid repeat (total of 3 
repeats) of Ile-Ala-Ala-Leu-Glu/Lys-Lys/Glu, where E3 denots a Glu-Lys and K3 a 
Lys-Glu (sequences in Figure 6.9). 
In most experiments described in this thesis until now, the E12 splice variant of E2a was 
used. With the publication of the LMO2-LDB1/Tal1-E47/DNA complex structure in 
2013,
124
 it was decided to take advantage of the structural details available for E47 so that 
variant was used in the engineered tethered coiled-coils. An EMSA experiment 
comparing binding of E2a proteins, E12 and E47, to E-box sites (Figure 6.6) indicates 
that E47 is more prone to form E2a homodimers compared to E12. It was considered that 
this variant could benefit most from engineering in a preference to form heterodimers.  
 
Coiled-coils are characterised by heptad repeats
159,160
 (Figure 6.7A). The coils are 
stabilised by a hydrophobic core formed by residues at positions A and D in each coil. In 
Figure 6.6 EMSA experiments of Tal1 and E2a splice variants on radiolabelled DNA. E-box 
dsDNA oligonucleotides (7 nM), labelled with 
32
P, were incubated with varying concentrations 
of co-purified HIS-Tal1 and E2a splice variants (0–0.6 µM); E12 (left panel) or E47 (right 
panel).  
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IAAL E3/K3 the core is surrounded by charged residues at positions E and G, which 
were designed to bias the formation of heterodimers by ionic attraction of heterodimers 
and repulsion of homodimers (Figure 6.7B).  
It was thought that the preservation of the heptad repeat pattern would be an important 
design factor to maintain structural integrity of the helical extensions. The heptad repeat 
pattern of the IAAL E3/K3 coiled-coils is shown in Figure 6.7B. The sequence of both 
IAAL E3 and K3 begin at position G. In order to not interrupt the coiled-coils, the heptad 
repeat pattern must continue through from the bHLH proteins to the IAAL peptides.  
The sequences of the bHLH domains were analysed using three in silico coiled-coil 
prediction programs. These programs generally search for heptad repeats of hydrophobic 
and charged amino acids that are able to form favourable interactions in helices. The 
consensus between COILS,
161
 MultiCOIL
162
 and MARCOIL
163
 was combined with 
structural data to identify heptad repeat positions for Tal1 and E47 (Figure 6.8).  
The predictions for Tal1 were consistent for all three programs and the structural data, but 
those for E47 were different in the MARCOIL prediction (Figure 6.8A). This probably 
arises because MARCOIL performs calculations differently to COILS and MultiCOIL. 
Amongst the predictions by MARCOIL for E47 are two highly charged arginine residues 
that were assigned to charged positions ‘E’ and ‘G’. MARCOIL has been found to be 
sensitive to false positioning of highly charged residues,
164
 so the combination of the 
arginine residues and this problem led to a misassignment of the heptad repeat. Structural 
data (Figure 6.8C) was fully consistent with the positioning predicted by MultiCOIL and 
COILS so this assignment of heptad repeat positions was used in the design steps. 
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As IAAL E3 and K3 start at position g the sequence directly preceding this should end at 
position F in the heptad. It was chosen at random that E47 would be tethered to IAAL E3 
and Tal1 to IAAL K3. For E47 this involved ending the sequence at L73 (assigned F) 
before introducing the IAAL E3 sequence. The bHLH domain of Tal1 ends at E67 
(assigned E) so a non-native residue was introduced at position F before the start of the 
IAAL K3 sequence (Figure 6.9). These two new constructs are named E47_E3 and 
Tal1_K3, respectively. A second set of constructs were designed in which a short (6 or 
Figure 6.7 Helical wheel representation of coiled-coils heptad repeats. A) A typical 
representation of the heptad repeat positions termed A-–G. B) The heptad repeat positions 
of the IAAL E3/K3 coiled-coils from Litowsk et.  al. (2002)
158
.  
A 
B 
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8-residue) Gly/Ser linker was introduced between the bHLH proteins and the IAAL 
coiled-coils to allow some flexibility between the two binding domains. These constructs 
were named Tal1GSK3 and E47GSE3. Full sequences of these constructs can be found in 
Appendix A.2.5. 
 
Figure 6.8 Prediction of Tal1 and E47 coiled-coils heptad repeats. A) Calculated results 
from COILS, MultiCOIL and MARCOIL for the C-terminal residues of the bHLH domains 
of Tal1 and E47. B) The resulting heptad repeat positions (from A) of Tal1 and E47 shown 
in a helical wheel representation. C) The structure of Tal1 and E47 showing predicted 
hydrophobic positions (‘A’ blue and ‘D’ purple) and charged positions (‘E’ yellow and ‘G’ 
red) as sticks. (PDB: 2YPB) 
A 
B 
C 
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6.3.2 Expression and purification of tethered complexes 
The pairs of bHLH tethered complexes (Tal1_K3/E47_E3 and Tal1GSK3/E47GSE3) were 
each cloned into the pETDUET vector (Figure 4.2A) for co-expression as a matched pair. 
Overexpression trials were performed at varying temperatures, with and without 
supplementation with glucose in BL21(DE3) cells (Figure 6.10A).  
Little to no expression could be observed in those cells, so expression was trialled in 
Rosetta II cells (Figure 6.10B). After incubating lysates with Ni-NTA beads, two distinct 
bound species could be observed at the expected sizes for HIS-Tal1_K3 (~11.9 kDa) and 
E47_E3 (~10.5 kDa). Less distinct bands were observed at the expected sizes for 
HIS-Tal1GSK3 (~12.3 kDa) and E47GSE3 (~11.1 kDa). In both cases, expression appeared 
to be marginally better when 2% (w/v) glucose was added to expression media. All 
further production of these bHLH complexes was conducted in Rosetta II cells with 2% 
(w/v) glucose at 22 ˚C. 
Purification was carried out according to co-purification protocols developed for the 
parent bHLH heterodimers, with batch cation-exchange chromatography followed by 
batch Ni-NTA affinity chromatography (Figure 6.11). In general, both sets of bHLH 
tethered complexes, despite showing high levels of insoluble material, resulted in higher 
yields following expression and purification than observed previously for the parent 
bHLH constructs (as illustrated in Section 4.1.2). Indeed, particularly with 
Tal1_K3-E47_E3, the cation-exchange resin was saturated and excess protein eluted 
during flow-through and wash steps.  
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Figure 6.10 Trial expression of bHLH coiled-coil tethered complexes. SDS-PAGE gels 
showing the co-expression of Tal1_K3-E47_E3 (top panels) and Tal1GSK3-E47GSE3 (bottom 
panels) in A) BL21 (DE3) and B) Rosetta™ II E. coli cells. The gels show pre- and post-
-IPTG-induction samples, soluble fraction and samples bound to Ni-NTA beads. Expression was 
performed for ~15 h at 18 ˚C , 20 ˚C  and 25 ˚C for BL21(DE3) trials and 22 ˚C  for Rosetta™ II 
trials. Masses of standard bands are indicated in kDa. 
A 
B 
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Figure 6.11 Purification of tethered 
bHLH coiled-coils. SDS-PAGE gels of 
the purification of Tal1-E47 (top panels), 
Tal1_K3-E47_E3 (middle panels) and 
Tal1GSK3-E47GSE3 (bottom panels). A) 
Cation-exchange chromatography 
showing insoluble and soluble fractions 
of whole cell lysate, the flow through, 
beads after binding and E1–6, fractions 
eluted with increasing concentrations of 
NaCl (150– 600 mM NaCl). B) Ni-NTA 
affinity chromatography. Showing the 
sample loaded from cation-exchange, the 
flow through, beads after binding and 
E1–6, fractions eluted with increasing 
imidazole concentrations (0-250 mM 
imidazole). C) Final purified samples 
following desalting and concentration. 
 
A 
B 
C 
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Reasonably pure fractions (>80% pure as judged by SDS-PAGE, Figure 6.11B) from 
Ni-NTA chromatography of coiled-coil tethered complexes were desalted to remove 
imidazole and excess salt and then concentrated. These samples were stored at 4 ˚C and 
subsequently used in stability experiments. 
The newly designed bHLH tethered coiled-coils were subjected to matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF/MS) to confirm 
their identity (Figure 6.12). For each combination of bHLH proteins two sets of peaks 
were observed, one singly and one doubly charged, resulting in one set of peaks half the 
mass/charge of the other. This is typical of MALDI-TOF/MS and gives confidence to the 
data. Experimental masses were compared to theoretical masses (Figure 6.12D). The 
experimentally determined masses were within error of the theoretical masses minus the 
mass for methionine. It is not uncommon to see the initial methionine removed from 
proteins in vivo in bacteria via a process known as N-terminal methionine excision.
165
 
This data confirmed the identity and integrity of the constructs with high confidence. 
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6.3.3 Increased stability of heterodimers 
The higher levels of protein yield implied that both engineered bHLH pairs were 
stabilised compared to the parent Tal1/E2a heterodimers. To test this further, the stability 
of the heterodimers was assayed by thermal denaturation using thermofluor assays
166
 
(Section 2.8.4).  The protein complexes were mixed with SYPRO Orange fluorescent dye 
and gradually heated. This dye fluoresces strongly when bound to hydrophobic surfaces. 
As the proteins denature, hydrophobic regions become exposed and fluorescence thereby 
Figure 6.12 MALDI-TOF/MS of bHLH tethered complexes. MALDI-TOF/MS profiles of A) 
HIS-Tal1-E47 B) HIS-Tal1_K3-E47_E3 and C) HIS-Tal1GSK3-E47GSE3. D) Theoretical mass of 
HIS-TAL1 and E47 of each bHLH version both full length and without the initial methionine (-M) and 
experimental mass determined by the MALTI-TOF/MS. All masses are in Da.  
B A 
C D 
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increases. The data is processed to determine the fraction of unfolded protein, where the 
maximum fluorescence is assumed to correspond to completely unfolded protein.  
Tal1-E47 and Tal1GSK3-E47GSE3 exhibit predominantly monophasic denaturation 
whereas Tal1_K3-E47_E3 shows biphasic unfolding (Figure 6.13). After reaching 
maximum fluorescence (normalised to 1.0 in Figure 6.13) the fluorescence levels 
decrease. This phenomenon is often observed in this type of assay and is thought to be 
caused by reduced affinity of the dye for hydrophobic residues
167
 and hydrophobic 
residues becoming buried due to aggregation of unfolded proteins
168
. It is not an 
indication of refolding. These data indicate that Tal1GSK3-E47GSE3 denatures at a 
slightly higher temperature than Tal1-E47. The Tm (mid-point of denaturation) is ~42 ˚C 
for the parent and ~ 45 ˚C for the engineered heterodimer. More strikingly, 
Tal1_K3-E47_E3 appears to be substantially more stable with a Tm for the initial phase of 
~48 ˚C and ~67 ˚C for the second phase. The reason for the two phases in this pair is not 
known, but for all the bHLH complexes, denaturation likely involves both the 
dissociation of the dimer and unfolding of (possibly multiple) domains, so it is unlikely to 
be true two-state unfolding. 
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The protein samples were subjected to analytical SEC/MALLS to assess the solution 
molecular weight of each species. Tal1-E47 was not produced at sufficiently high 
concentrations for good quality data collection; however, MALLS data showed a mix of 
species of various molecular weights, including high molecular weight aggregates (data 
not shown). Tal1_K3-E47_E3 and Tal1GSK3-E47GSE43 both eluted as one major peak 
(Figure 6.14) corresponding to a weight average molecular weight of ~26 kDa. A 
shoulder peak eluting after the major peak was observed for Tal1GSK3-E47GSE43, with a 
molecular weight estimate of ~24 kDa; although this estimate would likely be influenced 
by the overlap from the major peak.  
 
Figure 6.13 Thermal denaturation of Tal1-E47 constructs. SYPRO Orange fluorescence 
was measured with increasing temperature. The fraction unfolded was calculated where 
maximum fluorescence was assumed to represent complete denaturation. Constructs were 
assayed at 0.6 mg mL
-1
 and 12 replicates for each construct are shown. 
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Figure 6.14 SEC/MALLS analysis of tethered Tal1-E47 coiled coils. A) Protein concentration 
in refractive index units (solid line) and the calculated molecular weight (·) of BSA, 
Tal1_K3-E47_E3 and Tal1GSK3-E47GSE3. B) MALLS data from A, showing the theoretical 
molecular weight of monomeric BSA and each dimer combination for the bHLH proteins, the 
calculated experimental weight-averaged molecular weight and polydispersity of each peak. The 
error of fit for the weight-average molecular weight was <1% in each case, but the error of the 
method is assumed ~10%. C) SDS-PAGE analysis of samples eluted from SEC/MALLS 
experiments. Note that although there is no peak2 from Tal1_K3-E47_E3, a sample taken at the 
equivalent volume to that of Tal1GSK3-E47GSE3 peak2 was taken for SDS-PAGE analysis for 
comparison. 
 
 Theoretical MW (kDa) MALLS 
 Tal1-Tal1 E47-E47 Tal1-E47 MW (kDa) Polydispersity 
∎BSA   66.5 61.8 1.006  
∎Tal1_K3-E47_E3 23.8 21.2 22.5 *26.1 1.008 
∎Tal1GSK3-E47GSE3 24.6 22.2 23.4 *25.8 1.003 
    *23.5 1.000 
 
A 
B 
C 
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SDS-PAGE analysis of the samples from these experiments showed that the major peak 
contains both proteins for each Tal1 and E47 species (Figure 6.14C), whereas the sample 
from the latter Tal1GSK3-E47GSE3 shoulder peak appeared to contain predominantly a 
band that corresponds to Tal1GSK3, indicating that this may be Tal1 homodimer. It 
should be noted, however, that it is possible that the peak contains both proteins, which 
may have not separated well during SDS-PAGE. The weight-average molecular weights 
for the main peaks are slightly higher than expected for heterodimers, indicating that 
there could be small amounts of higher molecular weight species present. It is possible 
that the main peaks contain mixtures of homo- and heterodimers, but the close to equal 
weighting of the bands in SDS-PAGE indicate there is a combination of heterodimer 
and/or homodimers with equal quantities of both Tal1 and E47-containing homodimers 
and the simplest explanation for this is that heterodimers are present. Binding data has 
indicated that E2a homodimers have a much lower association constant than Tal1-E2a 
heterodimers in the absence of DNA,
71
 therefore it is more likely that heterodimers are 
formed. Overall the data for both tethered complexes are consistent with a high 
proportion of heterodimers in solution, especially in the case of Tal1_K3-E47_E3.  
6.3.4 Maintenance of higher order complex formation 
EMSAs were used to assess binding of the engineered and wild-type heterodimers to 
E-box oligonucleotides. As shown previously, Tal1-E47 titrations resulted in two shifted 
bands, where the higher band is supershifted by anti-HIS antibodies and corresponds to 
the Tal1-E47 heterodimer bound to DNA, while the lower band corresponds to the E47 
homodimer bound to DNA (Figure 6.15A). Under these conditions, the heterodimer band 
is very faint, consistent with a strong preference for E47-E47-DNA complexes over 
Tal1-E47-DNA complexes (Figure 6.6).  
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Tal1_K3-E47_E3 also resulted in two shifted bands, at slightly higher positions, 
consistent with these proteins having higher molecular weights than Tal1-E47. Again, 
super-shifting indicated that the higher band corresponds to heterodimer on DNA, 
whereas the non-super-shifted lower band corresponds to E47_E3 homodimers on DNA. 
In this case, however, the heterodimer band was much more intense than the lower band, 
suggesting that the design strategy has induced preference for heterodimer formation. The 
Tal1GSK3-E47GSE3 titrations appeared to result in a single shifted band that was 
significantly decreased by super-shifting, suggesting that is corresponds to the 
heterodimer on DNA.   
The residual band in the super-shifted lane could correspond to an incomplete super-shift 
caused by insufficient antibody; however, given that the Tal1GSK3-E47GSE3 proteins are 
larger, and differences in size are harder to distinguish for larger complexes, it is also 
possible that some homodimer-DNA complex is formed, but this band overlaps the 
heterodimer-DNA band. Repeating the super-shift under the same conditions showed less 
residual band (Figure 6.15B).  
The experiment was also repeated with a longer running time to gain higher resolution of 
separation in the relevant part of the gel. This experiment showed three bands, two of 
which super-shifted with incubation of anti-HIS antibody (Figure 6.15C). Residual signal 
around the lowest band may correspond to small amounts of homodimer-DNA complex, 
but the top two bands clearly contained HIS-Tal1GSK3. Given that Tal1 alone does not 
show effective DNA binding,
71
 these bands likely represent alternate heterodimer-DNA 
conformations.  
Overall both engineered tethered bHLH constructs gave a substantially higher proportion 
of heterodimer-DNA compared to E47 homodimer-DNA complexes.  
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Figure 6.15 EMSA of tethered Tal1-E47 coiled-coils.  
A) Co-purified Tal1-E47 (0, 4, 8, 20 and 40 µM), Tal1_K3-E47A_E3 and Tal1GSK3-E47GSE3 heterodimers 
(0, 4, 8, 10 and 20 µM) were incubated with fluorescently labelled E-box dsDNA oligonucleotides (100 
nM). Samples were run on a 10% acrylamide gel at 16 mA for ~2 h. B) Co-purified Tal1_K3-E47_E3 and 
Tal1GSK3-E47GSE3 heterodimers (8 µM) were incubated with fluorescently labelled E-box dsDNA 
oligonucleotides (25 nM). Samples were run on a 10% acrylamide gel at 16 mA for ~2 h. C) Co-purified 
Tal1GSK3-E47GSE3 heterodimers (0, 0.1, 0.5, 1 and 2 µM ) were incubated with fluorescently labelled 
E-box dsDNA oligonucleotides (25 nM). Samples were run on a 10% acrylamide gel at 16 mA for ~4 h. 
The sample run in the last lane for each construct set was incubated in the presence of anti-HIS antibody.  
B 
A 
C 
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These newly designed bHLH tethered coiled-coils must be able to maintain binding to 
LMO proteins in order to use them in experiments involving higher order complexes. 
EMSAs indicate that both Tal1_K3-E47_E3 and Tal1GSK3-E47GSE3 in complex with 
DNA are able to undergo a second shift when incubated with increasing amounts of 
LMO2-LDB1 (note that for Tal1GSK3-E47GSE3, the initial complex bands were faint and 
are difficult to see in print, because of the low initial Tal1-E47 concentration used, but the 
positions of the bands are indicated). This second shift in each case indicates that LMO 
binding is maintained, despite the elongation of the bHLH heterodimers with non-native 
coiled-coils (Figure 6.16).  
 
  
Figure 6.16 EMSA of LMO2-LDB1 binding DNA:tethered Tal1-E47 coiled-coil complexes. 
Tal1_K3-E47_E3 (15 µM, left) or Tal1GSK3-E47GSE3 (8 µM, right) in complex with DNA 
(100 nM) were incubated with varying concentrations of purified LMO2-LDB1 (0, 0.1, 1, 4 and 
8 µM).  
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6.4 DISCUSSION  
6.4.1 Tal1-E2a binds LMO2 more tightly than LMO1 and LMO3 
Microscale thermophoresis was initially employed to determine binding affinities 
between bHLH and LMO proteins. Dissociation constants appeared to be severely 
underestimated with this technique, most likely due to the fluorescent labelling processes 
and complications arising from titrations of Tal1 and E12 at concentrations in the region 
of their dimerisation dissociation constants. In these experiments primary amines 
(N-terminus and lysines residues) of LMO-LDB1 proteins were labelled using the 
commercially available RED-NHS protein labelling Kit. Within the Tal1-E2a binding 
interface there is a lysine (K74, magenta Figure 6.17) which is of particular concern as 
bound dye could interfere with the interaction, leading to an underestimation of binding 
affinity. 
 
Preliminary MST data indicates LMO1-LDB1 and LMO3-LDB1 bind to Tal1-E2a with 
almost identical affinities, around three fold weaker than LMO2. Although unverified, as 
Figure 6.17 LMO2 K74 lies at the Tal1-E2a binding interface. The structure of 
LMO2-LDB1 (cyan) bound to Tal1-E2A (red and orange, respectively) showing 
LMO2-K75 (magenta), which lies at the binding interface. PDB: 2YPA 
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the experiments were not repeated and because the binding affinities appear to be 
underestimated in this approach, this is consistent with sequence and functional 
similarities between LMO1 and LMO3 compared to LMO2, and we would expect the 
two similar proteins to have similar behaviours. In particular, these relative binding 
affinities are consistent with EMSA and pulldown experiments from the previous chapter, 
that LMO4-LDB1 cannot bind Tal1-E12 with significant affinity. 
6.4.2 Tal1-E47 heterodimerisation bias by fusion to coiled-coils  
To attempt to more accurately determine the binding affinities of Tal1-E47 to LMO 
proteins the bHLH proteins were tethered to coiled-coils. As designed both versions (with 
or without a Gly/Ser linker) proved more generally stable from thermal denaturation 
experiments (Figure 6.13). It was notable that Tal1_K3-E47_E3 gave rise to biphasic 
denaturation curves. In the case of dimeric proteins, there are two events that expose 
hydrophobic patches that could manifest as distinct phases in denaturation experiments; 
monomerisation and protein unfolding. Dimer denaturation where monomers are 
intrinsically unstable would exhibit apparent monophasic (two-state) unfolding, as the 
monomers would immediately unfold upon dissociation. For three-state, (biphasic) 
denaturation to occur in this scenario, monomers must be sufficiently stable to form an 
intermediate population before unfolding
169
. In order to observe this biphasic 
denaturation, there must also be a significant difference between the stability of the dimer 
and monomer. It was notable that both the untethered and GS-linker versions do not 
exhibit a biphasic curve. These data may indicate that monomers Tal1_K3 and E47_E3 
are more stable than the wild-type or linker-containing monomers. If the design has 
worked as intended, the extension of a highly structured helix, without interruption by a 
linker, should have increased the stability of these Tal1_K3 and E47_E3 monomers. It 
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should be possible to test this in future experiments, by monitoring unfolding using 
far-UV circular dichorism spectropolarimetry. In this type of experiment one might 
expect to see coiled-coil characteristics at the start of the experiment (e.g., a ratio of 
ellipticity at 208 nm:222 nm<1) followed by dissociation into helical monomers 
(characterised by a ratio of ellipticity at 208 nm:222 nm >1), and finally by loss of 
helicity as the monomers unfold. 
Regardless of the basis for biphasic denaturation, both engineered dimers show an 
increase in apparent stability compared to the parent proteins, with Tal1_K3-E47_E3 (no 
linker), exhibiting the bigger shift in Tm of the initial unfolding phase, which indicates 
significantly higher stability. This improved dimer stability is echoed in SEC/MALLS 
experiments, where Tal1_K3-E47_E3 appears to have increased monodispersity.  
The EMSA experiments also support a higher proportion of heterodimer over homodimer 
bound to DNA for both Tal1_K3-E47_E3 and Tal1GSK3-E47GSE3 compared to Tal1-E47 
(Figure 6.15A). This proportion may be higher for Tal1GSK3-E47GSE3, but the presence 
of multiple bands of similar migration properties (Figure 6.15C) makes it difficult to 
distinguish between forms. Overall, however, these experiments indicate that the 
equilibria associated with bHLH monomer/dimer exchange (Figure 4.3A) have been 
altered to favour the formation of heterodimers.  
The additional (third) gel-shifted band formed by Tal1GSK3-E47GSE3 may arise from the 
presence of the GS linker. This small but likely flexible region could allow the bHLH and 
the coiled-coils portions of the tethered complexes to move independently, which could 
allow multiple complexes to form via domain swapping. For example, E47 could 
homodimerise leaving E3 free to heterodimerise with K3 from a Tal1GSK3 protein 
(Figure 6.18). The predicted rigidity of Tal1_K3 and E47_E3 proteins would reduce the 
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likelihood of the same type of domain swapping occurring in those complexes. Such a 
model would rely on these multimers being somehow favoured by DNA-binding, as 
MALLS data does not show a tetramer peak.  
 
In summary it is likely that both coiled-coil tethered complexes successfully improved 
heterodimer stability while maintaining the ability to form higher order complexes with 
LMO proteins. However, in solution Tal1_K3 and E47_E3 showed the highest propensity 
to form heterodimers and Tal1GSK3 and E47GSE3 exhibited additional conformational 
forms when bound to DNA and in solution. Therefore Tal1_K3 and E47_E3 are the most 
suitable for further interaction studies and will hopefully allow for binding data to be 
collected more confidently than previously. Unfortunately, time constraints meant that 
data could not be obtained as part of this thesis. 
Figure 6.18 Illustration of theoretical complex conformations. 
Possible conformations of bands observed in EMSA from 
Figure 6.15. Showing either the designed heterodimer (left) or 
E47 homodimers bound to DNA with E3-K3 coiled-coil domains 
forming heterodimers with other Tal1homodimers (forming a 
domain-swapped tetramer). Note that additional higher order 
complexes could be formed through the same mechanism. 
 
 C H A P T E R  S E V E N  
G a t a  I N T E R A C T I O N S  I N  L M O  
C O M P L E X E S  
7.1 INTRODUCTION 
7.1.1 Gata1–3 can interact with LMO1–3 
Gata proteins have two zinc fingers, the N-finger and the C-finger. The involvement of 
Gata1 in LMO2 haematopoietic transcriptional complexes has been known for over 15 
years.
20
 NMR data has showed that the NF of Gata1 and the second LIM domain (LIM2) 
of LMO2 are involved in the interaction and Figure 7.1 shows a model of the complex 
generated based on this data.
81
 Preliminary data has shown that Gata1–3 NF can interact 
with LMO1–3 but not LMO4170 and 
that constructs containing both the 
N-finger (NF) and C-finger (CF) of 
Gata1 can interact with LMO1–3, but 
not LMO4.
171
 The interaction 
between LMO2LIM2 and Gata1NF is 
relatively weak (KA ~5 x 10
4
 M
-1
);
81
 
however, it has been shown that both 
LMO1LIM2 and LMO3LIM2 bind Gata1 
with slightly higher affinity 
(KA ~4.7 x 10
5
 M
-1
 and 6.9 x 10
5
 M
-1
, 
respectively).
171
 The sequence similarity between family members for Gata1–3 and 
LMO1–3 provides a rationale for analogous binding between family members. Although 
Figure 7.1 Model of Gata1 bound to LMO2. Data 
driven model of the LDB1 (yellow) and the second 
LIM domain of LMO2 (blue) bound to Gata1 NF 
(red). Adapted from Wilkinson-White et. al. (2011). 
 
CHAPTER SEVEN: THE ROLE OF Gata IN LMO COMPLEXES 145 
 
some combinations have no biological relevance for normal development because they 
are not known to be co-expressed in the same cells, many combinations of interactions 
may have additional relevance for disease (see Sections 1.3.1 and 1.3.2).  
7.1.2 The Gata zinc fingers and DNA binding 
While both fingers of Gata1 have been shown to bind DNA (Figure 7.2), only the 
N-finger has been shown to bind proteins.
28,172
 The C-finger of Gata1 binds to motifs 
containing a [A/T]GATA[A/G] sequence with high affinity, whereas Gata1NF binds 
GATC/G or double GATA sites, as discussed in Section 1.2.4. 
 
A 
B 
Figure 7.2 Gata1. A) Schematic of full length Gata1.  B) The structure of both N-finger (magenta) 
and C-finger (cyan) binding DNA. (PDB: 3VD6).   
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7.2 Gata1–3 BIND LMO2 WITH SIMILAR AFFINITY 
To assess binding affinities between LMO2-LDB1 and the N-finger of Gata1–3 
(sequences in Appendix A.3 and from hereafter referred to as Gata1–3NF), MST 
experiments were carried out using three different methods of protein labelling 
(Figure 7.3). Either LMO2-LDB1 or Gata1NF were labelled through covalent attachment 
to primary amines (lysine side-chains or N-termini) using the Monolith™ Protein 
labelling kit, or LMO2-LDB1 was expressed and purified with a C-terminal cyan 
fluorescent protein (CFP) tag. Single experiments for each method were carried out to 
determine the best labelling approach for this system. As the interaction between LMO2 
and Gata1NF is relatively weak, high concentrations of proteins were required to detect 
the interaction. Despite this, each of the three methods produced clean capscans with 
sharp peaks and well-defined raw fluorescence scans indicating there was no sticking of 
sample to the capillaries, nor were there significant levels of aggregation. Although no 
aggregation was detected, it is possible that non-specific interactions could compromise 
accurate data fitting, especially towards the ends of the titration where protein 
concentrations were highest.  
The method in which primary amines of LMO2-LDB1 were labelled resulted in 
incomplete binding curves at the protein concentrations used, indicative of very weak 
interactions that cannot be accurately determined (see previous chapter, Section 6.2.1).  
Of the two methods where the interaction appeared to have reached completion, the 
experiment where Gata1 primary amines were labelled resulted in the lowest affinity 
estimates. As discussed in the previous chapter (Section 6.4.1), labelling of these 
functional groups may interfere with binding. For example the HADDOCK model of 
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Gata1NF:LMO2LIM2-LDB1 indicates that K137 of LMO2 lies at the Gata1 interface, hence 
labelling of this residue may affect LMO2 binding.  
 
The titration of Gata1 with CFP-labelled LMO2-LDB1 (Figure 7.3C) was more complete. 
It is possible this is due to the binding interface residues no longer being obstructed (note 
that the C-terminus of the construct in not implicated in binding to Gata1NF).
81
  This 
method was subsequently used to estimate the affinities of LMO2-LDB1 for Gata1–3NF 
(Figure 7.4). All three GataNF proteins gave similar affinities to LMO2-LDB1, with 
Gata1NF appearing to have a slightly higher affinity (KA ~1.5 x 10
5
 M
-1
) than Gata2NF and 
Gata3NF (KA ~4.4  10
4
 M
-1
 and ~7.7  104 M-1, respectively). 
Figure 7.3 MST trials for LMO2-LDB1 to Gata1NF binding using different methods of labelling. A) 
LMO2-LDB1 (1.25 mM) was titrated into Gata1NF (100 nM) labelled with amine reactive dye. B) Gata1NF 
(850 µM) was titrated into LMO2-LDB1 (50 nM) labelled with amine reactive dye. C) Gata1NF (360 µM) 
was titrated into LMO2-LDB1-CFP (100 nM). Normalised fluorescence was plotted at a function of 
concentration of the titrated partner. Experiments A) and B) were performed at 25 ˚C and C) at 18 ˚C in 
20 mM Tris (pH 7.5), 150 mM NaCl and 1 mM DTT. D) Summary table of fitted dissociation constants and 
corresponding affinities, where errors are standard errors of the fit. 
 
A B C 
D Labelled 
partner 
Label KD (µM) KA (M
-1) R2 
Gata1NF  Amine reactive dye N/A N/A 0.985 
LMO2-LDB1 Amine reactive dye 38 ± 7 (2.6 ± 0.5) x 104 0.987 
LMO2-LDB1 Tethered CFP  7.7 ± 1.6 (1.3 ± 0.3) x 105 0.982 
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The estimate for CFP-tethered LMO2-LDB1 binding to Gata1NF was slightly higher than 
that determined using NMR data from chemical shift perturbation titration experiments 
(KA = 5  10
4
 M
-1
).
81
 However, it should be noted that the published affinity was 
determined for the LIM2 domain of LMO2 only, whereas both LIM domains were 
present in the LMO2 constructs used here. Data from similar NMR titrations using 
LMO2 did not yield good estimates of binding affinity because of spectral overlap, but 
were suggestive of slightly tighter binding (Wilkinson-White, unpublished data) in line 
with the data obtained here.  
 
 
Figure 7.4 MST of LMO2-LDB1 binding to Gata1–3NF. A) Gata1NF (361 µM) B) Gata2NF (800 µM) or 
C) Gata3NF (~360 µM) were titrated into LMO2-LDB1-CFP (100 nM). Normalised fluorescence was 
plotted at a function of concentration GataNF. Experiments were performed at 18 ˚C in 20 mM Tris (pH 
7.5), 150 mM NaCl and 1 mM DTT. D) Summary table of averaged fitted dissociation constants (n=2) and 
corresponding affinities, where errors represent the range in the data.   
 
A B C 
D 
 KD (µM) KA (M
-1) R2 
Gata1NF 6.6 ± 1.1 (1.5 ± 0.2) x 10
5 0.981 
Gata2NF 23 ± 11 (4.4 ± 2.2) x 10
4 0.992 
Gata3NF 13 ± 6 (7.7 ± 3.7) x 10
4 0.950 
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7.3 Gata1–3 DNA SITE PREFERENCES 
7.3.1 The N-finger of Gata1–3 binds DNA weakly 
MST was used to determine binding affinities of Gata1–3NF to dsDNA oligonucleotides 
containing GATC and GATG sites (described in Section 7.1.2, sequences in Appendix B) 
where the DNA was labelled with a fluorescein on the 5’ termini (Figure 7.5). 
Interactions between Gata1–3NF and both DNA sequences were so weak that binding 
curves at physiological salt (150 mM NaCl) did not reach completion, even with very 
high concentrations of protein (~1 mM; Figure 7.5C). For this reason, experiments were 
run at 30 mM NaCl, where binding can be detected. In each case, Gata2NF and Gata3NF 
bound with similar affinities. There was a slight preference for GATG- over 
GATC-containing oligonucleotides for these proteins. In contrast, Gata1NF bound both 
sequences with the same affinity. Although these data were each obtained from a single 
experiment, they indicate that GATC sequences have a slight preference for binding by 
Gata1NF and GATG sequences for binding by Gata2NF and Gata3NF.  
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Figure 7.5 MST of Gata1–3NF binding DNA at GATC and GATG sites. Gata1NF (1.3 mM), Gata2NF 
(1.8 mM) or Gata3NF (1.5 mM) were titrated into DNA with a A) and B) GATC site (100 nM) or a C) and D) 
GATG site (100 nM) in 150 mM or 30 mM NaCl, respectively. Fraction bound is plotted as a function of 
Gata1–3NF concentration. Fraction bound was calculated from fitted values for M1 (change in FNORM signal) 
and T1 (starting FNORM signal). Experiments were performed at 25 ˚C in 20 mM Tris (pH 7.5), 1 mM DTT and 
NaCl (150 mM or 30 mM). E) Summary table of fitted dissociation constants of B) and D) and corresponding 
affinities calculated from single experiments, where errors are standard errors of the fit. 
 
A B 
C D 
E DNA Protein KD (µM) KA (M
-1) R2 
 Gata1NF 25 ± 2 (4.0 ± 0.3) x 10
4 0.998 
GATC Gata2NF 110 ± 10 (9.5 ± 0.9) x 10
3 0.996 
 Gata3NF 90 ± 10 (1.1 ± 0.1) x 10
4 0.993 
 Gata1NF 27 ± 10 (3.8 ± 1.4)  x 10
4 0.947 
GATG Gata2NF 2.5 ± 0.9 (4.1 ± 1.5) x 10
5 0.956 
 Gata3NF 3.6 ± 1.1 (2.8 ± 0.9)  x 10
5 0.979 
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7.3.2 The C-finger of Gata1 binds DNA more tightly than the 
N-finger 
Similar experiments were performed using Gata1CF (sequence in Appendix A.3) at 
physiological salt concentrations for direct comparison with Gata1NF (Figure 7.6). When 
binding both GATC- and GATG-containing oligonucleotides, Gata1CF bound to both 
sequences with affinities that were at least several orders of magnitude higher than 
Gata1NF. However, the data from these experiments could not be fitted by a one binding 
site model so estimates of binding affinities are indicative only. 
 
Isothermal titration calorimetry was employed to obtain better estimates for Gata1CF 
binding affinities (Figure 7.7). Experiments were initially run at 25 ˚C (data not shown), 
Figure 7.6 MST Gata1NF vs. Gata1CF binding DNA containing GATC and GATG sites. A) Gata1NF 
(1.3 mM) or Gata1CF (20 µM) were titrated into DNA containing a GATC site (100 nM). B) Gata1NF 
(425 µM) or Gata1CF (17 µM) were titrated into DNA containing a GATG site (100 nM). Fraction bound is 
plotted as a function of Gata1 concentration. Fraction bound was calculated from fitted values for M1 
(change in FNORM signal) and T1 (starting FNORM signal). Experiments were performed at 25 ˚C in 20 mM 
Tris (pH 7.5), 150 mM NaCl and 1 mM DTT. C) Summary table of fitted dissociation constants and 
corresponding affinities calculated from single experiments, where errors are standard errors of the fit. 
 
A B 
C 
DNA Protein KD (µM) KA (M
-1) R2 
GATC 
Gata1NF N/A N/A N/A 
Gata1CF 1.1 ± 0.6 (9.1 ± 5.1) x 10
5 0.884 
GATG 
Gata1NF N/A N/A N/A 
Gata1CF 0.74 ± 0.2 (1.4 ± 0.4) x 10
6 0.969 
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but the low enthalpy changes at this temperature, resulted in low confidence levels for the 
fitted data. Changes in enthalpy were significantly increased when the experiments were 
performed at 15 ˚C. Experiments with GATG-containing oligonucleotides showed some 
evidence of non-specific binding in the form of steady state enthalpy changes at the end 
of the titrations, even following correction for Gata1CF into buffer. For these experiments 
baselines that were manually estimated from the data were subtracted and data fit to a one 
binding site model.  
The interactions between Gata1CF and GATC- or GATG- containing oligonucleotides 
were robust and very similar; KA ~1.7  10
7
 M
-1
 and ~1.5  107 M-1, respectively. Both 
interactions also gave stoichiometry of ~1, indicating 1:1 binding.  
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7.4 DISCUSSION 
7.4.1 Gata1–3 in LMO transcriptional complexes 
Gata1–3NF can directly interact with LMO2 with similar affinities in vitro, providing 
experimental evidence to support a role for Gata2 and Gata3 in LMO2-containing 
transcriptional complexes where those proteins substitute for Gata1 as described in 
Section 1.3.1. While Gata1 and Gata2 are co-expressed with LMO2 in developing red 
blood cells and haematopoietic stem cells, respectively, Gata3 is not normally 
Figure 7.7 ITC data for GATA1CF titrated into DNA containing GATC and GATG sites. GATA1CF 
(100 µM) was titrated into DNA at A) GATC-containing or B) GATG-containing oligonucleotides 
(10 µM). Experiments were performed in 20 mM Tris (pH 7.5), 150 mM NaCl and 1 mM DTT at 15 ˚C.  
Baseline data were measured by titration of GATA1CF into buffer, and subtracted from experimental data. 
Integrated heats were plotted as a function of GATA1CF:DNA molar ratio. C) Data were analysed using 
the Origin 7.0 ITC Data analysis software package (MicroCal) to generate estimates of association 
constants, stoichiometry and change in enthalpy.  
 
 
A B 
C 
 KA (M
-1) ΔH (kcal mol-1) N 
GATC (1.7 ± 0.9) x 107 6030  ± 230 0.98 ± 0.02 
GATG (1.5 ± 0.6) x 107 5150 ± 140 1.21 ± 0.02 
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co-expressed with LMO2. However, Gata3 is expressed in developing T-cells, and has 
been shown to complex with Tal1 and LMO2 in leukaemia.
110
 In contrast, Gata1 is not 
normally expressed during T-cell development or in leukaemic T-cells.
173
 
7.4.2 DNA binding abilities of Gata1 N- and C-fingers 
The CF of Gata proteins bind DNA at (A/T)GATA(A/G) sites with high specificity and 
affinity. The N-finger, despite predominantly acting to interact with other proteins, has 
been found to bind DNA at GAT(C/G) sequences under some circumstances, such as 
binding pseudo-palindromic double GATA sites (Section 1.2.4). The data from this 
chapter shows that the isolated N-finger does not show significant levels of binding to 
GATC- or GATG-containing DNA under physiological concentrations of salt, in support 
of chromatin binding studies, where there was no evidence of Gata1 binding to isolated 
GAT(C/G) sites.
174
 Even if Gata1 binding to such sites had been detected, it would be 
more likely to be mediated by Gata1CF as this domain binds DNA containing those sites 
with an affinity at least three orders of magnitude higher than that of the Gata1NF (Figure 
7.5). DNA binding by the Gata1NF is therefore likely to be restricted to making contacts 
with GATC and GATG sequences at pseudo-palindromic double GATA sites, where 
binding is mediated via the C-finger and binding of the N-finger (to GATC/G sites) only 
acts to stabilise the interaction. 
 
 C H A P T E R  E I G H T  
M E C H A N I S T I C  I M P L I C A T I O N S  O F  L M O  
T R A N S C R I P T I O N A L  C O M P L E X E S  
8.1 CONSTITUENTS OF LMO COMPLEXES IN T-ALL 
This thesis has outlined the characterisation of protein interactions between proposed 
members of complexes involved in T-ALL. These complexes resemble the core 
pentameric LMO2 transcriptional complex, as described Chapter 1, but where 
endogenous or ectopically expressed homologues substitute for the complex subunits. 
Interactions between LMO1-3 and Tal1-E2a or Lyl1-E2a complexes have indicated 
LMO1 and LMO3 could replace LMO2, and Lyl1 likely replaces Tal1 to form alternate 
complexes, some of which are important for T-ALL.  
LMO1, LMO2, Tal1 and Lyl1 are all known T-ALL oncogenes and have each been 
observed to have aberrant levels of expression in leukaemic T-cells, (often in 
combination), as described in Chapter 1. Although, LMO3 has not previously been 
implicated in T-ALL, a recent chromatin cross-linking study identified LMO3 as a 
potentially leukaemogenic translocation partner of TCRβ.175 This type of translocation is 
very similar to those involving the other T-ALL oncogenes, which typically cause the 
up-regulation of the target gene in T-cells (see section 1.3). With binding data presented 
here, those data hint at a previously unrecognised oncogenic function for LMO3. 
The interaction of LMO2 with Tal1 appears to be an important feature of transcriptional 
regulation in blood cell development. However, the interactions involving LMO1 and 
LMO3 with Tal1 and Lyl1 appear to be opportunistic in T-ALL precursors. Preliminary 
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data presented in Chapter 6 shows that apparent binding affinities of LMO1–3 all appear 
very similar, although it is noted that the affinities measured by MST (~10
5
 M
-1
) appear 
to be significantly under-estimated. It is likely that LMO1–3 interact with bHLH proteins 
to form larger oncogenic complexes where local expression patterns, whether ectopic or 
endogenous, are utilised. Similar LMO/bHLH interactions have been observed in other 
cancers. For example, LMO3 interacts, and acts synergistically, with the bHLH protein 
HEN2 in neuroblastomas.
34,147
 It seems likely, therefore, that similar transcriptional 
complexes are active in other LMO related cancers. 
All haematopoietic Gata proteins, Gata1–3, were shown to interact with LMO2 in MST 
experiments with reasonable and similar affinities (10
4–105 M-1). Although Gata proteins 
are not known as T-ALL oncogenes, Gata3 is the only endogenous Gata in T-cells 
making it likely that Gata3 takes the place of Gata1 in transcriptional complexes that give 
rise to T-ALL. Indeed, it has been demonstrated that Gata3 can act synergistically with 
Tal1 and LMO1, where a 2–3-fold increase in transcriptional activity of Tal1 and LMO2 
was observed in CAT-reporter assays when Gata3 was expressed.
109
  
In early erythropoiesis the dynamic temporal regulation of Gata1 and Gata2 leads to only 
one member having a predominant presence at any one time.
176
 Gata2 is expressed during 
the early stages of erythropoiesis and has been found to co-localise with Tal1-E2a
177,178
 
and LMO2
179
 prior to displacement by Gata1. Thus Gata2 is the Gata family protein in 
transcriptional complexes during early erythropoiesis, when Gata2 levels are high and 
Gata1 levels are low. The displacement of Gata2 by Gata1 is crucial for the control of 
haematopoiesis.
176
 The ability for Gata1 to functionally compete with Gata2 therefore 
becomes critical. The MST data presented in replicate in Chapter 7 indicate a slightly 
higher affinity of Gata1 (KA ~1.5 x 10
5
 M
-1
) for transcriptional complex binding partner, 
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LMO2, compared to Gata2 (KA ~4.4 x 10
4
 M
-1
). This difference provides a likely 
mechanism for subunit exchange within active transcriptional complexes.  
In summary, variants of the core pentameric LMO2 transcriptional complex likely form 
in T-cells leading to changes in transcriptional programs that trigger the onset of T-ALL. 
These complexes may contain different combinations of ectopically expressed LMO 
proteins (LMO1–3) and bHLH heterodimers (Tal1-E2a or Lyl1-E2a) or endogenously 
expressed Gata3.  
8.2 LMO PROTEINS ACT SYNERGISTICALLY WITH 
Tal1/Lyl1 TO LOCK E2a PROTEINS INTO HETERODIMERS 
Strong evidence has shown that the LMO-containing complexes affect transcriptional 
programs in T-ALL by sequestering E2a proteins to suppress expression of genes that 
promote T-cell maturation and reactive genes that give the cells stem cell-like properties 
(see Section 1.3.3). E2a proteins have important roles in lymphocyte development. 
E2a-deficient mice develop T-cell leukaemia following a partial block in 
differentiation.
120
 It has previously been shown that LMO2 stabilises Tal1-E12 
complexes, thereby helping to sequester E2a proteins.
71
 Chapter 5 demonstrated that Tal1 
forms DNA-bound complexes with both E12 and E47 in EMSA experiments, although in 
the absence of other proteins, Tal1-E12 complexes form more readily on DNA than 
equivalent Tal1-E47 complexes (Figure 6.6). Moreover, it was shown that each of 
LMO1–3 stabilises Tal1-E2a, and LMO2 stabilises Lyl1-E2a complexes on DNA 
(Figures 5.4 and 5.5) and promote increased sequestration of E2a proteins from 
homodimers on DNA (Figures 5.6 and 5.7). This stabilising effect appears to be brought 
about by conformational changes adopted by the heterodimer when bound to LMO2. As 
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shown by a comparison of Tal1-E47 and LMO2-LDB1/Tal1-E47 structures, when 
Tal1-E47 binds LMO2 the creation of a new bonds between Tal1 and E47 are generated 
(Figure 8.1).
124
 It is likely that similar conformational changes take place upon binding of 
the other LMO proteins, LMO1 and LMO3.  
In support of these mechanistic details, Tal1 and LMO2 have been shown to cooperate in 
repression of E2a regulated genes. CD4, a glycoprotein expressed during T-cell 
maturation, is under regulation of E2a proteins.
180
 The CD4 enhancer was partially 
repressed in the presence of ectopically expressed Tal1 or LMO2, but was completely 
repressed when both proteins were expressed; this repression was reversed by the 
introduction of further E2a proteins.
98
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Data presented in Chapter 5 indicates that LMO proteins have a greater effect on Lyl1- 
over Tal1-driven E2a sequestration. These data provide a possible explanation for why 
overlapping expression of Lyl1 and LMO2 are particularly important in some types of 
T-ALL. In a recent study LMO2-transgenic mice showed a decrease in thymocyte 
self-renewal and the block of T-cell differentiation in the absence of Lyl1 but not with 
deletion of Tal1.
157
 It was concluded that Lyl1 is more critical to the oncogenic functions 
of LMO2 in T-ALL compared to Tal1. From the data presented in this thesis, it seems 
likely that Lyl1 forms DNA-binding heterodimers with E2a much less effectively than 
Tal1. For example, in the absence of an LMO-LDB1 construct, no obvious gel-shift band 
Figure 8.1 Tal1-E47 alone and bound to LMO2. Structures of Tal1 (red) and E47 (orange) alone or 
bound to LMO2 aligned. Structure of the heterodimer alone is represented in lightened colours. Upon 
binding of LMO2 conformational changes in the heterodimer create the formation of three new bonds 
between Tal1 and E47. These include two new hydrogen bonds (Q246:V603 and R230:D561) and one salt 
bridge (R230:E568). PDB: 2YPB (Tal1-E47 alone) and 2YPA (LMO2 bound Tal1-E47). 
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containing Lyl1 was observed by EMSA, but Lyl1-containing gel-shift bands formed 
readily upon the addition of LMO2-LDB1 (Figure 5.5). This suggests that Lyl1 is much 
more dependent on LMO2 for sequestration of E2a proteins. 
8.3 N-FINGER DNA BINDING OF Gata PROTEINS 
As described in Chapter 1, the C-finger is the major DNA binding domain of Gata 
proteins. Despite suggestions that the N-finger can independently bind variant DNA 
sites,
82
 the MST data from Chapter 7 shows that the N-finger cannot bind DNA 
independently under physiological salt concentrations in vitro, suggesting that it is 
unlikely to bind DNA independently in vivo (Figure 7.5). These observations are 
consistent with chromatin binding studies that report canonical GATA- and 
pseudo-palindromic sites as the key Gata1NF-binding motifs in vivo, where the N-finger 
aids the C-finger to stabilise DNA binding.
174
 This is supported by studies that suggest 
that the N-finger of Gata proteins increase DNA binding at pseudo-palindromic sites by 
an approximate order of magnitude.
181
 At this stage it is difficult to establish the 
importance of DNA-binding by the N-finger, because Gata1 at active gene sites is 
thought to be part of the pentameric complex,
182-184
 and the N-finger cannot 
simultaneously bind DNA and LMO2.
81
  
It is possible that the ability of the N-finger to bind DNA assists Gata1/DNA binding 
during cell division. Prior to cell division most transcription factors are cleared, where 
only a few are retained for ‘bookmarking’ function. Gata1 is one of these ‘bookmarking’ 
transcription factors.
185
 It is possible that the N-finger aids the C-finger to stabilise 
DNA-binding during this time, when other transcription factors are scarce. After mitosis, 
when other transcription factors become available, DNA binding of the N-finger would 
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be minimised by competition with protein binders, such as LMO2. Indeed LMO2 binding 
to the N-finger of Gata1 (Figure 7.4; KA ~ 1.5  10
5
 M
-1
) should successfully compete 
with binding to GATG/C sites (where affinities in physiological salt were too low to 
measure with MST; Figure 7.6). This would result in the N-finger releasing DNA and 
binding LMO2, while the C-finger remains bound to DNA (Figure 8.2). 
Although Gata1-activated genes containing both GATA and pseudo-palindromic GATA 
sites are associated with co-binding by other members of the pentameric complex, there 
is a poor association between pseudo-palindromic GATA and E-box motifs. However, 
several pieces of evidence indicate that pseudo-palindromic sequences lacking an obvious 
Tal1-binding E-box may still recruit the Tal1/LMO2 transcriptional complexes. 
Co-occupancy determined by ChIP-Seq studies show that Tal1 recruitment by Gata 
proteins is a better determinant of DNA localisation of Tal1 than the presence of specific 
E-box sites.
156
 The DNA-binding domain of Tal1 was not essential for its function in 
early haematopoiesis.
186,187
 Finally, a de novo search for motifs (from ChIP-seq data) has 
revealed that GATA motifs (96%) were more highly represented than E-box motifs 
(76%) in Tal1 binding sites.
188
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8.4 CONCLUDING REMARKS 
Changes in gene expression drive every process associated with cell development and 
homeostasis. This process is regulated by transcription factors and the complexes they 
form. It is apparent that tight control over the specific spatial and temporal populations of 
these proteins is crucial and disruption of these populations is often pathogenic. For 
example, many human cancers result from aberrant expression of transcription factors 
and transcriptional regulators. Therefore, by targeting specific protein-protein 
interactions, these regulators are potential therapeutic targets for the treatment of these 
cancers. However, a detailed characterisation of these interactions and a mechanistic 
Figure 8.2 LMO2 competes with DNA for Gata1NF on double GATA sites. A) Structure of the 
N-finger (red) and the C-finger (blue) bound to a double GATA site. PDB:3VEK B) The N-finger likely 
undergoes a conformational change and a movement relative to the C-finger to release DNA and bind 
LMO2. The structure of Gata1CF (blue) bound to double GATA site is superimposed on the haddock 
model of LMO2LIM2-LDB1 (magenta) bound to Gata1NF  (red). PDB: 3VEK, 2L6Y. 
 
A B 
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understanding of the assembly of the target system are required before modulators of 
specific transcriptional complexes can be developed. This thesis has expanded our 
understanding of specific interactions within a set of related transcriptional complexes 
that change gene expression patterns and contribute to the onset of T-ALL. There is 
plenty of scope for future research on these complexes; however, this work has shed new 
light on the interactions at a biophysical level and expanded our mechanistic 
understanding of the assembly of these complexes in normal development and T-ALL.  
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 A P P E N D I X  A  
P R O T E I N  C O N S T R U C T S  
A.1 LMO-LDB1 FUSION CONSTRUCTS 
A.1.1 LIM1 and LIM2 sequences of LMO proteins used in fusion 
constructs 
 
 10 20 30 40 50 
LMO1 MMVLDKEDGV PMLSVQPKGK QKGCAGCNRK IKDRYLLKAL DKYWHEDCLK  
 16 26 36 46 56 
LMO2  RKSLDPSEEP VDEVLQIPPS LLTCGGCQQN IGDRYFLKAI DQYWHEDCLS  
   9 19 29 39 
LMO3             MLSVQPDTK PKGCAGCNRK IKDRYLLKAL DKYWHEDCLK  
  19 29 39 49 
LMO4  MVNPGSSSQ PPPVTAGSLS WKRCAGCGGK IADRFLLYAM DSYWHSRCLK  
 
 60 70 80 90  100 
LMO1 CACCDCRLGE VGSTLYTKAN LILCRRDYLR LFGTTGNCAA CSKLIPAFEM  
 66 76 86 96  106 
LMO2 CDLCGCRLGE VGRRLYYKLG RKLCRRDYLR LFGQDGLCAS CDKRIRAYEM  
 49 59 69 79 89 
LMO3 CACCDCRLGE VGSTLYTKAN LILCRRDYLR LFGVTGNCAA CSKLIPAFEM  
 59 69 79 89  99 
LMO4 CSCCQAQLGD IGTSCYTKSG MILCRNDYIR LFGNSGACSA CGQSIPASEL  
 
 110 120 130 140  150 
LMO1 VMRARDNVYH LDCFACQLCN QRFCVGDKFF LKNNMILCQV DYEEGHLNGT FESQVQ 
 116 126 136 146  156 
LMO2 TMRVKDKVYH LECFKCAACQ KHFCVGDRYL LINSDIVCEQ DIYEWTKING II 
 99 109 119 129  139 
LMO3 VMRAKDNVYH LDCFACQLCN QRFCVGDKFF LKNNMILCQT DYEEGLMKEG YAPQVR 
 109 119 129 139  149 
LMO4 VMRAQGNVYH LKCFTCSTCR NRLVPGDRFH YINGSLFCEH DRPTALINGH LNSLQS 
 
Sequences used in LMO-LDB1 fusion constructs are coloured in blue  
APPENDIX 184 
 
A.1.2 Sequences of LDB1 used in fusion constructs 
 260  270 280 290 300  
EPARQQPSKR RKRKMSGGST MSSGGGNTNN SNSKKKSPAS TFALSSQVPD  
 310 320 330 340 350 
VMVVGEPTLM GGEFGDEDER LITRLENTQF DAANGIDDED SFNNSPALGA  
Sequences used in LMO-LDB1 fusion constructs are coloured in purple  
A.1.3 Sequences of LMO-LDB1 fusion constructs 
LMO1-LDB1 GS GKQKGCAGCN RKIKDRYLLK ALDKYWHEDC LKCACCDCRL GEVGSTLYTK 
LMO2-LDB1 GS  PSLLTCGGCQ QNIGDRYFLK AIDQYWHEDC LSCDLCGCRL GEVGRRLYYK 
LMO3-LDB1 GS TKPKGCAGCN RKIKDRYLLK ALDKYWHEDC LKCACCDCRL GEVGSTLYTK 
LMO4-LDB1 GS  LSWKRCAGCG GKIADRFLLY AMDSYWHSRC LKCSCCQAQL GDIGTSCYTK 
 
LMO1-LDB1 ANLILCRRDY LRLFGTTGNC AACSKLIPAF EMVMRARDNV YHLDCFACQL 
LMO2-LDB1 LGRKLCRRDY LRLFGQDGLC ASCDKRIRAY EMTMRVKDKV YHLECFKCAA 
LMO3-LDB1 ANLILCRRDY LRLFGVTGNC AACSKLIPAF EMVMRAKDNV YHLDCFACQL 
LMO4-LDB1 SGMILCRNDY IRLFGNSGAC SACGQSIPAS ELVMRAQGNV YHLKCFTCST 
 
LMO1-LDB1 CNQRFCVGDK FFLKNNMILC QVDYEEGHLN GTGGSGGSGG SGGSSQVPDV 
LMO2-LDB1 CQKHFCVGDR YLLINSDIVC EQDIYEWTKI NGGGSGGSGG SGGSSQVPDV 
LMO3-LDB1 CNQRFCVGDK FFLKNNMILC QTDYEEGLMK EGGGSGGSGG SGGSSQVPDV 
LMO4-LDB1 CRNRLVPGDR FHYINGSLFC EHDRPTALIN GHGGSGGSGG SGGSSQVPDV 
 
LMO1-LDB1 MVVGEPTLMG GEFGDEDERL ITRLENTQFD AANGIDDE 
LMO2-LDB1 MVVGEPTLMG GEFGDEDERL ITRLENTQFD AANGIDDE 
LMO3-LDB1 MVVGEPTLMG GEFGDEDERL ITRLENTQFD AANGIDDE 
LMO4-LDB1 MVVGEPTLMG GEFGDEDERL ITRLENTQFD AANGIDDE 
 
Sequences are post cleavage from GST-tags from expression in pGEX-2T. Sequences 
from LMO proteins are coloured in blue and from LDB1 are coloured in purple. 
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A.2 bHLH CONSTRUCTS 
A.2.1 bHLH sequences of Lyl1 used in constructs 
 130 140 150 160  170  180 
SHSELDLADG HQPQKVARRV FTNSRERWRQ QNVNGAFAEL RKLLPTHPPD RKLSKNEVLR  
 
 190 200 
LAMKYIGFLV RLLRDQAAAL AAGPTPP 
 
Sequences used in constructs are coloured in red and sequences used in extension 
constructs are boardered  
 
A.2.2 Lyl1 constructs from expression in pGEX-6P  
 
Lyl1(1) GSVARRVFTN SRERWRQQNV NGAFAELRKL LPTHPPDRKL SKNEVLRLAM  
 
 KYIGFLVRLL RDQ 
 
 
Lyl1(2) GSHQPQKVAR RVFTNSRERW RQQNVNGAFA ELRKLLPTHP PDRKLSKNEV  
 LRLAMKYIGF LVRLLRDQ 
 
 
Lyl1(3) GSVARRVFTN SRERWRQQNV NGAFAELRKL LPTHPPDRKL SKNEVLRLAM  
 
 KYIGFLVRLL RDQAAALA 
 
 
Lyl1(4) GSHQPQKVAR RVFTNSRERW RQQNVNGAFA ELRKLLPTHP PDRKLSKNEV  
 
 LRLAMKYIGF LVRLLRDQAA ALA 
 
 
Sequences are post cleavage from GST-tags. 
A.2.3 Lyl1 constructs from expression in pETDUET 
 
Lyl1 MGSSHHHHHH SQDPVARRVF TNSRERWRQQ NVNGAFAELR KLLPTHPPDR  
 
 KLSKNEVLRL AMKYIGFLVR LLRDQ 
 
Sequences are with HIS tag from expression in the MCSI of pETDUET vector.   
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A.2.4 bHLH sequences of Tal1 used in constructs 
 
 190 200 210  220 230 240 
GPHTKVVRRI FTNSRERWRQ QNVNGAFAEL RKLIPTHPPD KKLSKNEILR LAMKYINFLA 
  
 250 260 270  280 290 300 
KLLNDQEEEG TQRAKTGKDP VVGAGGGGGG GGGGAPPDDL LQDVLSPNSS CGSSLDGAAS 
 
Sequences used in untethered constructs are coloured in red and those used in coiled-coil 
tethered constructs are boardered  
A.2.5 Tal1 constructs from expression in pETDUET 
 
Tal1 MGSSHHHHHH SQDPVVRRIF TNSRERWRQQ NVNGAFAELR KLIPTHPPDK 
 
 KLSKNEILRL AMKYINFLAK LLNDQ 
 
Tal1_K3 MGSSHHHHHH SQDPGPHTKV VRRIFTNSRE RWRQQNVNGA FAELRKLIPT  
 HPPDKKLSKN EILRLAMKYI NFLAKLLNDQ EAKIAALKEK IAALKEKIAA  
 LKE 
 
Tal1GSK3 MGSSHHHHHH SQDPGPHTKV VRRIFTNSRE RWRQQNVNGA FAELRKLIPT  
 HPPDKKLSKN EILRLAMKYI NFLAKLLNDQ EGGSGGSGGK IAALKEKIAA  
 LKEKIAALKE 
 
Sequences are with HIS tag from expression in the MCSI of pETDUET vector. 
Sequences from Tal1 are coloured in red and K3 sequences are coloured in green.  
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A.2.6 bHLH sequences of E2a proteins used in constructs 
 
 150 160  170 180 190 
E12 EQKAEREKER RVANNARERL RVRDINEAFK ELGRMCQLHL NSEKPQTKLL 
 147 157  167 177 187 
E47 EEKDLRDRER RMANNARERV RVRDINEAFR ELGRMCQLHL KSDKAQTKLL 
 
 
 
 200  210 
E12 ILHQAVSVIL NLEQQVRERN LN 
 197  207 
E47 ILQQAVQVIL GLEQQVRERN LN  
 
Sequences used in untethered constructs are coloured in yellow and those used in 
coiled-coil tethered constructs are boardered  
 
A.2.7 E2a protein constructs from expression in pETDUET 
 
E12 MADERRVANN ARERLRVRDI NEAFKELGRM CQLHLNSEKP QTKLLILHQA  
 
 VSVILNLEQQ VRERN 
 
E47 MADRRMANNA RERVRVRDIN EAFRELGRMC QLHLKSDKAQ TKLLILQQAV  
 
 QVIL GLEQQVRER 
 
E47_E3 MADLRDRERR MANNARERVR VRDINEAFRE LGRMCQLHLK SDKAQTKLLI  
 LQQAVQVILG LEQQVRERNL EIAALEKEIA ALEKEIAALE K 
 
E47GSE3 MADLRDRERR MANNARERVR VRDINEAFRE LGRMCQLHLK SDKAQTKLLI  
 LQQAVQVILG LEQQVRERNL NSGGSGGEIA ALEKEIAALE KEIAALEK 
 
Sequences are from expression in the MCSII of pETDUET vector. Sequences from E12 
or E47 are coloured in yellow and E3 sequences are coloured in green. 
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A.3 Gata CONSTRUCTS 
A.3.1 Zinc-fingers used in Gata constructs  
 
 210  220 230 240 
Gata1 E ARECVNCGAT ATPLWRRDRT GHYLCNACGLY HKMNGQNRPLI  
 301  311 321 331 
Gata2 E GRECVNCGAT ATPLWRRDGT GHYLCNACGLY HKMNGQNRPLI  
 269  279 289 299 
Gata3 E GRECVNCGAT STPLWRRDGT GHYLCNACGLY HKMNGQNRPLI 
 
 250  260 270 280 
Gata1 RPKKRMIVSK RAGTQCTNCQ TTTTTLWRRN ASGDPVCNAC  
 341  351 361 371 
Gata2 KPKRRLSAAR RAGTCCANCQ TTTTTLWRRN ANGDPVCNAC  
 309  319 329 339 
Gata3 KPKRRLSAAR RAGTSCANCQT TTTTLWRRN ANGDPVCNAC   
 
 290  300 310 
Gata1 GLYFKLHQVN RPLTMRKDGI QTRNRKASGK GKKKRG 
 381  391 401 
Gata2 GLYYKLHNVN RPLTMKKEGI QTRNRKMSSK SKKSKK 
 349  359 369 
Gata3 GLYYKLHNIN RPLTMKKEGIQ TRNRKMSSK SKKCKK 
 
Sequences used in Gata1–3NF constructs are coloured in cyan and the sequence used in 
The Gata1CF construct is boardered  
 
A.3.2 Gata1–3NF constructs from expression in pGEX-2T 
Gata1NF GSEARECVNC GATATPLWRR DGTGHYLCNA CGLYHKMNGQ NRPLIRPKKR M 
 
Gata2NF GSEGRECVNC GATATPLWRR DGTGHYLCNA CGLYHKMNGQ NRPLIKPKRR L 
 
Gata3NF GSEGRECVNC GATSTPLWRR DGTGHYLCNA CGLYHKMNGQ NRPLIKPKRR L 
 
 
Sequences are post cleavage from GST-tags from expression in pGEX-2T. Sequences 
from Gata proteins are coloured in cyan . 
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A.3.3 Gata1CF construct from expression in pET11A 
QNRPLIRPKK RMIVSKRAG TQCTNCQTTT TTLWRRNASG DPVCNACGLY FKLHQVNRPL 
TMRKDGIQTR NRKASGKGKK KR 
 
 
 
 A P P E N D I X  B  
D N A  O L I G O N U C L E O T I D E S  
Sequences of oligonucleotides used in EMSA, MST and ITC 
experiments 
 
Name Sequence of leading strand (5’ to 3’) 
E-box TTAACAGATGGTGA 
GATC GCAACTGATCTGGACT 
GATG AGTCCATCTGTTAAGACTTA 
 
 
